

1 **The architecture of protein synthesis in the developing neocortex at near-atomic**
2 **resolution reveals Ebp1-mediated neuronal proteostasis at the 60S tunnel exit**

3
4 Matthew L. Kraushar,^{1,*} Ferdinand Krupp,¹ Paul Turko,² Mateusz C. Ambrozkiwicz,³ Thiemo
5 Sprink,¹ Koshi Imami,⁴ Carlos H. Vieira-Vieira,⁴ Theres Schaub,³ Dermot Harnett,⁵ Agnieszka
6 Münster-Wandowski,² Jörg Bürger,^{1,6} Ulrike Zinnall,⁵ Ekaterina Borisova,³ Hiroshi Yamamoto,¹
7 Mladen-Roko Rasin,⁷ Dieter Beule,^{4,8} Markus Landthaler,⁵ Thorsten Mielke,⁶ Victor Tarabykin,³
8 Imre Vida,² Matthias Selbach,⁴ Christian M.T. Spahn^{1,9,*}

9
10 ¹Institute of Medical Physics and Biophysics, Charité-Universitätsmedizin Berlin, 10117 Berlin,
11 Germany

12 ²Institute for Integrative Neuroanatomy, Charité-Universitätsmedizin Berlin, 10117 Berlin,
13 Germany

14 ³Institute of Cell Biology and Neurobiology, Charité-Universitätsmedizin Berlin, 10117 Berlin,
15 Germany

16 ⁴Max Delbrück Center for Molecular Medicine, 13092 Berlin, Germany

17 ⁵Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine,
18 10115 Berlin, Germany

19 ⁶Max Planck Institute for Molecular Genetics, Microscopy and Cryo-Electron Microscopy
20 Service Group, 14195 Berlin, Germany

21 ⁷Department of Neuroscience and Cell Biology, Rutgers University-Robert Wood Johnson
22 Medical School, Piscataway, NJ, 08854 USA

23 ⁸Core Unit Bioinformatics, Berlin Institute of Health, 10117 Berlin, Germany

24 ⁹Lead Contact

25 *Correspondence: matthew.kraushar@gmail.com (M.L.K.), christian.spahn@charite.de
26 (C.M.T.S.)

27 **SUMMARY**

28 Protein synthesis must be finely tuned in the nervous system, as it represents an essential
29 feature of neurodevelopmental gene expression, and dominant pathology in neurological
30 disease. However, the architecture of ribosomal complexes in the developing mammalian brain
31 has not been analyzed at high resolution. This study investigates the architecture of ribosomes
32 *ex vivo* from the embryonic and perinatal mouse neocortex, revealing Ebp1 as a 60S peptide
33 tunnel exit binding factor at near-atomic resolution by multiparticle cryo-electron microscopy.
34 The impact of Ebp1 on the neuronal proteome was analyzed by pSILAC and BONCAT coupled
35 mass spectrometry, implicating Ebp1 in neurite outgrowth proteostasis, with *in vivo* embryonic
36 Ebp1 knockdown resulting in dysregulation of neurite outgrowth. Our findings reveal Ebp1 as a
37 central component of neocortical protein synthesis, and the 60S peptide tunnel exit as a focal
38 point of gene expression control in the molecular specification of neuronal morphology.

39

40 **KEYWORDS:** Ebp1, ribosome, proteostasis, brain, neocortex, neurons, development, cryo-EM,
41 pSILAC, BONCAT

42 INTRODUCTION

43 Proteostasis, the fine-tuned balance of protein homeostasis, is fundamental in establishing the
44 molecular landscape of the nervous system. The demand for spatially targeted and precisely
45 timed protein synthesis is exceptionally high in mammalian nervous system development, where
46 neurogenesis relies on spatiotemporal gene expression, driving amorphous neural stem cells to
47 generate intricately branched neuronal architecture (Hanus and Schuman, 2013; Hipp *et al.*,
48 2019; Holt and Schuman, 2013; Jayaraj *et al.*, 2019; Jung *et al.*, 2014; Sossin and Costa-
49 Mattioli, 2018). This is particularly true in the evolutionarily advanced mammalian neocortex, the
50 central neuronal circuit of complex cognition in the brain (Rakic, 2009). Concordantly, the
51 nervous system is uniquely susceptible to abnormal proteostasis, a major driver of
52 neurodevelopmental and neurodegenerative disease (Bosco *et al.*, 2011; Kapur and Ackerman,
53 2018; Kapur *et al.*, 2017; Sossin and Costa-Mattioli, 2018). How proteostasis is achieved,
54 therefore, stands as a crucial question towards understanding neurogenesis in the neocortex.

55 The neurogenic phase of stem cell maturation in neocortical development follows a
56 general trajectory conserved across mammalian species (DeBoer *et al.*, 2013; Kwan *et al.*,
57 2012; Molyneaux *et al.*, 2007) (**Figure 1A**). Neural stem cells (NSCs) lining the lateral cortical
58 ventricular zone initially undergo symmetric divisions to expand a pool of cells forming the basis
59 of the cortical plate. NSC divisions then transition to asymmetric with newly born neurons
60 migrating superficially, ultimately forming a layered cortical plate composed of structurally and
61 functionally distinct neurons. Predominantly subcortically projecting lower layer neurons are
62 born first, followed by intracortically projecting upper layer neurons born second. In mice, lower
63 layer neocortical neurons are born at approximately embryonic day 12.5 (E12.5), with the switch
64 to upper layer neurogenesis at E15.5. By postnatal day 0 (P0) neurogenesis is largely complete,
65 with ongoing stem cell divisions yielding cells of the glial lineage. The distinct functional
66 connectivity of neurons in different neocortical layers emerges from the architecture of their
67 projections, where the refinement and targeting of dendritic inputs and axonal outputs pattern
68 neocortical circuits (Harris and Shepherd, 2015). The elaboration of intricate neuronal
69 projections requires proteostasis of the neurite outgrowth and synaptic proteome (Hanus and
70 Schuman, 2013; Jung *et al.*, 2012), a fine-tuned balance of proteins like cell adhesion molecules
71 that establish neuronal connectivity (de Wit and Ghosh, 2016).

72 Analysis of the molecular landscape in the developing neocortex has largely focused on
73 transcriptional regulation (Lein *et al.*, 2017; Silbereis *et al.*, 2016), with the neocortical
74 transcriptome coming into focus recently at the single-cell level (scRNAseq) (Nowakowski *et al.*,
75 2017; Telley *et al.*, 2019; Yuzwa *et al.*, 2017). However, the functional output of gene

76 expression is protein, and bridging the neocortical transcriptome to proteome is the current
77 challenge. The ribosome is the gatekeeper of proteostasis, poised at the final essential step of
78 gene expression as the macromolecular hub of protein synthesis. Mounting evidence positions
79 the ribosome in a dynamic and executive role at the crossroads of cellular proliferation,
80 differentiation, and disease (Kraushar et al., 2016; Mills and Green, 2017; Shi and Barna, 2015;
81 Xue and Barna, 2012); however, the architecture of ribosomal complexes and proteostasis
82 control in neocortical development remain unknown.

83 In this study, we analyze the molecular architecture of native ribosome complexes from
84 the *ex vivo* mammalian neocortex during developmental neurogenesis at near-atomic resolution.
85 With a combination of mass spectrometry, biochemistry, and multiparticle cryo-electron
86 microscopy, we reveal that ErbB3-binding protein 1 (Ebp1) participates in high occupancy
87 binding to the 60S subunit of both non-translating and translating ribosomes through high affinity
88 electrostatic interactions with the peptide tunnel exit site in the embryonic and perinatal
89 neocortex. Ebp1's role in nervous system development and specific function in protein synthesis
90 is unknown. Ebp1 enrichment scales directly with ribosome levels and is cell type-specific:
91 dominantly expressed in early-born NSCs, compared to later-born NSCs and post-mitotic
92 neurons – in contrast to other exit tunnel cofactors. Ebp1•ribosome interaction occurs in the
93 cytoplasm of NSCs in the neocortical ventricular zone at early embryonic stages when
94 ribosomal complex levels are highest, and persists in post-mitotic neurons of the expanding
95 cortical plate as steady state ribosome levels decline. With a combination of pulsed stable
96 isotope labeling by amino acids in cell culture (pSILAC) and bioorthogonal noncanonical amino
97 acid tagging (BONCAT) coupled mass spectrometry, we show that Ebp1 maintains neuronal
98 proteostasis, particularly impacting the synthesis of cell adhesion, synaptogenic, and neurite
99 outgrowth associated proteins. Concordantly, *in vivo* embryonic Ebp1 knockdown selectively in
100 early-born neocortical NSCs results in increased branching of neurites projected by maturing
101 neurons in the cortical plate. This study is the first near-atomic resolution analysis of protein
102 synthesis in the nervous system, positioning Ebp1 and the 60S peptide tunnel exit as a focal
103 point of gene expression control during neocortical neurogenesis.

104

105 **RESULTS**

106 **Neocortical ribosome mass spectrometry identifies Ebp1 as an abundant, high** 107 **occupancy translation cofactor during development**

108 To analyze the architecture of neocortical ribosome complexes across development, we first
109 optimized a protocol to purify actively translating ribosomes *ex vivo* rapidly and stably without

110 the use of chemical inhibitors, which bias the conformational state of the ribosome. The goal
111 was to capture the full repertoire of integral translation cofactors binding ribosomes engaged in
112 various stages of the translation cycle throughout neocortical neurogenesis, spanning the early
113 neural stem cell (NSC) predominant embryonic stage (E12.5) to the post-mitotic neuronal post-
114 natal stage (P0). We focused our analysis on complexes of isolated 80S ribosomes
115 (monosomes), and chains of multiple 80S actively translating mRNA (polysomes) (**Figure 1A**).
116 Neocortex lysates were fractionated by sucrose density gradient ultracentrifugation to purify 80S
117 monosomes, actively translating polysomes, with corresponding input total lysates for mass
118 spectrometry (MS) analysis (**Figure S1**). Sample reproducibility was observed in hierarchical
119 clustering of the MS data, with the data clustering by biological triplicate, 80S vs. polysomes,
120 and early vs. late developmental stages (**Figure S2**).

121 Results from the neocortical polysome MS are shown in **Figure 1B**, comparing protein
122 levels at E12.5 with each subsequent developmental stage. As expected, core ribosomal
123 proteins (RPs) were among the most enriched proteins in the polysomes, including RPs of the
124 large 60S subunit (Rpl) and small 40S subunit (Rps). Known translation-associated proteins
125 were enriched to varying degrees in polysomes throughout development. Unexpectedly, we
126 observed Ebp1 co-purifying at levels comparable to the RPs themselves in polysomes, higher
127 than any other translation-associated protein. Ebp1 is metazoan-specific and was only observed
128 to play a niche role in protein synthesis, promoting non-canonical internal ribosome entry site
129 (IRES) dependent translation of a specific viral mRNA (Pilipenko et al., 2000), and suppressing
130 eIF2a phosphorylation in conditions of cellular stress (Squatrito et al., 2006), by unknown
131 mechanisms. Largely studied in the context of cancer, Ebp1 influences cell proliferation and
132 differentiation (Nguyen et al., 2018), in pathways including the epidermal growth factor receptor
133 ErbB3 (Lessor et al., 2000; Yoo et al., 2000), and other mitogenic signaling cascades. Its role in
134 the developing nervous system, general function in protein synthesis, and whether translational
135 regulation is connected to its role in cancer are unknown. Thus, we were intrigued by Ebp1's
136 exceptionally high enrichment in polysomes of the developing neocortex, and observed a
137 similarly robust association with 80S complexes measured by MS (**Figure S3A**). Furthermore,
138 Ebp1 was among the most abundant proteins measured in total neocortical lysates across
139 development (**Figure S3B**), similar to the RPs.

140 The core of the eukaryotic 80S ribosome is a macromolecular machine consisting of ~79
141 RPs on a scaffold of 4 rRNAs, with translation-associated proteins transiently binding to
142 catalyze and modulate ribosomal functions. To quantify the balance between translation-
143 associated cofactors and core RPs in neocortical ribosomes across development, we generated

144 stoichiometry matrices at the five developmental stages measured by MS (**Figures 1C and**
145 **S3C-D**). Hierarchical clustering of these data visualizes the distribution of super-stoichiometric,
146 stoichiometric, and sub-stoichiometric proteins associated with ribosomal complexes. The
147 majority of core RPs approximate stoichiometric levels throughout development in polysome
148 (**Figure 1C**) and 80S (**Figure S3C**) complexes, and are likewise maintained at similar levels in
149 total steady state (**Figure S3D**). While the majority of translation-associated proteins are sub-
150 stoichiometric to core RPs in ribosomal complexes, Ebp1 is nearly stoichiometric in polysome
151 and 80S complexes. Across development in polysomes, the ratio of Ebp1 to the Rpl or Rps
152 median is 0.63-0.86 to 1, indicating that Ebp1 may play an integral role in neocortical translation,
153 rather than niche for a small subset of transcripts or during transient conditions as previously
154 reported (Pilipenko et al., 2000; Squatrito et al., 2006).

155

156 **Ebp1 enrichment is cell type and temporally specific, scaling with the dynamic level of** 157 **ribosomal complexes**

158 The unusual abundance of Ebp1 as a translation-associated protein may correspond to a
159 particular expression pattern in neocortical development. We next assessed the cell type and
160 temporal specificity of *Ebp1* mRNA expression in scRNAseq data (Telley et al., 2019)
161 measuring the transcriptome of early and late born NSCs maturing into lower and upper layer
162 neurons, respectively (**Figure 2A**). Strikingly, *Ebp1* mRNA is particularly enriched in early born
163 NSCs in the ventricular zone, with levels decreasing abruptly during both neuronal
164 differentiation, and in the later born NSC pool. The particular enrichment of *Ebp1* mRNA is in
165 contrast to *Rpl* and *Rps* mRNA expression patterns, which are maintained at stable levels in
166 NSCs regardless of birthdate, but likewise decline during differentiation. This observation was
167 reflected in analysis of total neocortical lysates across development by RNAseq (**Figure 2B**),
168 with *Ebp1* mRNA steadily decreasing from E12.5, while *Rpl* and *Rps* mRNA decreases lag
169 behind at E17. However, corresponding MS measurement revealed Ebp1 protein levels decline
170 abruptly at E15.5 along with Rpl and Rps proteins in the neocortex, suggesting their levels are
171 regulated in concert, with protein changes anticipating mRNA changes for the RPs. Notably,
172 total Ebp1 protein is consistently maintained 2-5 fold higher than the median level of RPs, in
173 contrast to the corresponding mRNA. Concordant with the above findings,
174 immunohistochemistry analysis (**Figures 2C and S4**) demonstrated particularly high Ebp1
175 levels in the ventricular zone (VZ) and nascent cortical plate (CP) at E12.5-E14, including the
176 ventricular and pial surfaces. Ebp1 is persistent in maturing neurons laminating the CP at later
177 stages, albeit at lower levels. Interestingly, Ebp1 was observed in the P0 VZ that contains early

178 gliogenic progenitor cells (Kriegstein and Alvarez-Buylla, 2009) at substantially lower levels than
179 in the neurogenic E12.5 VZ. This observation may relate to a prior immunohistochemical study
180 in the postnatal hippocampus, where Ebp1 was reported to be particularly enriched in neurons
181 compared to astroglia (Ko et al., 2017). Thus, *Ebp1* enrichment is specific to both differentiation
182 status and NSC birthdate in the neocortex.

183 We observed that, along with Ebp1, total steady state RP levels decrease at E15.5-P0 in
184 the developing neocortex by MS (**Figure 2B**). We next asked whether this reflects a timed
185 global shift in the balance of actively translating ribosomal complexes during prenatal
186 neurogenesis. Neocortical lysates were subjected to analytic quantitative sucrose density
187 gradient fractionation corresponding the stages analyzed by MS, loading equivalent A260
188 optical density units to directly compare the distribution of 40S-60S, 80S, and polysome levels
189 at each stage (**Figure 2D**). Gradient curves demonstrated a timed decrease from high levels of
190 80S and polysomes at E12.5-E14, to a lower steady state from E15.5-P0. A decrease of 35%
191 80S and 64% polysome levels during the transition from E14 to E15.5 was calculated by area-
192 under-the-curve with a Riemann sum (**Figure 2E**). This decrease in ribosomes is not wholly
193 accounted for by the availability of individual subunits in the cytoplasm, as 40S-60S levels
194 decrease 4% from E14 to E15.5. Taken together, these findings suggest mature, active
195 ribosomal complexes exist at elevated levels during early neocortical neurogenesis, and
196 transition to a lower steady state level at later stages, concordant with MS findings. These data
197 are in line with previous observations of RP downregulation in the mouse forebrain between
198 E8.5-E10.5 during neural tube closure (Chau et al., 2018), and dynamic levels of ribosomal
199 complex proteins in the E13-P0 neocortex (Kraushar et al., 2015). Global shifts in steady state
200 ribosomal complex levels may reflect a dynamic equilibrium of cellular homeostasis (Delarue et
201 al., 2018; Mills and Green, 2017; Sinturel et al., 2017) in neocortex development.

202 Ebp1 has been previously reported to exist as a full-length 48kDa protein (“p48”), and a
203 42kDa isoform (“p42”) with a 54 amino acid N-terminal truncation generated by *Ebp1* mRNA
204 splicing (Liu et al., 2006). Total neocortical lysates across developmental stages were analyzed
205 by Western blot, probing for Ebp1 with a C-terminal targeting antibody (Ebp1^{CT}) that recognizes
206 both long and short isoforms (**Figures 2F and S5A**), and with a N-terminal specific antibody
207 (Ebp1^{NT}) that recognizes only full-length Ebp1 (**Figure S5B**), compared to signal for
208 recombinant full-length Ebp1 with a N-terminal histidine tag (Ebp1-His). Results showed that the
209 dominant protein isoform of Ebp1 in neocortical development is full-length. Furthermore, the
210 Western blot measurements mirror the MS measurements (**Figure 2B**), demonstrating higher
211 total Ebp1 levels at E12.5-E14, with a decrease at E15.5 to a lower steady state. Notably, total

212 neocortical Ebp1 levels are higher overall in the embryonic and perinatal period, while
213 measurements at P7, and particularly P14, show decreased enrichment – in agreement with
214 previous measurements in whole brain lysates (Ko et al., 2017). Taken together, full-length
215 Ebp1 is the dominant isoform expressed in the neocortex with a particular enrichment in
216 embryonic development, and its levels decrease at E15.5 in concert with a global decrease in
217 80S and polysome levels.

218 We next sought to measure the balance of ribosome-associated Ebp1 compared to “free”
219 extra-ribosomal Ebp1 in neocortical development. Input normalized neocortical lysates at E12.5,
220 E15.5, and P0 were fractionated to separate extra-ribosomal free Ebp1 vs. 80S and polysome
221 associated Ebp1 (**Figure S5C**). Western blot analysis of individual gradient fractions (**Figure**
222 **S5D**), and pooled fractions constituting free, 80S, and polysome complexes (**Figure 2G**)
223 showed that free extra-ribosomal Ebp1 is maintained at high levels throughout development,
224 while only ribosome-associated Ebp1 decreases at E15.5. These findings suggest that total
225 Ebp1 levels decline from E12.5-P0 secondary to a decrease in ribosomal complexes along with
226 ribosome-associated Ebp1.

227

228 **Ebp1 binds the 60S with high affinity in the cytoplasm of neocortical neural stem cells** 229 **and neurons**

230 While previous studies suggested that Ebp1-ribosome interaction is rRNA-dependent and
231 dissociates in high salt conditions (Squatrito et al., 2004, 2006), its specific binding mode is
232 unknown. We next performed *in vitro* binding assays with recombinant Ebp1 and purified 40S,
233 60S, and reconstituted 80S derived from rabbit reticulocyte lysate (RRL). Samples were pelleted
234 through a sucrose cushion, followed by Western blot analysis of the supernatant (unbound
235 Ebp1) and pellet (ribosome-bound Ebp1) (**Figure 3A**). Ebp1 co-pelleted with the 60S and 80S
236 exclusively, demonstrating concomitant decreases of Ebp1 in the supernatants. These findings
237 were reinforced by a binding assay with mouse neocortex derived 40S and 60S (**Figure S6A**).
238 Thus, Ebp1 specifically binds the 60S subunit and is persistent in 80S complexes, suggesting
239 Ebp1 interactions do not interfere with the subunit interface, nor does its binding require mRNA.
240 Furthermore, Ebp1•60S binding is conserved between mouse and rabbit species, and across
241 reticulocyte and neocortical derived ribosomes.

242 We next determined the relative affinity range of Ebp1•60S binding, where experiments
243 were similarly conducted with a constant rabbit 60S concentration, combined with doubling
244 concentrations of Ebp1 measured in the pellet vs. supernatant (**Figure 3B**), and data plotted
245 (**Figure 3C**). The curve best fit to data ($r^2=0.99$) indicates Ebp1 reaches a $K_{d(app)}$ at ~124 nM,

246 with saturated Ebp1•60S binding at ~200 nM, relative to 100 nM 60S. These data indicate Ebp1
247 binds the 60S with a high relative affinity, reaching saturation at ~2-fold excess Ebp1 over the
248 60S. Given the 2-5 fold excess of total steady state Ebp1 levels over the 60S RPs measured by
249 MS (**Figure 2B**), superstoichiometric Ebp1 would be hypothetically sufficient to yield a high
250 degree of Ebp1•60S association *in vivo*. Furthermore, a nonlinear least squares fit, with one-site
251 binding and Hill slope accommodation, suggested Ebp1 binding includes 60S conformational
252 activation (**Figures 3C and S6B**).

253 While isolated 60S was sufficient for Ebp1 binding, whether its binding mode undergoes
254 dynamic Ebp1 turnover, is diminished/enhanced by active mRNA translation, or can be
255 modulated by translation inhibitors is unknown. To answer these questions, the following
256 binding conditions were constituted in parallel: (1) saturating levels of Ebp1-His in the presence
257 of rabbit 60S; (2) RRL containing native Ebp1; (3) saturating Ebp1-His added to RRL; native
258 Ebp1 in RRL translating *Luciferase* mRNA (*Luc*) with (4) and without (5) cycloheximide to stall
259 elongation. Results are shown in **Figure 3D**, with Ebp1-His and 60S inputs as markers for the
260 binding pellet of each condition (1-5). Native Ebp1 in RRL (2) co-pelleted with the ribosome as
261 did Ebp1-His to the 60S (1), undergoing dynamic binding (3) demonstrated by the nearly
262 complete turnover of native Ebp1 with saturating Ebp1-His. Active *in vitro* translation of a
263 *Luciferase* mRNA (4) did not impact the stability of Ebp1•60S binding, nor did elongation stalling
264 by cycloheximide (5). These findings indicate the Ebp1•60S binding mode occurs with dynamic
265 turnover, in conditions irrespective of active mRNA translation.

266 Ebp1 has been reported to localize to both the cytoplasm and nucleus/nucleolus in
267 cultured cells lines (Liu et al., 2006; Radomski and Jost, 1995). Whether Ebp1•60S complexes
268 are formed during 60S assembly in the nucleolus as previously suggested (Squatrito et al.,
269 2004), at the nuclear membrane for 60S export, or on mature 60S in the cytoplasm remained
270 unclear in the neocortex. We next prepared coronal sections of the neocortex at E12.5, E15.5,
271 and P0 for immuno-electron microscopy (immuno-EM), probing for Ebp1 with both Ebp1^{NT} (full-
272 length isoform only; **Figure 3E**) and Ebp1^{CT} (full-length and truncated isoforms; **Figure S7A**)
273 antibodies. At all developmental stages analyzed, immunogold labeling for Ebp1 demonstrated
274 predominantly cytoplasmic signal, occurring in clusters throughout the cytoplasm of both NSCs
275 in the ventricular zone, and neurons populating the cortical plate. Ebp1 was largely absent from
276 the nuclei and nuclear membrane of NSCs and neurons, including the nucleolus. Furthermore,
277 Ebp1 was not observed in mitochondria, or in strict proximity to the endoplasmic reticulum or
278 plasma membrane. Notably, Ebp1 was also observed in dendrites of maturing neurons at P0
279 (**Figure S7B**), suggesting Ebp1 localizes throughout cytoplasmic compartments of both

280 neocortical NSCs and neurons. Thus, Ebp1 may function to regulate protein synthesis with 60S
281 binding in the cytoplasm, rather than as a nuclear assembly or export factor, during neocortical
282 neurogenesis.

283

284 **The structure of neocortical Ebp1•ribosome complexes *ex vivo* at near-atomic resolution**

285 To analyze the architecture of neocortical ribosome complexes and visualize the physiologic
286 binding mode of Ebp1 at near-atomic resolution, 80S and polysomes were purified by sucrose
287 density gradient fractionation from P0 neocortex lysates, pooled together, and frozen on grids
288 for cryo-electron microscopy (cryo-EM). Micrographs confirmed the presence of both 80S and
289 polysome complexes in the sample (**Figure 4A**). High-resolution cryo-EM data collection
290 (**Figure S8**) and initial single-particle reconstruction yielded a map of the complete 80S, along
291 with extra-ribosomal density (red) adjacent to the 60S peptide tunnel exit (**Figure 4B**). Fitting
292 the crystal structure of mouse Ebp1 (PDB 2V6C) (Monie et al., 2007) to the extra-ribosomal
293 density unequivocally identified Ebp1 in complex with the neocortical 60S. Furthermore, robust
294 density was present for nearly the entire N-terminus, identifying the full-length isoform of Ebp1 is
295 bound. The direct visualization of native full-length Ebp1 binding to 60S *ex vivo* strongly
296 supports the physiologic nature of this Ebp1•60S binding mode in the neocortex.

297 To disentangle the ribosome conformational states bound by Ebp1, we proceeded with
298 hierarchical multiparticle sorting and 3D classification of both large and small scale
299 heterogeneity intrinsic to the data (Behrmann et al., 2015; Loerke et al., 2010) (**Figure S9**).
300 Ribosome complexes in both the rotated and classical conformations were first sorted, including
301 populations with (1) eEF2 and (2) eEF2+P/E tRNA in the rotated state, and populations with (3)
302 A/A+P/P tRNAs, (4) E/E tRNA, and (5) without tRNAs in the classical state. In each of these five
303 states, a strategy of modified focused classification (see Methods) was utilized to separate sub-
304 states with and without Ebp1, yielding ten total classes. Across all states, Ebp1 was bound to
305 48% of ribosomes. Likewise, Ebp1 was bound to ~50% of the ribosomes within each of the five
306 sub-states. We proceeded with high-resolution refinement of Ebp1-bound and unbound
307 populations in the rotated state with eEF2 (3.1 Å global resolutions), and the classical state with
308 A/A+P/P tRNAs (3.3 Å global resolutions). High-resolution cryo-EM maps are shown in **Figure**
309 **4C**, representing both actively translating (classical state with A/A+P/P tRNAs) and non-
310 translating (rotated state with eEF2) ribosomes with Ebp1 bound to the 60S. Taken together,
311 our findings suggest Ebp1 occupies its neocortical 60S binding site with high occupancy *in vivo*
312 based on both MS estimates (**Figures 1B-C**), and conservative estimates with multiparticle
313 sorting (**Figure S9**) (assuming some destabilization during sample freezing), approximating

314 50% occupancy. Furthermore, Ebp1 binds to both actively translating and non-translating
315 neocortical ribosome states with approximately equal probability.

316 The near-atomic resolution of our data (**Figures S8 and S10**) permitted modeling of the
317 entire neocortical Ebp1•60S complex. **Figure 4D** visualizes the peptide tunnel exit (TE) surface
318 in electrostatic proximity to Ebp1, including four RPs (eL19, uL23, uL24, uL29) and three rRNA
319 helices (H24, H53, H59). An aerial view of the Ebp1 footprint over the TE surface highlights the
320 60S RP residues and rRNA nucleosides making electrostatic interactions with Ebp1 (**Figure 4E**),
321 demonstrating that Ebp1 contacts the immediate TE surface. A side view of the Ebp1 model at
322 the TE (**Figure 4F**) shows Ebp1 forming a concavity above the TE vestibule, stabilized by
323 electrostatic interactions (**Figures 4G-H**) at the concavity rim with gaps (~26 Å at the widest
324 point) that would permit peptide chain exit. Therefore, Ebp1 binds the 60S peptide TE, creating
325 a pocket above the TE vestibule with a porous interface.

326

327 **Ebp1 binding requires a conserved 60S helix H59-H53 swinging latch mechanism**

328 Multiparticle sorting of our data into Ebp1-bound and unbound states enabled identification of
329 60S structural changes facilitating Ebp1 interactions with an internal negative control (**Figures**
330 **S11A-B**). We observed that in the Ebp1-bound state, the tip of H59 undergoes a backbone
331 rearrangement enabled by a 235° flip of H59 G-2690, releasing contact with H53 G-2501, G-
332 2502, and C-2513 as seen in the canonical unbound state (**Figure 5A**) – resulting in H59 G-
333 2690 transitioning to intra-helical base stacking interactions. This “swinging latch” mechanism
334 further includes a 73° flip of H59 U-2687, with the base reaching into the insert domain of Ebp1
335 (**Figure S11C**), locking Ebp1 into position. This particular movement of H59 U-2687 was
336 previously observed for the binding of the yeast nuclear export (Bradatsch et al., 2007) and
337 peptide tunnel quality control factor (Greber et al., 2016) Arx1 to the 60S – thus representing a
338 conserved binding mechanism. However, unlike Arx1, Ebp1 binding does not require
339 stabilization by rRNA expansion segment ES27 on the solvent side (Greber et al., 2016),
340 suggesting that aspects of its binding mode are distinct. Furthermore, the concerted
341 restructuring of H59 may represent a 60S “activation step” to facilitate Ebp1 binding, reflected in
342 the Ebp1•60S binding curve with Hill slope accommodation (**Figures 3C and S6B**). Thus, in
343 this model, increasing concentrations of Ebp1 increase the probability that H59 is stabilized in
344 the activated structural state, permitting Ebp1 re-binding events to occur more frequently for
345 higher aggregate 60S occupancy. Taken together, Ebp1-ribosome binding requires a 60S H59
346 swinging latch mechanism likewise utilized by yeast Arx1.

347

348 **Ebp1•60S binding is incompatible with simultaneous binding of all other eukaryotic**
349 **peptide tunnel exit cofactors**

350 The neocortical Ebp1•60S complex establishes previously unassigned functions to Ebp1
351 structural domains (**Figure 5B**; adapted from (Kowalinski et al., 2007)). Ribosome binding by
352 Ebp1's insert domain and $\alpha 5$ helix positions β -sheets 1, 3, 4, 5, 7, and 13 directly over the TE.
353 The alignment of mouse Ebp1 with orthologs across eukaryotic taxa, in addition to Metap2 and
354 Arx1, demonstrates conservation of key binding residues (**Figure S12**). Previous studies have
355 commented on the structural similarity between Ebp1 and the methionine aminopeptidase
356 Metap2 (Kowalinski et al., 2007; Monie et al., 2007), and between Arx1 and Metap2 (Greber et
357 al., 2016). Indeed, Ebp1, Metap2, and Arx1 share similar structural features, and putative
358 binding motifs (**Figure 5C**). A common β - α --- α - β insert domain facilitates 60S binding, the "pita-
359 bread" $\beta 6$ fold motif is positioned over the peptide TE, and a solvent-side $\alpha 4$ motif is available
360 for potential molecular interactions. Their binding ultimately creates different electrochemical
361 environments at the TE (**Figure 5D**). In the event of Ebp1 or Metap2 binding, emerging peptide
362 chain would encounter a deep, strongly electronegative pocket; however, the key residues in
363 the Metap2 β -sheet pita-bread fold catalyzing aminopeptidase activity (Nonato et al., 2006) are
364 absent in Ebp1 (Kowalinski et al., 2007; Monie et al., 2007), rendering Ebp1 catalytically inactive.
365 Furthermore, the Ebp1 $\alpha 5$ domain facilitating electrostatic contacts with H24 and uL24 is absent
366 in Metap2 (**Figure S11D**); however, a Metap2•60S complex structure has not yet been solved,
367 and thus Metap2 structural adjustments may exist. In contrast, the yeast Arx1 pita-bread fold
368 threads Rei1 into the peptide tunnel to probe the 60S as a quality-control step preempting active
369 translation (Greber et al., 2016). Thus, while sharing structural features and a conserved binding
370 mode, the binding of Ebp1, Metap2, and Arx1 engage distinct functional states of 60S-nascent
371 chain complexes, with an emerging nascent peptide chain encountering distinct environments.

372 The binding of Ebp1 would be sterically incompatible with the simultaneous docking of
373 other 60S TE cofactors, competing for limited real estate surrounding an emerging nascent
374 peptide chain (**Figure 5E**). The footprint of Ebp1 is shown superimposed on the footprints of
375 Metap2 (Nonato et al., 2006) and Arx1 (Greber et al., 2016), in addition to: the ER translocation
376 channel Sec61 (Voorhees et al., 2014); the Ltn1-NEMF ubiquitin ligase complex (Shao et al.,
377 2015); the N-terminal acetyltransferase NatA (Knorr et al., 2019); the ribosome-associated
378 complex (RAC) coupling nascent chain elongation and folding (Zhang et al., 2014); and the
379 nascent polypeptide-associated complex (NAC) preventing ER mistargeting and suppressing
380 aggregation of synthesized proteins (Gamerdinger et al., 2015; Shen et al., 2019). While the
381 particular abundance of Ebp1 among these TE cofactors would potentially support its

382 occupancy, the dynamic turnover of Ebp1 might allow for other TE cofactors to bind if recruited
383 by their associated nascent chain moieties as needed. Furthermore, the neocortical cell-type
384 and temporal specificity of Ebp1 enrichment is in contrast to some of the other TE cofactors,
385 such as Ltn1, while similar to others, such as RAC (**Figure S13**). Dynamic enrichment of Ebp1
386 vs. other TE cofactors in neocortical development may represent the dynamic regulation of
387 protein synthesis in response to the unique demands of particular stages of neurogenesis.
388 Given Ebp1's high occupancy of the neocortical ribosome tunnel exit, we hypothesized that
389 depletion of Ebp1 would disrupt the balance of proteostasis in neuronal protein synthesis.

390

391 **Neuronal Ebp1 regulates acute protein synthesis and chronic proteostasis impacting** 392 **axonal, dendritic, and synaptic proteomes**

393 To interrogate the potential function of Ebp1 in maintaining neuronal proteostasis, we
394 established a system to measure the impact of Ebp1 depletion on acute protein synthesis and
395 chronic proteostasis in a mouse neuronal cell line. Neuro2a cells dominantly express the full-
396 length isoform of Ebp1 (**Figure S14A**), which associates with 80S and polysomes (**Figures**
397 **S14B-C**), similar to mouse neocortex. We next confirmed robust and specific knockdown of
398 Ebp1 in Neuro2a by siRNA, with *siEbp1* targeting the mouse sequence effecting nearly
399 complete knockdown, in contrast to oligos targeting the human sequence, and non-targeting
400 control (**Figure 6A**).

401 The strategy to measure the response of the Neuro2a proteome with a combination of
402 pulsed stable isotope labeling by amino acids in cell culture (pSILAC) (Schwanhäusser et al.,
403 2009) and bioorthogonal noncanonical amino acid tagging (BONACT) (Dieterich et al., 2006) by
404 MS (Eichelbaum et al., 2012; Howden et al., 2013) in this Ebp1 knockdown system is shown in
405 **Figure 6B**. SILAC isotopes labeled all newly made proteins throughout the course of Ebp1
406 knockdown for longitudinal proteome changes, while pulse labeling with a methionine analog
407 (AHA) captured a snapshot of newly synthesized proteins at the nadir of Ebp1 knockdown.
408 pSILAC (**Figure 6C**) and pSILAC-AHA (**Figure 6D**) proteomes were measured by LC-MS/MS,
409 and analyzed for differential protein enrichment in *siEbp1* vs. *siControl* conditions. Importantly,
410 Ebp1 levels were below the quantification threshold in *siEbp1* conditions, confirming robust
411 knockdown. Thus, this approach captured the impact of Ebp1 depletion on both longitudinal
412 proteostasis (pSILAC) and acute protein synthesis (pSILAC-AHA) in neurons.

413 Results for both the pSILAC and pSILAC-AHA MS showed that in *siEbp1* conditions,
414 proportionately more proteins decrease compared to those with increased protein levels relative
415 to control, suggesting Ebp1 largely enhances protein expression. Cell adhesion molecules

416 (CAMs) (de Wit and Ghosh, 2016), such as L1cam, Mcam, Cadm1, and Cdh15, were
417 particularly impacted by Ebp1 depletion. Notably, Ebp1 maintains the balance of CAM levels,
418 promoting L1cam (Maness and Schachner, 2007) and Mcam (Taira et al., 2005), while
419 suppressing Cadm1 (Robbins et al., 2010) and Cdh15 (Bhalla et al., 2008), in addition to
420 regulating CAM modulators such as Slc3a2 (Feral et al., 2005). CAMs play a critical role in
421 neuronal migration, synaptogenesis, and neurite outgrowth/branching during development,
422 plasticity, and disease (Biederer et al., 2017; Maness and Schachner, 2007; Missler et al., 2012;
423 de Wit and Ghosh, 2016). Notably, six proteins were detected as significantly changing in
424 common between the pSILAC and pSILAC-AHA datasets, such as L1cam, reinforcing that their
425 regulation by Ebp1 is direct and protein synthesis specific, rather than a secondary effect.
426 Collectively, gene ontology (GO) analysis of Ebp1 regulated proteins (**Figure S14D**)
427 demonstrated cell adhesion ($P<0.01$; biological process) and secretory granule ($P<0.01$; cellular
428 component) pathways as the most significantly impacted. Some of Ebp1-regulated proteins are
429 predominantly locally translated in neurites (Zappulo et al., 2017), such as Cnn2, Mcam, and
430 Sparc (**Figure S14E**). A schematic summarizing the impact of Ebp1 depletion on proteins with a
431 known neuronal function is shown in **Figures 6E and S14F**, implicating Ebp1 in the regulation
432 of cell-cell adhesion, synaptogenesis, and neurite outgrowth in neurons.

433 Given that Ebp1 influences the neurogenic proteome associated with neuronal
434 processes in Neuro2a cells, and is enriched in early-born neocortical NSCs, we next sought to
435 visualize native Ebp1 expression during the progressive differentiation of early-born neocortical
436 NSCs into post-mitotic pyramidal neurons undergoing neurite outgrowth. Primary cultures were
437 prepared from the E12.5 neocortex of *Nex:Cre;Ai9* mice (Turko et al., 2018), which label post-
438 mitotic pyramidal neurons with tdTomato by activation of the *Nex* locus, followed by
439 immunohistochemical analysis of Ebp1 expression at div 0, 2, 4, and 5 (**Figure 6F**). Ebp1 is
440 enriched in cytoplasmic foci colocalizing with Nestin labeling in NSCs at div 0, in addition to the
441 earliest differentiating Nex-positive cells. Cytoplasmic Ebp1 expression persists in differentiating
442 Nex-positive neurons and extends into growing neurites, albeit at overall lower levels with
443 differentiation. A decreasing enrichment pattern in dissociated cell culture reinforces *Ebp1*
444 mRNA (**Figures 2A-B**) and protein (**Figures 2B-C and S4**) levels in neocortex tissue,
445 suggesting that the trajectory of decreased Ebp1 enrichment during neuronal maturation may be
446 cell autonomous, rather than in response to a signal in the tissue environment. At div 5, puncta
447 of Ebp1 expression in neurites and growth cones is particularly apparent with further
448 magnification, including the most distal aspects of extending processes. Ebp1 localization to
449 neuronal processes and growth cones is reinforced by prior cell culture studies (Ko et al., 2017;

450 Kwon and Ahn, 2011), which observed enhancement of axon regeneration after injury with Ebp1
451 overexpression in hippocampal slice culture. Taken together, these findings correlate with
452 Ebp1's maintenance of neurogenic, neurite, and synaptic proteostasis. Therefore, we
453 hypothesized Ebp1 regulates neurite outgrowth in early-born neocortical NSCs.

454

455 **Ebp1 regulates neurite branching of early-born neocortical neurons *in vivo***

456 Since we observed particularly high Ebp1 enrichment in early-born NSCs of the developing
457 neocortex (**Figures 2A-C and S4**), we next sought to study the effect of early Ebp1 depletion in
458 NSCs during their maturation into neocortical neurons *in vivo*. *In utero* electroporation (IUE) of a
459 *shEbp1* knockdown plasmid along with a CAG-GFP transfection reporter at E12 was compared
460 to scrambled shRNA control, followed by analysis at E16 during initial neurite outgrowth (**Figure**
461 **7A**). Analysis of GFP signal in coronal sections of the E16 neocortex demonstrated increased
462 branching of neuronal processes in *shEbp1* conditions compared to control, as normal
463 pyramidal neuron projections include a single unbranched axon extending towards basal white
464 matter (WM) tracts, along with an apical dendrite oriented towards the pial surface. Tracing the
465 morphology of transfected neurons (**Figure 7B**) highlighted the impact of Ebp1 depletion on
466 neurite outgrowth at various neurite lengths, with Sholl analysis (**Figures 7C-D**) demonstrating a
467 significantly increased branch number in *shEbp1* conditions – an approximately two-fold
468 increase for proximal segments (**Figure 7C**). Importantly, this increased branching phenotype
469 was rescued by co-electroporation of an Ebp1 overexpression plasmid (*oeEbp1*) along with
470 *shEbp1*, with neuronal morphology tracing and branching analysis quantified as
471 indistinguishable from control conditions.

472 These findings reinforce the impact of Ebp1 on neurite outgrowth during neocortical NSC
473 maturation in neurons, indicating that Ebp1 constrains the overproduction of neuronal processes,
474 possibly through its maintenance of neurite associated proteostasis.

475

476 **DISCUSSION**

477 Taken together, this study analyzes the architecture of protein synthesis in the developing
478 neocortex at high resolution, positioning Ebp1 among 60S TE cofactors to fine-tune neuronal
479 proteostasis in the molecular specification of morphology during neural stem cell differentiation.
480 With a multidisciplinary approach, we demonstrate that Ebp1 is a chief component – rather than
481 a niche regulator – of the protein synthesis machinery in neocortical development. Ebp1
482 expression is cell-type and temporally specific, with enrichment in the early-born neural stem
483 cell pool, in direct proportion to the transient abundance of ribosomal complexes at this

484 developmental stage. Therefore, Ebp1 is well positioned to shift the balance of proteostasis
485 control on the ribosome surface.

486 Transcriptional control has been the principal focus in the analysis of gene expression
487 during neocortical neurogenesis (Lein et al., 2017; Silbereis et al., 2016). Recent excellent work
488 has advanced the resolution of this analysis to the single-cell level, with an emerging map of
489 neocortical neural stem cell transcriptional programming coming into focus (Oberst et al., 2019;
490 Telley et al., 2019). However, while these studies have assigned transcriptional signatures to
491 cell subtypes, they also strongly suggest that generic gene expression programs are refined by
492 successive layers of regulation (Cadwell et al., 2019), such as post-transcriptional mechanisms
493 and environmental signals. Neocortical neurogenesis hinges on spatiotemporal gene expression
494 (DeBoer et al., 2013; Kwan et al., 2012; Molyneaux et al., 2007), with the ribosome poised at
495 the final essential step (Kraushar et al., 2016) for precisely timed and targeted protein synthesis
496 (Hanus and Schuman, 2013; Holt and Schuman, 2013; Jung et al., 2014). By visualizing
497 neocortical protein synthesis at near-atomic resolution, we find that the 60S TE is a locus of
498 control in neurogenic gene expression.

499 The interaction of 60S TE cofactors exists in a dynamic equilibrium, competing for a
500 common binding surface to sculpt protein synthesized by a dynamic macromolecular machine
501 (Balchin et al., 2016; Deuerling et al., 2019). While the regime of *Rpl* and *Rps* mRNA expression
502 appears to follow generally elevated levels in all neocortical NSCs compared to their daughter
503 neurons (**Figure 2A**), there is a great diversity of TE cofactor expression patterns in the
504 developing neocortex (**Figure S13**). Ebp1 is particularly enriched in early-born NSCs, similar to
505 RAC subdomains, but in stark contrast to Metap2, Ltn1, or NAC. Modulating the balance of TE
506 cofactors may be a key determinant of cell type-specific proteostasis, gatekeepers at the very
507 moment a nascent protein emerges from the tunnel.

508 Our data indicate that Ebp1 participates in high occupancy binding with strong affinity to
509 the 60S TE. This is supported by the abundance of Ebp1 available in the neocortical cytoplasm
510 relative to other TE factors, and permissive binding requirements, including both translating and
511 non-translating ribosomes. Whether Ebp1's role in active and inactive complexes is linked or
512 distinct remains unclear; for example, Ebp1 binding may protect a reserve of inactive, dormant
513 ribosomes available to participate in translation. Ebp1's potential interaction with nascent
514 peptide chain and/or recruitment of other ribosome cofactors remains to be established. Since
515 our *ex vivo* cryo-EM analysis of native Ebp1•ribosome complexes includes ribosomes engaging
516 with the entire translated proteome, nascent chain density is highly fragmented in the tunnel,
517 and lacking entirely at the TE vestibule, secondary to heterogeneity intrinsic in the data. Future

518 studies in a more homogenous system will be required to interpret potential Ebp1-nascent chain
519 interactions at high resolution.

520 The neuronal proteins most impacted by Ebp1 are in cell adhesion, synaptogenic,
521 neuronal migration, and neurite outgrowth pathways, with neocortical Ebp1 knockdown resulting
522 in increased neurite branching. While the mechanism of how Ebp1 knockdown overstimulates
523 neurite branching is not clear, it is likely that maintaining a balance of proteins like Marcks that
524 promote neurite outgrowth (Tanabe et al., 2012; Theis et al., 2013; Weimer et al., 2009; Xu et
525 al., 2014), and Sparc that suppress synapse formation (Kucukdereli et al., 2011; López-Murcia
526 et al., 2015), is required to elaborate appropriate projections and synapses. A balance of protein
527 synthesis and degradation, such as through ubiquitin ligases (Ambrozkiwicz and Kawabe,
528 2015), is likely to be essential. Ribosomes locally translate mRNAs in neurites (Zappulo et al.,
529 2017) and synaptic compartments (Hafner et al., 2019), including both presynaptic terminals
530 and postsynaptic dendritic spines, providing an immediate and dynamic supply of proteins for
531 synaptic activity and plasticity. Notably, many of the proteins impacted by Ebp1 knockdown are
532 membrane or vesicle associated proteins (**Fig. S14D**), and thus Ebp1 may potentially play a role
533 analogous to NAC in coordinating the subcellular targeting of neuronal protein synthesis
534 (Gamerding et al., 2015). The enrichment of Ebp1 along with actively translating ribosomes at
535 the synapse would allow for local proteostasis control, and the subcellular action of
536 Ebp1•ribosome complexes is an interesting direction for future study.

537 Finally, it will be important to delineate the ribosomal and extra-ribosomal mechanisms
538 of Ebp1 function in the nervous system. Ebp1 deletion restricts growth in mice (Zhang et al.,
539 2008) and *Arabidopsis* (Horváth et al., 2006; Li et al., 2018). Ebp1 influences gene expression
540 in stem cells of the neuroectoderm lineage (Somanath et al., 2018), and helps specify the neural
541 border zone, neural crest, and cranial placode domains in *Xenopus* (Neilson et al., 2017). In
542 *Drosophila*, overexpression of the Ebp1 homolog CG10576 results in ectopic neurogenic-like
543 patches in muscle tissue (Bidet et al., 2003). The nervous system is uniquely sensitive to
544 fluctuations in its proteome, and likewise particularly susceptible to abnormal proteostasis
545 pathology in neurodevelopmental and neurodegenerative disease (Hipp et al., 2019; Jayaraj et
546 al., 2019; Sossin and Costa-Mattioli, 2018). How Ebp1 and the dynamic architecture of
547 ribosomal complexes at the 60S TE contribute to both nervous system development and
548 dysfunction as gatekeepers of functional gene expression is an interesting direction for future
549 study.

550

551

552 **ACKNOWLEDGMENTS**

553 We apologize to the authors of key papers who we could not cite due to space limitations. We
554 are particularly grateful to Rainer Nikolay, Anett Unbehaun, Tatyana Budkevich, Justus Loerke,
555 and Dennis Kwiatkowski for fruitful scientific discussions and technical support. We thank
556 Ludovic Telley (Denis Jabaudon lab) for technical support with the scRNAseq data. M.L.K.
557 would like to thank James Millonig and Daniel Mehan of the Rutgers-RWJMS-Princeton
558 Universities MD/PhD Program for encouraging this international postdoctoral research project
559 during his training. M.L.K. was supported by an EMBO Long-Term Postdoctoral Fellowship
560 (190-2016), Alexander von Humboldt Foundation Postdoctoral Fellowship, and a NIH NRSA
561 F30 MD/PhD Fellowship (1F30MH106220). The study was further supported by funding from
562 the Deutsche Forschungsgemeinschaft (DFG; SFB-740) to C.M.T.S. and T.M. High resolution
563 cryo-electron microscopy data collection was performed with support from an iNEXT Cryo-
564 electron Microscopy Instrumentation Grant (PID:2227; EMBL Heidelberg, special thanks to Wim
565 Hagen and Felix Weis), and an Instruct Structural Biology Pilot R&D Grant (APPID: 2016-232;
566 Diamond Light Source Oxfordshire, special thanks to Jason van Rooyen) awarded to M.L.K.
567 Funding from a NeuroCure/Charité Cluster of Excellence Innovation Project Grant awarded to
568 M.L.K. and C.M.T.S. further supported this work. This work was also supported by funding from
569 the German Research Foundation (Grant #EXC 257 to I.V.).

570

571 **AUTHOR CONTRIBUTIONS**

572 M.L.K. designed and conducted the study. C.M.T.S. supervised the study, with contributions
573 from M.S., I.V., V.T., T.M., M.L., and D.B. M.C.A. and E.B. performed *in utero* electroporation
574 experiments. P.T. and T.S. (Schaub) prepared pSILAC and BONCAT samples. K.I. and C.H.V.-
575 V. processed, measured, and analyzed mass spectrometry samples. U.Z. processed and
576 measured RNA sequencing samples. D.H. further analyzed mass spectrometry and RNA
577 sequencing data. M.L.K. prepared, and J.B. froze cryo-electron microscopy samples. J.B. and
578 T.M. performed initial cryo-electron microscopy data collection. F.K. and M.L.K. performed
579 multiparticle cryo-electron microscopy sorting and refinement, T.S. (Sprink) modeled the data,
580 and C.M.T.S. and M.L.K. interpreted the data. A.M.W. processed and imaged samples for
581 immuno-electron microscopy. Primary cell culture and immunocytochemistry was performed by
582 P.T. Tissue preparation and immunohistochemistry was performed by M.L.K. H.Y. cloned and
583 purified recombinant Ebp1-His. M.-R.R. provided mice for a pilot study and expertise. M.L.K.
584 wrote the manuscript and prepared the figures, with valuable input from all authors.

585

586 **DECLARATION OF INTERESTS**

587 The authors declare no competing interests.

588

589 **FIGURE LEGENDS**

590 **Figure 1. Ebp1 is nearly stoichiometric to ribosomal proteins in translating ribosomes**
591 **during neocortical development**

592 **(A)** Schematic of the experimental system to measure the architecture of active protein
593 synthesis (polysomal ribosomes) from the *ex vivo* neocortex across embryonic (E12.5, E14,
594 E15.5, E17) and early postnatal (P0) neurogenesis. See text for details. **(B)** MS analysis of
595 neocortical polysomal complexes across development. Scatter plots compare early
596 neurogenesis E12.5 vs. each subsequent stage, demonstrating the enrichment of Ebp1 (red
597 arrow) among ribosomal proteins (RPs) of the large (Rpl, blue) and small (Rps, yellow) subunits,
598 in contrast to other translation-associated proteins (black). **(C)** Stoichiometry cluster heat maps
599 quantifying the differential enrichment of each RP (Rpl, blue; Rps, yellow), translation-
600 associated protein (black), and Ebp1 (red arrow) per developmental stage. Expression of
601 adjacent proteins on the x-axis is shown as higher (orange), lower (purple), or similar (black)
602 relative to each protein on the y-axis. Legend and histogram at top left for each stage. See also
603 **Figures S1-3.**

604

605 **Figure 2. Ebp1 expression is cell type and temporally specific in early-born NSCs, in**
606 **concert with transiently elevated ribosomal complex levels**

607 **(A)** Expression heat maps of *Ebp1* compared to averaged *Rpl* and *Rps* family mRNA
608 enrichment in scRNAseq analysis of the developing mouse neocortex derived from (Telley et al.,
609 2019). Relative expression shown for apical progenitor (AP) NSCs during their differentiation
610 into mature neurons (N4d) on the y-axis, corresponding to NSC birthdates E12, E13, E14, E15
611 on the x-axis. **(B)** Neocortical expression of *Ebp1* (red), *Rpl* (blue), *Rps* (yellow), and translation-
612 associated (black) genes measured in total steady state levels by RNAseq (top) and MS
613 (bottom) across developmental stages. The median expression is plotted \pm s.d. Significant
614 changes assessed by one-way ANOVA and Bonferroni corrected *post hoc* test vs. E12.5,
615 $p < 0.05$ considered significant. **(C)** Immunohistochemistry analysis of Ebp1 expression in
616 coronal sections of the developing neocortex ventricular zone (VZ) populated by NSCs, and
617 cortical plate (CP) populated by maturing neurons. Early-born NSCs generate lower layer (LL)
618 neurons, while later-born NSCs generate upper layer (UL) neurons. White matter (WM) axons,
619 nuclear DAPI staining in grey. Zoomed images (inset) correspond to the VZ and leading-edge of

620 the CP at each stage, with Ebp1 (red) and DAPI (blue) labeling. Similar results were obtained
621 with the Ebp1^{NT} antibody (**Figure S4**). **(D)** Analytic quantitative sucrose density gradient
622 ultracentrifugation of A260 normalized neocortical lysates measuring the relative abundance of
623 ribosomal subunits, 80S ribosomes, and polysomes. A260 curves plotted as mean \pm s.d. across
624 replicates for each stage. **(E)** Curves from (D) subdivided for area-under-the-curve (AUC)
625 analysis as shown (grey boxes) calculated by a Reimann sum, and graphed as mean \pm s.d. with
626 significance testing by one-way ANOVA and Dunnett's *post hoc* test vs. E12.5. * $p < 0.05$;
627 ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. **(F)** Western blot analysis of Ebp1 enrichment in total
628 neocortical lysates, in comparison to full-length histidine-tagged Ebp1 (Ebp1-His). Full blots are
629 shown in **Figures S5A-B**. **(G)** Western blot analysis of Ebp1 enrichment in pooled extra-
630 ribosomal (free), 80S, and polysome fractions (**Figures S5C-D**).

631

632 **Figure 3. Ebp1 binds the 60S subunit with high affinity in the cytoplasm of neocortical**
633 **NSCs and neurons**

634 **(A)** Western blot analysis of recombinant Ebp1-His binding to purified rabbit reticulocyte lysate
635 (RRL) 40S, 60S, and reconstituted 80S in the pellet (pel) compared to unbound in the sucrose
636 cushion supernatant (sup). Ebp1 signal shown compared to 60S RP (uL30) and 40S RP (uS7)
637 markers. Binding assay with mouse neocortical 40S and 60S shown in **Figure S6A**. **(B)** Relative
638 binding affinity of escalating Ebp1-His concentrations (15.6-500nM) to 100nM 60S measured by
639 pelleting assay and Western blot analysis. Binding first detected in the pellet (P) at 62.5nM
640 (arrow), with excess Ebp1 in the supernatant (S) seen at 500nM (star) in comparison to
641 saturating signal in the pellet. **(C)** Results from (B) (white circles) plotted with an independent
642 replicate experiment (grey circles), and curve best fit to the data (red line, nonlinear least
643 squares fit, with one-site binding and Hill slope accommodation). Interpretation of binding curves
644 further described in **Figure S6B**. **(D)** Ebp1 binding dynamics assessed by pelleting assay and
645 Western blot. Binding pellet signal for (1) super-saturating levels of Ebp1-His (350nM) in the
646 presence of rabbit 60S (100nM) compared to (2) native Ebp1 in RRL (~100nM ribosomes), (3)
647 saturating Ebp1-His in RRL, and native Ebp1 in RRL translating *Luciferase* mRNA (*Luc*) with (4)
648 and without (5) cycloheximide to stall elongation. Signal for native Ebp1 (arrow) in comparison
649 to the slightly larger Ebp1-His (star). **(E)** Immuno-electron micrographs showing immunogold
650 labeling for anti-Ebp1^{NT} (black dots) in coronal sections of the neocortex at E12.5, E15.5, and
651 P0 at low (12000x) and high (30000x) magnification. Neural stem cells (NSC) and neurons (N)
652 are identified by their distinctive nuclear morphology (blue, NSC; red, N) and their localization in
653 the developing cortical layers (ventricular zone, NSC; expanding cortical plate, N). Nucleoli (n),

654 mitochondria (m, green), endoplasmic reticulum (er), cell-cell junctions (arrows; blue on NSC
655 side, red on N side). See also **Figure S7**.

656

657 **Figure 4. Structure of the neocortical ribosome with Ebp1 bound to the 60S subunit at the**
658 **peptide tunnel exit**

659 **(A)** Cryo-electron microscopy (cryo-EM) micrograph of pooled 80S and polysome complexes
660 (arrows) from P0 mouse neocortical lysates *ex vivo*. **(B)** Cryo-EM map generated by 3D
661 refinement of (A) with extra-ribosomal density (red) conforming to the crystal structure of mouse
662 Ebp1 (PDB 2V6C (Monie et al., 2007), red ribbon) on the 60S surface (rRNA, dark blue; RPs,
663 light blue). Ebp1 density includes the N-terminal residues (NT, black ribbon) corresponding to
664 full-length Ebp1. **(C)** Multiparticle classification and high-resolution map refinement (**Figures S8-**
665 **S10**) of both actively translating (left, classical state with A/A, pink, and P/P, green, tRNAs) and
666 non-translating (right, rotated state with eEF2, purple) ribosomal complexes. Ebp1 (red), 60S
667 rRNA (dark blue), 60S RPs (light blue), 40S rRNA (orange), 40S RPs (yellow), nascent chain
668 fragments (black). **(D)** Model of the Ebp1 (red ribbon) binding surface at the 60S peptide tunnel
669 exit, including 60S rRNA helices H24 (purple), H53 (magenta), H59 (blue), and 60S RPs eL19
670 (lime green), uL23 (olive), uL24 (forest green), uL29 (aquamarine). **(E)** Aerial view of the Ebp1
671 footprint (red outline) over the 60S peptide tunnel exit (TE), with rRNA helices and RP model
672 surfaces colored as in (D), and residues/nucleosides making electrostatic interactions with Ebp1
673 highlighted in yellow. **(F-H)** Zoomed views of the Ebp1•60S model, colored as in (D-E), with
674 binding residues/nucleosides likewise highlighted in yellow.

675

676 **Figure 5. The Ebp1 insert domain utilizes a conserved H59 latch mechanism for 60S**
677 **binding incompatible with simultaneous binding by other tunnel exit proteins**

678 **(A)** 60S rRNA H59 and H53 models corresponding to states with Ebp1 (blue) vs. without Ebp1
679 (green), adjacent to the Ebp1 (red) insert domain. See also **Figures S11A-C**. **(B)** 2D structure
680 diagram of Ebp1 3D domains adapted from (Kowalinski et al., 2007), orienting Ebp1 on the
681 ribosome surface, and highlighting the domains involved in Ebp1•60S binding (yellow). **(C)**
682 Global alignment of Ebp1, Metap2, and Arx1 demonstrate the conserved orientation of the β - α --
683 α - β insert domain (orange) for 60S binding, pita-bread β 6 fold motif (light blue) positioned over
684 the TE, and solvent-side α 4 motif (dark blue). See also **Figure S12**. **(D)** Electrostatic potential
685 maps of Ebp1, Metap2, and Arx1 oriented as in (C), and viewed from within the TE from the
686 perspective of emerging nascent chain, with 60S rRNA helices and RPs colored as in **Figure**
687 **4D**. Methionine•Zn•H₂O and Rei1 models in yellow. See also **Figure S11D**. **(E)** Schematic with

688 the mouse neocortical 60S model surface centered on the peptide tunnel exit, and the
689 overlapping footprints of known eukaryotic tunnel exit surface binding factors. See also **Figure**
690 **S13**. PDB IDs: Metap2 1KQ9 (Nonato et al., 2006), Arx1 5APN (Greber et al., 2016), Sec61
691 3J7R (Voorhees et al., 2014), Ltn1 3J92 (Shao et al., 2015), NatA 6HD7 (Knorr et al., 2019).
692 EMD IDs: RAC 6105 (Zhang et al., 2014), NAC 4938 (Gamerding et al., 2019).

693

694 **Figure 6. Ebp1 knockdown disrupts acute protein synthesis and chronic proteostasis in**
695 **neuronal cells, impacting neurite and synaptic proteins**

696 **(A)** Western blot confirmation of Ebp1 knockdown in mouse Neuro2a cells with siRNA oligos
697 targeting mouse vs. human *Ebp1* mRNA sequences, in comparison to mock transfection and
698 scrambled siRNA controls, in biological duplicate. **(B)** Schematic of the strategy to measure
699 both the chronic proteostasis and acute protein synthesis responses to Ebp1 knockdown in
700 Neuro2a cells with pSILAC and BONCAT coupled mass spectrometry. Cultures with
701 transfection of *siControl* vs. *siEbp1* were concurrently incubated with medium (purple) vs. heavy
702 (orange) SILAC amino acids, respectively, after the initiation of knockdown to label all proteins
703 synthesized while Ebp1 levels are depleted (pSILAC) over 3 days *in vitro* (div). On div 4, AHA
704 was pulsed before sample collection to label newly made proteins at the nadir of Ebp1
705 knockdown (pSILAC-AHA). **(C)** pSILAC and **(D)** pSILAC-AHA labeled protein levels with *siEbp1*
706 conditions plotted relative to *siControl* conditions. Proteins with significantly lower (orange) or
707 higher (purple) levels in *siEbp1* conditions are highlighted, while unchanged proteins are shown
708 in grey. Confirming robust knockdown, Ebp1 levels were below the MS quantification threshold
709 in *siEbp1* conditions, and thus not plotted. The threshold for significant change is set to >2-fold
710 change from control in both replicates (dotted lines). **(E)** Schematic representation of the
711 subcellular localization and function of known neuron-associated proteins significantly impacted
712 by Ebp1 depletion from (C-D). Proteins with levels promoted by Ebp1 (*siEbp1* < control) are
713 highlighted in orange, and proteins suppressed by Ebp1 (*siEbp1* > control) are highlighted in
714 purple. **(F)** Primary neuronal cultures from the E12.5 neocortex of *Nex:Cre;Ai9* mice analyzed
715 by immunocytochemistry at div 0, 2, 4, and 5 to monitor Ebp1 expression and localization in
716 Nestin-positive (cyan arrows) neural stem cells (NSCs) throughout their maturation into Nex-
717 positive (red arrows) postmitotic pyramidal neurons. Ebp1 localization in growing neurites is
718 indicated (green arrows). Zoomed images at div 5 with clustered Ebp1 foci in neurites and
719 growth cones (dotted arrows), including the leading edge of neurite protrusions (solid arrows).
720 See also **Figure S14**.

721

722 **Figure 7. Ebp1 regulates neurite branching of early-born neocortical neurons during**
723 **development *in vivo***

724 **(A)** E12 *in utero* electroporation (IUE) followed by analysis at E16, comparing *shEbp1* vs.
725 scrambled shRNA control transfection, and rescue by co-electroporation of *shEbp1* with an
726 Ebp1 overexpression plasmid (*oeEbp1*). Transfected cells are labeled by co-electroporation with
727 CAG-GFP, and analyzed in coronal sections showing the WM to pial surface (top), with
728 individual cells in each condition magnified (bottom), including labeled basally projecting axons
729 (yellow arrows). **(B)** Morphology tracing of individual GFP labeled neurons in control, *shEbp1*,
730 and rescue *sh+oeEbp1* conditions from (A). **(C)** Sholl analysis of (B), comparing branching per
731 unit distance from the soma in control (black, $n = 15$), *shEbp1* (orange, $n = 15$), and rescue
732 *sh+oeEbp1* (purple, $n = 15$) conditions. **(D)** Sum total branches of Sholl analysis in (C). Data in
733 (C) and (D) shown as mean \pm s.d. Significance in (D) assessed by one-way ANOVA with
734 Bonferroni corrected *post hoc* test vs. control (** $p < 0.01$).

735

745 **STAR★METHODS**

746 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
anti-Ebp1CT	rabbit, Abcam	ab35424
anti-Ebp1NT	rabbit, Millipore	ABE43
anti-eEF2	rabbit, Cell Signaling	2332S
anti-Gapdh	mouse, Millipore	MAB374
anti-GFP	chicken, Abcam	ab13970
anti-Map2	chicken, Millipore	AB5543
anti-Nestin	mouse, Millipore	MAB353
anti-Rpl7 (uL30)	rabbit, Abcam	ab72550
anti-Rps5 (uS7)	mouse, Santa Cruz	sc-390935
Gold-conjugated-anti-rabbit IgG	goat, Nanoprobes	2003
HRP-anti-rabbit-Light Chain	mouse, Dianova	211-032-171
HRP-anti-mouse-Heavy Chain	goat, Millipore	71045
488-anti-chicken	donkey, Jackson ImmunoResearch	703-545-155
488-anti-rabbit	donkey, Jackson ImmunoResearch	711-545-152
594-anti-mouse	donkey, Jackson ImmunoResearch	715-585-150
647-anti-chicken	donkey, Jackson ImmunoResearch	703-605-155

747

Recombinant DNA		
Control siRNA (non-targeting)	Dharmacon	D-001810-10-05
<i>Homo sapiens</i> siPa2g4 siRNA	Dharmacon	SMARTpool ON-TARGETplus #5036, #L008860-00-0005
<i>Luciferase</i> reporter pSPUTK-luc+	(Rakwalska and Rospert, 2004)	
<i>Mus musculus</i> Pa2g4 cDNA	Source BioScience	IRAVp968A0190D
<i>Mus musculus</i> shPa2g4 shRNA	Sigma Mission	TRCN0000236756, RefSeq NM_011119
<i>Mus musculus</i> siPa2g4 siRNA	Dharmacon	SMARTpool ON-TARGETplus #18813, #L-042883-01-0005
pCAGIG (pCAG-IRES-GFP)	(Ambrozkiwicz et al., 2018)	
pET-28a(+)	Novagen	69864-3
pSuper-Neo-GFP	OligoEngine	VEC-pBS-0006

748

pSuper-Neo-GFP-sh-Scramble	(Ambrozkiwicz et al., 2018)	
----------------------------	-----------------------------	--

Chemicals, Peptides, and Recombinant Proteins		
Acetonitrile	CHEMSOLUTE	2697
Acetonitrile (Alkyne-agarose enrichment)	Sigma-Aldrich	271004
Acetylated Bovine Serum Albumin (BSA-c)	Aurion	900.022
Agarose	Sigma-Aldrich	A9539
Alkyne-agarose beads	Click-Chemistry Tools	1033
Ammonium bicarbonate (ABC)	Sigma-Aldrich	9830
B27	Thermo Fisher	17504044
Bovine serum albumin	Sigma-Aldrich	A3294
Copper(II) sulfate pentahydrate	Sigma-Aldrich	209198
Cycloheximide	Sigma-Aldrich	C7698
DAPI (Nuc Blue, Molecular Probes)	Invitrogen	R37606
Dithiothreitol (DTT)	Sigma-Aldrich/Roche	DTT-RO
Dithiothreitol (DTT) (Alkyne agarose enrichment)	BioMol	40010.25
DMEM	Gibco	31966047
DMEM - methionine free	Sigma-Aldrich	D0422
Ebp1 recombinant protein	mouse, this paper	
EcoRI restriction enzyme	New England Biolabs	R0101
Ethylenediaminetetraacetic acid (EDTA)	Sigma-Aldrich	E-5143
Epoxy embedding medium Epon 812	Sigma-Aldrich	45345
Ethanol	J.T. Baker	8025
Fetal Bovine Serum	Gibco	10270106
Fetal Bovine Serum - dialyzed	PAN-Biotech	P30-2102
Fluoromount-G	Southern Biotech	0100-01
Formic acid	Sigma-Aldrich	33015
Glutamax	Thermo Fisher	35050-038
Glutaraldehyde	Sigma-Aldrich	G5882
HEPES	Sigma-Aldrich	391338
IGEPAL CA-630	Sigma-Aldrich	I8896
Iodoacetamide (IAA)	Sigma-Aldrich	I6125
KCl	Roth	6781.1

L-Arginine:HCl (13C6, 99%; 15N4, 99%) (Arg-10)	Cambridge Isotope Labs	CNLM-539
L-Arginine:HCl (13C6, 99%) (Arg-6)	Cambridge Isotope Labs	CLM-2265
L-azidohomoalaine (AHA)	Anaspec	AS-63669
L-Lysine:2HCl (13C6, 99%; 15N2, 99%) (Lys-8)	Cambridge Isotope Labs	CNLM-291
L-Lysine:2HCl (4,4,5,5-D4, 96-98%) (Lys-4)	Cambridge Isotope Labs	DLM-2640
Lead citrate	Fluka	GA10655
Lipofectamine RNAiMAX Transfection Reagent	Thermo Fisher	13778075
Liquid ethane		
Lysyl endopeptidase (LysC)	Wako	12505061
Methanol	Merck Millipore	1.06009.2511
MgCl ₂	Ambion	AM9530G
Nanogold silver enhancement	Nanoprobes	
Neurobasal medium	Thermo Fisher	21103049
Neurobasal custom medium (-met / -arg / -lys)	Gibco	041-96642M
Normal goat serum	PAN-Biotech	P30-1002
Osmium tetroxide (OsO ₄)	Polysciences	0972A
Papain	Sigma-Aldrich	P4762
Paraformaldehyde (PFA)	Sigma-Aldrich	P6148
Penicillin-Streptomycin	Thermo Fisher	15140-122
Poly-L-Lysine	Sigma-Aldrich	P1399
Protease Inhibitor Cocktail Set III, EDTA-Free	Calbiochem/Sigma-Aldrich	539134
Protease Inhibitor cOmplete EDTA-free	Roche	5056489001
Rabbit reticulocyte lysate nuclease-treated	Promega	L4960
ReproSil-Pur C18-AQ 3-µm resin	Dr. Maisch GmbH	r13.aq
RNasin Plus RNase inhibitor	Promega	N2615
SeeBlue Plus2 Prestained Protein Ladder	Thermo Fisher	LC5925
SILAC-DMEM	PAN-Biotech	P04-02505
Sodium borohydride (NaBH ₄)	Sigma-Aldrich	452882
Sodium deoxycholate	Sigma-Aldrich	D6750
Sodium dodecyl sulfate (SDS)	Roth	2326.1
Sodium L-ascorbate	Sigma-Aldrich	A7631
Spermidine•3HCl	Sigma-Aldrich	S2501

Spermine•4HCl	Sigma-Aldrich	S2876
Sucrose	Sigma-Aldrich	S0389
SUPERase-In RNase inhibitor	ThermoFisher	AM2694
Tris-HCl	Roth	9090.3
Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA)	Sigma-Aldrich	762342
Triton-X 100	Sigma-Aldrich	T8787
TRIzol-LS	Invitrogen	10296010
Trypsin	Promega	V511A
Tween	Sigma-Aldrich	P9416
Uranyl acetate	Merck	1.08473.0100
Urea	Sigma-Aldrich	51459
Vectashield Antifade Mounting Medium	Vector Laboratories	H-1000

749

Critical Commercial Assays		
Amersham ECL Prime	GE Healthcare	RPN2232
TruSeq Stranded mRNA kit	Illumina	20020594

750

Deposited Data		
Neocortex total input, 80S, polysome mass spectrometry	this paper	ProteomeXchange PXD014841 Username: reviewer22269@ebi.ac.uk Password: 8Vro0crd
Neuro2a pSILAC/AHA mass spectrometry	this paper	ProteomeXchange PXD014740 Username: reviewer84416@ebi.ac.uk Password: BwylH8kX
Neocortex total input lysate RNA sequencing	this paper	NIH GEO GSE136199 Password: cbkfgscwvlszfab
Cryo-EM maps of the P0 neocortical ribosome	this paper	Worldwide Protein Data Bank EMD-10321
Atomic model of the P0 neocortical 60S•Ebp1 complex	this paper	Worldwide Protein Data Bank PDB ID 6SWA

751

Experimental Models: Cell Lines		
Neuro2a	Thermo Fisher	RRID: CVCL_0470

752

753

Experimental Models: Organisms/Strains		
CD1 WT	Charles River	
<i>Nex:Cre;Ai9</i>	(Turko et al., 2018)	
NMRI WT	Charles River and Janvier Labs	
Software and Algorithms		
Andromeda	(Cox et al., 2011)	
APBS	(Jurrus et al., 2018)	
CCP4Interface CONTACT	(Potterton et al., 2003)	
CLUSTAL Omega MSA (1.2.4)	(Sievers et al., 2011)	https://www.ebi.ac.uk/Tools/msa/clustalo/
COOT	(Emsley and Cowtan, 2004)	
CTFfind4	(Mindell and Grigorieff, 2003)	
DAVID	(Huang et al., 2009)	
EMAN2	(Tang et al., 2007)	
EPU	FEI Company	
ERRASER	(Chou et al., 2013)	
FIJI	(Schindelin et al., 2012)	https://fiji.sc/
GraphPad Prism 7	GraphPad Software Inc	https://www.graphpad.com/
IBAQ	(Schwanhäusser et al., 2011)	
Illustrator	Adobe Creative Cloud	
Image stitching plugin (FIJI)	(Preibisch et al., 2009)	
Leginon	(Carragher et al., 2000; Suloway et al., 2005)	
LFQ	(Cox et al., 2014)	
MaxQuant	(Cox and Mann, 2008)	
MolProbity	(Chen et al., 2010)	
Morpheus		https://software.broadinstitute.org/morpheus
MotionCor2	(Zheng et al., 2017)	
Neurite Tracer plugin (FIJI)	(Longair et al., 2011)	
Perseus	(Tyanova et al., 2016)	
PHENIX	(Adams et al., 2010)	
Photoshop	Adobe Creative Cloud	
Sholl analysis plugin (FIJI)	(Ferreira et al., 2014)	
SPHIRE/SPARX	(Moriya et al., 2017)	

SPIDER	(Frank et al., 1996)	
STAR	(Dobin et al., 2013)	
UCSF Chimera	(Pettersen et al., 2004)	
UCSF ChimeraX	(Goddard et al., 2018)	

754

Primers		
Ebp1-His forward (recombinant protein)	Eurofins	5'AATTCCATGGGCCACCA TCACCATCACCATTTCGGG CGAGGACGAGCAAC3'
Ebp1-His reverse (recombinant protein)	Eurofins	5'TTAAGGATCCTTAGTCC CCAGCTTCATTTTCTTC3'
Ebp1-HA forward (overexpression plasmid)	Eurofins	5'gtctcatcattttggcaaagATGT ACCCATACGATGTTCCAG ATTACGCTTCGGGCGAAG ACGAG3'
Ebp1-HA reverse (overexpression plasmid)	Eurofins	5'cgcccgcatatcctcgaggTCA GTCCCAGCTCCATT3'

755

756

CONTACT FOR REAGENT AND RESOURCE SHARING

757 Further information and requests for reagents may be directed to and will be fulfilled by the Lead

758 Contact, christian.spahn@charite.de (C.M.T.S.).

759

760

EXPERIMENTAL MODEL AND SUBJECT DETAILS

761

Mice

762 All experiments and associated procedures involving animals in this study were conducted in

763 compliance with the welfare guidelines of the Landesamt für Gesundheit und Soziales

764 (LAGeSo) Berlin and Charité Universitätsmedizin Berlin under certified protocols (Spahn Lab:

765 T0267/15; Vida Lab: T0215/11; Tarabykin Lab: G00206/16, G0054/19), and the Rutgers-Robert

766 Wood Johnson Medical School Institutional Animal Care and Use Committee (IACUC) (Rasin

767 Lab: I12-065-10). Mice were utilized in the embryonic (E12.5, E14, E15.5, E17) and early post-

768 natal (P0) period, inclusive of both sexes in each litter without discrimination, towards the aim of

769 studying common developmental mechanisms. Timed pregnant wild-type (WT) CD-1 mice were

770 obtained from the Charles River Company and utilized for all experiments, with two exceptions:

771 (1) for primary neocortical cell cultures and immunocytochemistry (**Figure 6F**), homozygous

772 *Nex:Cre* females (C57BL/6) were crossed with hemizygous *Ai9* males (C57BL/6J) to produce

773 *Nex:Cre;Ai9* mice as described previously (Turko et al., 2018), labeling post-mitotic

774 glutamatergic neocortical neurons with tdTomato (protocol T0215/11); (2) for *in utero*

775 electroporation (**Figures 7A-D**), NMRI WT (Charles River and Janvier Labs
776 RRID:IMSR_TAC:nmri) mice were utilized (protocols G00206/16, G0054/19).

777

778 **Cell lines**

779 Mouse neuroblastoma Neuro2a cells were obtained from Thermo Fisher (RRID: CVCL_0470)
780 for pulsed stable isotope labeling by amino acids in cell culture (pSILAC) (Schwanhäusser et al.,
781 2009) and bioorthogonal noncanonical amino acid tagging (BONCAT) (Dieterich et al., 2006)
782 coupled mass spectrometry experiments.

783

784 **METHOD DETAILS**

785 **Neocortex dissection and lysis**

786 For all experiments, embryonic (E12.5, E14, E15.5, E17) and postnatal (P0) mouse neocortices
787 were dissected in a 4°C room in ice-cold phosphate buffered saline (PBS; ThermoFisher
788 #14040133), frozen as tissue pellets in 1.5mL tubes on dry ice, and stored at -80°C. Once
789 sufficient stocks of tissue were generated, each experiment was performed in biological
790 replicates, such that each replicate incorporated an equivalent number of neocortices pooled
791 from distinct litters of mice to meet the input requirements. Frozen tissue pellets were gently
792 lysed by cryogenic grinding on ice using a P1000 tip in 1.5 mL tubes, similar to prior studies
793 (Kraushar et al., 2014, 2015), but with the following lysis buffer: 20 mM HEPES, 100 mM KCl,
794 10 mM MgCl₂, pH 7.4, supplemented with 20 mM Dithiothreitol (DTT), 0.04 mM Spermine,
795 0.5 mM Spermidine, 1x Protease Inhibitor cOmplete EDTA-free (Roche #05056489001),
796 200 U/mL SUPERase-In RNase inhibitor (ThermoFisher #AM2694), 0.3% v/v IGEPAL CA-630
797 detergent (Sigma #I8896). Tissue lysates were clarified of membranes to post-nuclear, post-
798 mitochondrial supernatants by centrifugation at 16100g for 10 minutes at 4°C with a benchtop
799 centrifuge, and directly applied to downstream analysis. Ribosomal content was estimated by
800 A260 optical density units (ODU) with a NanoDrop 1000 Spectrophotometer. Two neocortical
801 hemispheres (one brain) yields ~ 2 ODU at P0, 1 ODU at E15.5, and 0.5 ODU at E12.5.

802

803 **Sucrose density gradient ultracentrifugation fractionation**

804 Sucrose density gradients were prepared in Beckman Coulter Ultra-Clear Tubes; #344057 for
805 preparative 5 mL 10-50% gradients (for mass spectrometry, western blot), #344060 for
806 quantitative/analytic 14 mL 5-45% gradients. Base buffer consisted of 20 mM HEPES, 100 mM
807 KCl, 10 mM MgCl₂, 20 mM Dithiothreitol (DTT), 0.04 mM Spermine, 0.5 mM Spermidine, 1x
808 Protease Inhibitor cOmplete EDTA-free (Roche #05056489001), 20 U/mL SUPERase-In RNase

809 inhibitor (ThermoFisher #AM2694), pH 7.4, prepared with either 5 & 45% or 10 & 50% sucrose
810 w/v. Overlaid 5 & 45% or 10 & 50% sucrose-buffer solutions were mixed to linearized gradients
811 with a BioComp Gradient Master 107ip. Neocortical lysates were balanced to equivalent ODU
812 and volume across samples for comparison in analytic gradients, with a minimum of 3 ODU
813 required for each biological replicate in each experiment. Lysates were overlaid on gradients
814 pre-cooled to 4°C. 5-45% gradients were centrifuged in a SW40 rotor (Beckman Coulter) for
815 5 hrs, 4°C, 25000 rpm; 10-50% gradients were centrifuged in a SW55 rotor (Beckman Coulter)
816 for 1hr, 4°C, 37000 rpm. Gradients were fractionated using a BioComp Piston Gradient
817 Fractionator and Pharmacia LKB SuperFrac, with real-time A260 measurement by an LKB
818 22238 Uvicord SII UV detector recorded using an ADC-16 PicoLogger and associated
819 PicoLogger software. Collected samples were stored at -80°C for downstream analysis. Notably,
820 with the gentle lysis technique described in the above Methods (0.3% v/v IGEPAL CA-630
821 detergent), only cytoplasmic mature ribosomal subunits and complexes were measured and
822 fractionated. Analytic gradient area-under-the-curve analysis for 40S-60S, 80S, and polysome
823 peaks was calculated with a Reimann sum, and significance testing by ANOVA with Dunnett's
824 *post hoc* test performed in GraphPad Prism software ([https://www.graphpad.com/scientific-
825 software/prism/](https://www.graphpad.com/scientific-software/prism/)), with $p < 0.05$ considered significant.

826

827 **Mass spectrometry analysis of total input, 80S, and polysomes**

828 *Sample preparation.* Samples were prepared in biological triplicate, with each sample including
829 mass spectrometry (MS) analysis of total input neocortex lysate, and purified corresponding 80S
830 and polysomes by preparative 10-50% sucrose density gradient ultracentrifugation (**Figure S1**)
831 as described in the Methods above. Notably, with the lysis method described above, only post-
832 nuclear, post-mitochondrial, cytoplasmic mature ribosomal subunits and complexes were
833 measured and fractionated. Each biological replicate incorporated 12 neocortices (6 animals) at
834 P0, 18 neocortices (9 animals) at E17, 24 neocortices (12 animals) at E15.5, 30 neocortices (15
835 animals) at E14, and 36 neocortices (18 animals) at E12.5. Tissues were pooled such that each
836 biological replicate included an equal number of neocortices derived from multiple distinct litters
837 of embryos/pups.

838 Samples were processed essentially as described previously (Imami et al., 2018). Briefly,
839 proteins were precipitated from input lysates, or directly from sucrose gradient fractions, with
840 ethanol, then resuspended in 50 μ L of 8 M urea and 0.1 M Tris-HCl, pH 8. Proteins were then
841 reduced with 10 mM dithiothreitol (DTT) at room temperature for 30 min, and alkylated with
842 50 mM iodoacetamide (IAA) at room temperature for 30 min in the dark room. Protein digestion

843 was first performed with lysyl endopeptidase (LysC) (Wako) at a protein-to-LysC ratio of 100:1
844 (w/w) at room temperature for 3 hrs. Then, the sample solution was diluted to final concentration
845 of 2 M urea with 50 mM ammonium bicarbonate (ABC). Trypsin (Promega) digestion was
846 performed at a protein-to-trypsin ratio of 100:1 (w/w) under constant agitation at room
847 temperature for 16 hrs. Peptides were desalted with C18 Stage tips (Rappsilber et al., 2007)
848 prior to LC-MS/MS analysis.

849

850 *NanoLC-MS/MS analysis.* Measurements were performed essentially as described previously
851 with minor adjustments. Reversed-phase liquid chromatography was performed by employing
852 an EASY nLC 1000 or 1200 (Thermo Fisher Scientific) using self-made fritless C18
853 microcolumns (Ishihama et al., 2002) (75 μ m ID packed with ReproSil-Pur C18-AQ 3- μ m resin,
854 Dr. Maisch GmbH) connected on-line to the electrospray ion source (Proxeon) of a Q Exactive
855 plus (Thermo Fisher Scientific). The mobile phases consisted of (A) 0.1% formic acid and 5%
856 acetonitrile and (B) 0.1% formic acid and 80% acetonitrile. Peptides were eluted from the
857 analytical column at a flow rate of 200 nL/min by altering the gradient: 5-6% B in 2 min, 6-8% B
858 in 18 min, 8-20% B in 80 min, 20-33% in 80 min, 33-45% B in 20 min, 45-60% B in 2 min, 60-
859 95% B in 1 min. The Q Exactive plus instrument was operated in the data dependent mode with
860 a full scan in the Orbitrap followed by top 10 MS/MS scans using higher-energy collision
861 dissociation (HCD). The full scans were performed with a resolution of 70,000, a target value of
862 3×10^6 ions and a maximum injection time of 20ms. The MS/MS scans were performed with a
863 17,500 resolution, a 1×10^6 target value, and a 60 ms maximum injection time. The isolation
864 window was set to 2 and normalized collision energy was 26. Ions with an unassigned charge
865 state and singly charged ions were rejected. Former target ions selected for MS/MS were
866 dynamically excluded for 30 s.

867

868 *Processing of mass spectrometry data.* All raw data were analyzed and processed by
869 MaxQuant (v1.5.1.2) (Cox and Mann, 2008). Default settings were kept except that 'match
870 between runs' was turned on. Search parameters included two missed cleavage sites, cysteine
871 carbamidomethyl fixed modification and variable modifications including methionine oxidation,
872 protein N-terminal acetylation and deamidation of glutamine and asparagine. The peptide mass
873 tolerance was 6ppm and the MS/MS tolerance was 20ppm. Minimal peptide length of 7 amino
874 acids was required. Database search was performed with Andromeda (Cox and Mann, 2008;
875 Cox et al., 2011) against the UniProt/SwissProt mouse database (downloaded 11/2014) with
876 common serum contaminants and enzyme sequences. The false discovery rate (FDR) was set

877 to 1% at peptide spectrum match (PSM) level and at protein level. Protein quantification across
878 samples was performed using the label-free quantification (LFQ) algorithm (Cox et al., 2014). A
879 minimum peptide count required for LFQ protein quantification was set to two. Only proteins
880 quantified in at least two out of the three biological replicates were considered for further
881 analyses. LFQ intensities were log₂-transformed and imputation for missing values was
882 performed in Perseus (Tyanova et al., 2016) software based on a simulated normal distribution
883 to represent low abundance values below the noise level (generated at 1.8 standard deviations
884 of the total intensity distribution, subtracted from the mean, and a width of 0.3 standard
885 deviations). Hierarchical clustering of the input, 80S, and polysome data for ANOVA significant
886 proteins (FDR = 0.05) in Morpheus (<https://software.broadinstitute.org/morpheus>) is shown in
887 **Figure S2**, with clustering based on one minus Pearson correlation using an average linkage
888 method. Proteins whose abundance differed significantly among developmental stages were
889 identified by multiple sample ANOVA test at a permutation-based FDR cutoff of 0.05. Log₂ LFQ
890 intensities were further z-transformed for only significantly changed proteins.

891 To estimate protein abundance within input and ribosome fractions, the intensity-based
892 absolute quantification (iBAQ) algorithm was used, which computes the sum of all the peptides'
893 intensities divided by the number of theoretically observable peptides. Stoichiometry matrices
894 (**Figures 1C and S3C-D**) compared the median iBAQ value across replicates for each gene,
895 fraction, and time point, plotting the log₂ transformed ratio for every pair of proteins as a heat
896 map. Mass spectrometry proteomics data have been deposited to the ProteomeXchange
897 Consortium (Vizcaíno et al., 2014) (<http://proteomecentral.proteomexchange.org>) via the PRIDE
898 partner repository for reviewer access, and for immediate release on publication:

899 ProteomeXchange PXD014841

900 Username: reviewer22269@ebi.ac.uk

901 Password: 8Vro0crd

902

903 **Single-cell RNA sequencing analysis derived from** (Telley et al., 2019)

904 The transcriptional birthdate and differentiation maps for individual genes (**Figures 2A and S13**)
905 were acquired from the open source website associated with (Telley et al., 2019)
906 (http://genebrowser.unige.ch/telagirdon/#query_the_atlas). Averaging the data across all *Rpl*
907 and *Rps* mRNAs into combined single maps for these gene families (**Figure 2A**) was performed
908 with the kind support of Ludovic Telley (Denis Jabaudon lab).

909

910 **RNA sequencing analysis of total neocortical lysates**

911 Total RNA was isolated from post-nuclear, post-mitochondrial, total neocortical lysates prepared
912 as described above in biological duplicate, with each replicate including the following number of
913 neocortical hemispheres (animals) at each developmental stage: E12.5, 80 (40); E14, 60 (30);
914 E15.5, 42 (21); E17, 40 (20); P0, 34 (17). Tissues were pooled such that each biological
915 replicate included an equal number of neocortices derived from multiple distinct litters of
916 embryos/pups. RNA was isolated with TRIzol-LS (Invitrogen #10296010), and 1 µg of RNA per
917 sample was used to prepare libraries with the TruSeq Stranded mRNA kit (Illumina #20020594)
918 according to manufacturer's instructions. Sequencing was performed on a HiSeq4000. Reads
919 were aligned to the mouse M12 genome using the splice aware aligner STAR (Dobin et al.,
920 2013), and GENCODE (Frankish et al., 2019) gene annotation GRCm38.p5. We used the STAR
921 parameters '--alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --outFilterMismatchNmax 999
922 --outFilterMismatchNoverLmax 0.04 --alignIntronMin 20' and default otherwise. Gene-level
923 counts were produced using the subread package, with duplicates and multi-mappers
924 discarded. TPMs were calculated using the total exon length for each gene. Significantly
925 changing levels over time of Ebp1, or the median value of Rpl, Rps, and translation-associated
926 gene groups, was assessed by one-way ANOVA followed by Bonferroni corrected *post hoc*
927 testing vs. E12.5, with $p < 0.05$ considered significant. RNAseq data have been deposited in the
928 NIH Gene Expression Omnibus (GEO) (Edgar et al., 2002) for reviewer access, and for
929 immediate release on publication:

930 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136199>)

931 NIH GEO GSE136199

932 Password: cbkfgscwvlszfab

933

934 **Western blot**

935 Analysis was performed with the NuPAGE (Invitrogen) Western blot system according to the
936 manufacturer's protocol, including 4-12% Bis-Tris NuPAGE gels (Invitrogen NP0321BOX,
937 NP0322BOX, NP0323BOX), MES running buffer, and transfer onto nitrocellulose membranes
938 (Amersham Protran 0.45 NC, GE Life Sciences #10600002) with NuPAGE transfer buffer
939 (NP0006) prepared with 10% methanol. All membranes were blocked in phosphate buffered
940 saline with Tween (PBST; 0.5% Tween) prepared with 5% milk (w/v) for 20 minutes at room
941 temperature, followed by overnight incubation with primary antibody at 4°C in PBST-5% milk.
942 Primary antibodies: anti-Ebp1^{CT} (rabbit, Abcam #ab35424), anti-Ebp1^{NT} (rabbit, Millipore
943 #ABE43), anti-Gapdh (mouse, Millipore #MAB374), anti-Rpl7/uL30 (rabbit, Abcam #ab72550),
944 anti-Rps5/uS7 (mouse, Santa Cruz # sc-390935). Membranes were then washed in PBST at

945 room temperature, HRP secondary antibodies applied in PBST-5% milk for 1 hour at room
946 temperature, and again washed in PBST before developing (Amersham ECL Prime Western
947 Blotting Detection Reagent, GE Healthcare #RPN2232) and imaging (GE Amersham Imager
948 600). Secondary antibodies: HRP-anti-rabbit-Light Chain (mouse, Dianova #211-032-171),
949 HRP-anti-mouse-Heavy Chain (goat, Millipore #71045). Importantly, note that HRP-anti-Light
950 Chain secondary antibody was used because probing with HRP-anti-Heavy Chain secondary
951 antibody introduced a non-specific band (~50 kDa) just above Ebp1 signal (48 kDa), obscuring
952 the interpretation of actual Ebp1 signal. Band molecular weights were compared to the SeeBlue
953 Plus2 Prestained Standard Protein Ladder (Thermo Fisher #LC5925) as shown in each figure.
954 Band signal intensity was measured using GE Amersham Imager 600 software, with
955 significance testing by ANOVA with Dunnett's *post hoc* test (≥ 3 comparisons), or two-tailed
956 unpaired t-test (≤ 2 comparisons), vs. E12.5 with GraphPad Prism software. Western blot signal
957 for endogenous Ebp1 in lysates was compared to full-length recombinant Ebp1 with a N-
958 terminal Histidine tag (Ebp1-His) as a marker, which was cloned in a pET-28a(+) backbone
959 (Novagen #69864-3) and purified as described (Kowalinski et al., 2007).

960

961 **Binding specificity and affinity analysis of Ebp1•ribosomal subunits**

962 40S and 60S subunits were purified from mouse neocortex and rabbit reticulocyte lysate (RRL)
963 essentially as described previously (Pisarev et al., 2007). Briefly, 40 frozen P0 neocortices (40
964 ODU) were lysed as described above, and ribosomes pelleted through a 1 M sucrose cushion in
965 base buffer (20 mM HEPES, 100 mM KCl, 10 mM MgCl₂, 42 U/mL SUPERase-In RNase
966 inhibitor, pH 7.4) in Beckman Coulter Ultra-Clear Tubes (#344057) with a SW55 rotor at
967 50000 rpm for 5.5 hrs, 4°C. 80S ribosome pellets were resuspended in base buffer, and
968 subjected to a puromycin reaction as described (Pisarev et al., 2007) to release 40S and 60S
969 subunits. Subunits were separated on a 10-30% sucrose high-salt gradient (20 mM HEPES,
970 0.5 M KCl, 10 mM MgCl₂, 8 U/mL SUPERase-In RNase inhibitor) prepared as described above,
971 by ultracentrifugation in Beckman Coulter Ultra-Clear Tubes (#344060) with a SW40 rotor at
972 27000 rpm for 12 hrs, 4°C. Subunits were fractionated and collected as described above, and
973 desalted using Amicon Ultra 0.5 mL 100 kDa MWCO spin columns (Millipore/Sigma
974 UFC510024) and reconstituted 1:3 v/v with low salt buffer (20 mM HEPES, 10 mM KCl, 2 mM
975 MgCl₂). 40S and 60S subunit concentrations were quantified by NanoDrop Spectrophotometer.

976 Recombinant Ebp1 with an N-terminal Histidine tag (Ebp1-His) was cloned into a pET-
977 28a(+) backbone (Novagen #69864-3) and purified as described (Kowalinski et al., 2007). For
978 Ebp1-His binding to mouse neocortex 40S and 60S subunits (**Figure S6A**), 5 nM and 20 nM of

979 Ebp1-His was reconstituted with 100 nM subunit in 20 mM HEPES, 100 mM KCl, 10 mM MgCl₂,
980 and incubated for 30 min at 37°C. Samples were pelleted through a 15% sucrose cushion
981 containing 20 mM HEPES, 100 mM KCl, 10 mM MgCl₂, 0.04 mM Spermine, 0.5 mM Spermidine
982 in Beckman Coulter 230 µL Thickwall Polypropylene Tubes (#343621) with a TLA100 rotor at
983 35000 rpm for 20 hrs at 4°C, separating unbound Ebp1-His from pelleted subunits with bound
984 Ebp1-His. Pellets of subunits•Ebp1-His were resuspended in 20 mM HEPES, 100 mM KCl,
985 10 mM MgCl₂. Binding was assessed by Western blot loading supernatant and pellet
986 resuspensions of 40S and 60S samples on the same gel, and probing with Ebp1^{CT} (rabbit,
987 Abcam #ab35424), uL30/Rpl7 (rabbit, Abcam #ab72550), and uS7/Rps5 (mouse, Santa Cruz #
988 sc-390935) antibodies on the same membrane.

989 Rabbit reticulocyte 40S and 60S subunits were purified and reconstituted to 80S
990 ribosomes as described (Pisarev *et al.*, 2007) from RRL (Promega #L4960). Binding of 200 nM
991 Ebp1-His to 100 nM rabbit 40S, 60S, and 80S (**Figure 3A**) was performed as described above.
992 For dose-response binding of Ebp1-His to 60S rabbit subunits (**Figure 3B**), 100 nM 60S was
993 reconstituted with 1:1 serial dilutions (to 0.5x concentrations) of Ebp1-His from 500 nM to
994 15.625 nM with 20 mM HEPES, 100 mM KCl, 10 mM MgCl₂, 0.04 mM Spermine, 0.5 mM
995 Spermidine. Binding was assessed by pelleting and Western blot as described above at each
996 dilution in parallel. This was repeated with a different Ebp1-His dose range between 325 nM to
997 81.25 nM. Western blot quantification was performed by normalizing Ebp1^{CT} signal to uL30
998 (Rpl7) signal, subtracting any signal detected in the supernatant, and generating a single dose-
999 response curve including both independent experiments; with the Ebp1-His concentration
1000 demonstrating maximum binding (Ebp1^{CT}/uL30) in each experiment set to 100%. Curves were
1001 fit using the GraphPad Prism software, with the best fit achieved by non-linear one site-specific
1002 binding with Hill slope accommodation (**Figures 3C and S6B**).

1003 Binding dynamics of Ebp1 to the rabbit 60S during mRNA translation were assessed by
1004 comparing the following mixtures: (1) 100 nM of rabbit 60S with saturating levels of (350 nM)
1005 Ebp1-His; (2) endogenous Ebp1 in RRL (~100 nM ribosomes estimated as described in the
1006 Methods below); (3) 350 nM Ebp1-His added to RRL (100 nM ribosomes); (4) endogenous
1007 Ebp1 in RRL (100 nM ribosomes) undergoing *in vitro* translation of a *Luciferase* mRNA; (5) the
1008 same conditions as (4) but with 0.1 mg/mL cycloheximide (Sigma-Aldrich #C7698) added to stall
1009 Luciferase peptide elongation. All the above mixtures were prepared in parallel, and incubated
1010 at 30°C for 30 min, 650 rpm – allowing for protein synthesis to occur to completion in (4) and (5).
1011 Mixtures were pelleted through a sucrose cushion as described above to separate unbound vs.
1012 bound Ebp1, and pellets likewise analyzed by Western blot (**Figure 3D**).

1013

1014 **Immuno-electron microscopy**

1015 Neocortex was dissected at E12.5, E15.5, and P0 at 4°C as described above, and immersion
1016 fixed at 4°C in phosphate buffered saline (PBS) containing 4% PFA and 0.1% Glutaraldehyde
1017 overnight, followed by 24 hours incubation in 4% PFA-PBS, and finally stored in 1% PFA-PBS.
1018 In order to identify the subcellular localization of EBP1 protein in neocortical precursor/stem and
1019 neuronal cells at different developmental stages, we performed pre-embedding nanogold-silver
1020 enhanced immunolabeling for Ebp1.

1021 Fixed brains were rinsed several times in PBS and sectioned on a Vibratome (Leica
1022 VT1000S) at 50-100 µm. Floating sections were washed again in PBS, followed by incubation in
1023 0.1% sodium borohydride (NaBH₄; Sigma-Aldrich #452882) in PBS for 15 min to inactivate
1024 residual aldehyde groups. Sections were then washed with PBS several times until the solution
1025 was clear of bubbles. To improve reagent penetration, the sections were then treated with PBS
1026 containing 0.05% Triton X-100 for 30 min and then washed 3x with PBS. To avoid nonspecific
1027 binding, sections were incubated for 1 hr in blocking solution containing 5% normal goat serum
1028 (NGS; PAN Biotech #P30-1002), and 5% bovine serum albumin (BSA; Sigma-Aldrich #A3294)
1029 in PBS. All following immuno-incubations were done with gentle agitation, overnight at 4°C.
1030 After blocking, sections were incubated with primary antibodies: rabbit anti-Ebp1^{NT} (rabbit,
1031 Millipore #ABE43) or rabbit anti-EBP1^{CT} (rabbit, Abcam #ab35424) diluted in PBS containing
1032 0.5% acetylated BSA (BSA-c, Aurion #900.022). After washes with PBS/BSA-c, sections were
1033 incubated in the secondary nanogold conjugated antibody (Nanoprobes #2003) goat anti-rabbit
1034 IgG diluted 1:100 in PBS/BSA-c. To remove unbound secondary antibodies, sections were
1035 washed thoroughly with PBS/BSA-c and then with PBS. Subsequently, sections were post-fixed
1036 with 2% GA in PBS for 2 hrs to crosslink nanogold in the tissue in order to prevent the loss of
1037 labeling during subsequent processing. Next, sections were washed several times in PBS and
1038 in double distilled water (ddH₂O) and prepared for silver enhancement according to the
1039 manufacturer's instruction (Nanoprobes). For structural stabilization, section were incubated
1040 with buffered 1% osmium tetroxide (OsO₄; Polysciences #0972A) for 1 hr and then washed in
1041 PBS followed by ddH₂O. Sections were dehydrated in increasing concentrations of ethanol and
1042 flat-embedded in Epoxy embedding medium (Epon 812; Sigma-Aldrich #45345) between two
1043 sheets of Aclar film (Plano #10501-10). After resin polymerization at 60°C, small pieces of
1044 cortex were dissected, mounted on plastic stubs, and sectioned *en face* into 60-65 nm sections
1045 on an Ultramicrotome (Reichert Ultracut S, Leica) and mounted on 200-mesh Formvar-coated
1046 nickel grids (Plano #G2710N). Ultrathin sections were finally stained with 2% aqueous uranyl

1047 acetate (Merck #1.08473.0100) for 2 min and with lead citrate (Fluka #GA10655) (Reynolds,
1048 1963) for 30 s. Sections were imaged using a Zeiss TEM-912 equipped with a digital camera
1049 (Proscan 2K Slow-Scan CCD-Camera, Zeiss). Subcellular profiles of interest were highlighted in
1050 the images with pseudo-color in Adobe Photoshop (**Figures 3E and S7**) as detailed in the guide
1051 by Eric Jay Miller
1052 ([http://www.nuance.northwestern.edu/docs/epic-](http://www.nuance.northwestern.edu/docs/epic-pdf/Basic_Photoshop_for_Electron_Microscopy_06-2015.pdf)
1053 [pdf/Basic_Photoshop_for_Electron_Microscopy_06-2015.pdf](http://www.nuance.northwestern.edu/docs/epic-pdf/Basic_Photoshop_for_Electron_Microscopy_06-2015.pdf)).

1054

1055 **Cryo-electron microscopy and data processing**

1056 *Sample and grid preparation.* Pooled 80S and polysomal ribosomes were purified *ex vivo* by
1057 preparative 10-50% sucrose density gradient ultracentrifugation from dissected frozen P0
1058 mouse neocortex tissue as described above, but with the following adaptations optimizing for
1059 cryo-electron microscopy (cryo-EM). Frozen P0 mouse neocortex (32 animals, 64 neocortex
1060 hemispheres) were lysed by cryogenic pulverization with 20 mM HEPES, 100 mM KCl, 10 mM
1061 MgCl₂, pH 7.4, supplemented with 20 mM Dithiothreitol (DTT), 0.04 mM Spermine, 0.5 mM
1062 Spermidine, 1x Protease Inhibitor cOmplete EDTA-free (Roche #05056489001), 480 U/mL
1063 RNasin Plus RNase inhibitor (Promega #N2615), 0.3% v/v IGEPAL CA-630 detergent (Sigma
1064 #I8896), and 0.1 mg/mL cycloheximide (Sigma-Aldrich #C7698). Lysates were subjected to
1065 further passive lysis by incubation for 1 hr on ice to enhance lipid membrane dissociation,
1066 followed by lysate clarification as above. 10-50% sucrose gradients in Beckman Coulter Ultra-
1067 Clear Tubes (#344057) were prepared with a base buffer of 10 mM HEPES, 50 mM KCl, 5 mM
1068 MgCl₂, to pH 7.4, supplemented with 20 mM Dithiothreitol (DTT), 0.04 mM Spermine, 0.5 mM
1069 Spermidine, 1x Protease Inhibitor cOmplete EDTA-free, 40 U/mL RNasin Plus RNase inhibitor,
1070 and 0.1 mg/mL cycloheximide. Samples were centrifuged in a SW55 rotor for 50 min at
1071 37000 rpm, 4°C. Fractions corresponding to the 80S and polysomal peaks were collected,
1072 pooled, and diluted 1:1 v/v with 20 mM HEPES, 100 mM KCl, 10 mM MgCl₂, pH 7.4,
1073 supplemented with 20 mM Dithiothreitol (DTT), 0.04 mM Spermine, 0.5 mM Spermidine, 1x
1074 Protease Inhibitor cOmplete EDTA-free, and 0.1 mg/mL cycloheximide to dilute the sucrose
1075 concentration to ≤ 20%. Samples were then pelleted by ultracentrifugation in Beckman Coulter
1076 Ultra-Clear Tubes (#344057) with a SW55 rotor for 50 min at 37000 rpm, 4°C. Pellets were
1077 resuspended in the same dilution buffer, testing for concentration and quality control by negative
1078 stain EM with 2% uranyl acetate. Samples were diluted 1:6 with resuspension buffer, and 3.6 μL
1079 of sample were applied to glow-discharged holey carbon grids (Quantifoil R3/3 100 Holey

1080 Carbon Films; 2 nM carbon; Micro Tools GmbH), blotted with a Vitrobot device (FEI) for 2-4 s at
1081 4°C, and plunged in liquid ethane. Samples were stored in liquid nitrogen until imaging.

1082

1083 *Cryo-EM data collection.* Initial datasets were collected for sample quality control and low-
1084 resolution ribosome reconstruction on a 120 keV Tecnai Spirit cryo-EM (FEI; MPI Molecular
1085 Genetics, Berlin) equipped with a CMOS camera (TVIPS), with automated Leginon software
1086 (Carragher et al., 2000; Suloway et al., 2005). Projection images were then analyzed by 3-D
1087 reconstruction and unsupervised classification for intrinsic ribosomal structure heterogeneity *in*
1088 *silico* with SPIDER (Frank et al., 1996) as described previously (Behrmann et al., 2015; Loerke
1089 et al., 2010). These data revealed the presence of extra-ribosomal density at the 60S exit tunnel.
1090 To validate these findings, an independent biological replicate sample was re-prepared, with
1091 new grids frozen, and likewise imaged using the same protocol, yielding identical density at the
1092 60S exit tunnel.

1093 High-resolution data (**Figures 4-5 and S8-S10**) were collected on a 300 keV Titan Krios
1094 (FEI; EMBL, Heidelberg) equipped with a Gatan Quantum K2 direct electron detector at a
1095 nominal magnification of 31000x, yielding a pixel size of 0.66 Å on the object scale. Movie
1096 stacks were collected in super-resolution mode with EPU automated software (FEI) with the
1097 following parameters: defocus range of 0.5-2.5 µm, 40 frames per movie, 20 s exposure time,
1098 electron dose of 1.589 e/Å²/s and a cumulative dose of 31.78 e/Å² per movie.

1099

1100 *Computational analysis.* High-resolution data collection yielded 5379 movies. The movies were
1101 aligned and dose-weighted using MotionCor2 (Zheng et al., 2017) and initial estimation of the
1102 contrast transfer function (CTF) was performed with the CTFfind4 package (Mindell and
1103 Grigorieff, 2003). Resulting micrographs were manually inspected to exclude images with
1104 substantial contaminants (typically lipid/membranes) or grid artifacts. Power spectra were
1105 manually inspected to exclude images with astigmatic, weak, or poorly defined spectra. The
1106 dataset included 4501 micrographs after these quality control steps (84% of total). Ribosomal
1107 particle images were identified using the “swarm” function within e2boxer from the EMAN2
1108 software package (Tang et al., 2007). After the manual removal of artifact particle images, the
1109 data set contained 208206 particle images (**Figure S8**).

1110 For multiparticle sorting and 3D refinement (**Figure S9**), the SPHIRE package (Moriya et
1111 al., 2017) was used for all steps except for 3D classification, which was performed using a
1112 python/SPARX-implementation of the incremental k-means algorithm described previously
1113 (Loerke et al., 2010). Therein, two modes for classification exist: (1) refinement, either global or

1114 local; and (2) focused classification based on a binary mask, defining a region of interest (ROI)
1115 (Penczek *et al.*, 2006). Such a focused mask was derived from 3D variability calculations, which
1116 visualizes regions of high heterogeneity with the 3D volume (Behrmann *et al.*, 2015).

1117 However, since heterogeneous regions outside the binary mask can influence the
1118 classification, a more sensitive approach was implemented. The “nue” mode, named after the
1119 hybrid beast in Japanese folklore, creates a hybrid map for each class in a simple procedure: a
1120 weighted average of all classes is calculated and used as the “outside”. The ROI within the
1121 focused mask is extracted for each class and used as the “inside”. Therefore, the focused mask
1122 is transformed into a soft mask by adding a smooth falloff at the edges. For each class, the
1123 “outside” map is combined with the respective “inside” map, normalized and filtered, forming the
1124 “nue”-map for each class. These “nue” maps are then used as references for focused
1125 classification. The “nue” maps only differ within the region of interest, reducing the influence of
1126 any peripheral variations. A new set of “nue” maps are calculated at the beginning of each
1127 iteration. A similar approach was implemented in FREALIGN/cisTEM, in which the outside area can
1128 be filtered or weighted down in order to reduce its influence during the classification (Grant *et al.*,
1129 2018; Grigorieff, 2016; Zhang *et al.*, 2019). A more detailed description of the procedure is in
1130 preparation (Krupp F, *et al.* In preparation).

1131 For the initial refinement, particle images were extracted at a box size of 360 pixels with
1132 a pixel size of 1.32 Å/px. All particles were aligned using *sxmeridian* using a filtered 80S yeast
1133 ribosome cryo-EM map as a reference. The refinement yielded a consensus map with sub-
1134 nanometer global resolution depicting fragmented densities for the small subunit, tRNAs, eEF2,
1135 and Ebp1. In order to separate this dataset into homogeneous sub-states, a hierarchical
1136 classification scheme (**Figure S9**) was employed as described previously (Behrmann *et al.*,
1137 2015). Three tiers of sorting were performed, whereby large-scale heterogeneity (e.g. subunit
1138 rotation) was classified first, before sorting based on more subtle differences (+/- Ebp1).

1139 In the first tier of sorting, particle images and parameters were decimated to 3.96 Å/px at
1140 a box size of 120px to minimize computational expense and limit the resolution for classification.
1141 This yielded a rotated 80S, classical 80S, and an artifact population, achieved by an incremental
1142 K-means procedure using global and local refinement.

1143 In the second tier of sorting, rotated and classical populations were separated and
1144 treated independently. Particle images were decimated to 2.64 Å/px at a box size of 180px.
1145 Focused classification was performed, since the maps already depicted high-resolution features.
1146 A strong signal of 3D variability was detected in the tRNA-binding site and at the eEF2 binding
1147 site, and thus focus masks were constructed in order to separate classes with different

1148 compositions of tRNA and eEF2. The “rotated”-branch was separated into two classes: (1)
1149 +eEF2, and (2) +eEF2 +P/E-tRNA. The “classical”-branch was separated into three classes: (1)
1150 +A-tRNA +P-tRNA, (2) +E-tRNA, and (3) empty 80S. However, within these five classes, the
1151 Ebp1 density still appeared fragmented, suggesting further heterogeneity in this region. These
1152 findings were confirmed by 3D variability calculations.

1153 In the final sorting tier, particle images were separated into these five classes, and
1154 decimated to 2.64 Å/px at a box size of 180 px. A focus mask enclosing the Ebp1 region was
1155 defined based on the 3D variability of each of the second-tier classes, and used for sorting into
1156 Ebp1-positive and Ebp1-negative classes. The results yielded a nearly equal distribution of
1157 Ebp1-positive and Ebp1-negative ribosomes in each sub-state, with an overall Ebp1•80S
1158 occupancy of 52% in our dataset (**Figure S9**).

1159 Finally, four of these classes were refined at 1.326 Å/px decimation with box size of
1160 360 px, yielding near-atomic global resolution for all ribosomal complexes, and allowing for the
1161 building of an atomic model of the mouse neocortical ribosome 60S•Ebp1. Euler distributions
1162 and global Fourier Shell Correlations (FSCs) were calculated (**Figures S10A-D**), in addition to
1163 the local resolutions of these maps (**Figures S10E-K'**) with SPHIRE. Local resolution for Ebp1
1164 ranges from 4 Å at the rRNA binding site to 6 Å at the solvent-side periphery (**Figures**
1165 **S10I,I',K,K'**). Ebp1-positive and Ebp1-negative maps yielded similar global and local resolutions
1166 from a similar particle number, permitting the use of the Ebp1-negative map as an internal
1167 control for the structural interpretation.

1168 Cryo-EM maps for the neocortical 80S•Ebp1 complex, including both the rotated state
1169 with eEF2 and the classical state with A/A+P/P tRNAs, are deposited in the Worldwide Protein
1170 Data Bank (wwPDB; <https://www.wwpdb.org/>) with accession code EMD-10321, for immediate
1171 release on publication.

1172

1173 **Model building**

1174 Since our focus was the interaction surface of Ebp1 on the mouse neocortical ribosome, we
1175 modeled the 60S subunit in complex with Ebp1 in the cryo-EM map. Modeling was performed in
1176 density for the rotated sub-state (+) Ebp1, since this map achieved the highest global resolution
1177 of 3.1 Å (**Figure S10C**). A 60S model derived from human polysomes (PDB 5AJ0) (Behrmann
1178 et al., 2015) was used as a starting model for the ribosomal proteins, and a rabbit 60S model
1179 (PDB 6GZ5) (Flis et al., 2018) was the starting model for rRNA. A pre-existing crystallographic
1180 model of mouse Ebp1 (PDB 2V6C) (Monie et al., 2007) was utilized to model Ebp1 density,
1181 downloaded from the Research Collaboratory for Structural Bioinformatics (RCSB) (Berman et

1182 al., 2000) website <https://www.rcsb.org/>. For all models, an initial rigid body docking was
1183 performed in UCSF Chimera v1.10.2 (Pettersen et al., 2004) (<http://www.rbvi.ucsf.edu/chimera>),
1184 with subsequent adjustment within the density performed in COOT (Emsley and Cowtan, 2004).
1185 Thereafter, the models were globally optimized by real-space refinement in PHENIX (Adams et
1186 al., 2010) and validated with MolProbity (Chen et al., 2010) (**Figure S8**). To prevent over-fitting
1187 during refinement, the applied weight was optimized by monitoring correlation of the map versus
1188 model in half-sets of the cryo-EM map (Brown et al., 2015; Greber et al., 2014; Sprink et al.,
1189 2016), using individually-determined weight factors. rRNA structures were further refined with
1190 ERRASER (Chou et al., 2013). Molecular graphics and analysis for figure preparation was
1191 performed with UCSF Chimera v1.10.2 and UCSF ChimeraX v0.9.0 (Goddard et al., 2018)
1192 (<https://www.cgl.ucsf.edu/chimerax/>). Analysis of atomic interactions between Ebp1 residues
1193 and ribosomal proteins/rRNA was aided by the CCP4Interface 7.0.073 (Potterton et al., 2003)
1194 CONTACT algorithm to compute atomic distances between the Ebp1 crystallographic model
1195 (PDB 2V6C) and modeled ribosomal proteins/rRNA as input. Atomic distances deemed
1196 significant and highlighted as electrostatic contacts (**Figures 4E-H**) were between 0.93-3.95Å.
1197 Electrostatic potential maps were generated for Ebp1 (PDB 2V6C), Metap2 (PDB 1KQ9), and
1198 Arx1 (PDB 5APN) in UCSF Chimera v1.10.2 using the APBS (Jurrus et al., 2018) interface and
1199 webserver http://nbc222.ucsd.edu/pdb2pqr_2.1.1/.

1200 The neocortical 60S•Ebp1 atomic model is deposited in the wwPDB with accession
1201 code PDB ID 6SWA, for immediate release on publication. A PDB validation report is available
1202 upon request with the submission of this manuscript.

1203

1204 **Pulsed SILAC and BONCAT coupled mass spectrometry**

1205 *Knockdown confirmation.* The mouse and human *siEbp1* oligos were obtained from the
1206 Dharmacon SMARTpool ON-TARGETplus collection (mouse *siPa2g4* #18813, order #L-
1207 042883-01-0005; human *siPa2g4* #5036; order #L008860-00-0005) and compared to non-
1208 targeting siRNA control (order #D-001810-10-05). Transfection was performed with
1209 Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher #13778075) according to the
1210 manufacturer's protocol. To confirm robust and specific knockdown with the mouse *siEbp1*
1211 oligos, Neuro2a cells were treated in parallel with the following conditions in biological duplicate,
1212 followed by Western blot analysis of total lysates (**Figure 6A**): (1) mock transfection, (2) control
1213 *siRNA*, (3) mouse *siEbp1*, (4) human *siEbp1*, and (5) 1:1 mouse + human *siEbp1*.

1214

1215 *Sample preparation.* For pulsed stable isotope labeling by amino acids in cell culture (pSILAC)
1216 (Schwanhäusser et al., 2009) and bioorthogonal noncanonical amino acid tagging (BONCAT)
1217 (Dieterich et al., 2006) coupled mass spectrometry (QuaNCAT) (Eichelbaum et al., 2012;
1218 Howden et al., 2013) (**Figures 6C-D**), eight 10 cm plates of Neuro2a cells were grown in
1219 standard DMEM (Gibco #31966047) with 1% FBS (Gibco #10270106) to a confluence of 50% in
1220 humidified 37°C, 5% CO₂. Then, mouse *siEbp1* vs. control siRNA transfection was performed
1221 with Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher #13778075) according to
1222 the manufacturer's protocol, in four plates each. The next morning, media was changed in each
1223 condition to either heavy SILAC (2 plates; Cambridge Isotope Labs #CNLM-539, CNLM-291) or
1224 medium SILAC (2 plates; Cambridge Isotope Labs #CLM-2265, DLM-2640) prepared with
1225 DMEM (Pan-Biotech #P04-02505), 1% dialyzed FBS (PAN-Biotech #P30-2102), GlutaMAX
1226 (Thermo Fisher #35050-038), and Penicillin-Streptomycin (Thermo Fisher #15140-122) along
1227 with repeated application of the siRNAs. Thus, throughout the course of Ebp1 vs. control
1228 knockdown, all newly made proteins were labeled with either heavy or light SILAC (pSILAC), i.e.
1229 "label swap" biological replicates. After 48 hr, SILAC media and siRNAs were refreshed. After
1230 another 24 hr, one heavy SILAC and one medium SILAC plate from each condition were pulsed
1231 with 1 mM L-azidohomoalaine (AHA; Anaspec #AS-63669) for four hours in the corresponding
1232 SILAC media prepared with methionine-free DMEM (Sigma-Aldrich #D0422) and 1% dialyzed
1233 FBS, labeling all newly made proteins during this acute interval with AHA in addition to the
1234 original SILAC label. Thus, acutely synthesized proteins at the point of maximal Ebp1
1235 knockdown were labeled with both SILAC and AHA in parallel (pSILAC-AHA).

1236 Media was then gently aspirated from each plate, followed by washing with ice-cold PBS,
1237 then scraping cells into 1 mL ice-cold PBS. Samples were lysed by the addition of 50 mM Tris
1238 pH 8, 150 mM NaCl, 1% IGEPAL CA-630 detergent (Sigma #I8896), and 0.5% Sodium
1239 Deoxycholate, followed by 5 min of boiling, then lysate clarification by centrifugation at 16000xg
1240 4°C for 30 min. 10% of each sample was frozen for Western blot confirmation of Ebp1
1241 knockdown. The remaining 90% of samples were then mixed 1:1 as per the following:

- 1242 (1) Control+Heavy SILAC : *siEbp1*+Medium SILAC
- 1243 (2) Control+Medium SILAC : *siEbp1*+Heavy SILAC
- 1244 (3) Control+Heavy SILAC-AHA : *siEbp1*+Medium SILAC-AHA
- 1245 (4) Control+Medium SILAC-AHA : *siEbp1*+Heavy SILAC-AHA

1246 Mixtures (1) and (2) were combined with nine volumes of ice-cold ethanol, and frozen at -80°C
1247 for downstream MS analysis. Mixtures (3) and (4) were subjected to AHA-enrichment.

1248

1249 *AHA-enrichment.* In preparation for on-bead digestion, azide-containing proteins were enriched
1250 from Neuro2a cell lysates using alkyne-agarose beads (Click-Chemistry Tools #1033). Alkyne-
1251 agarose beads were rinsed 2 times in pure injection grade water (AMPUWA) before use. To
1252 facilitate azide-alkyne binding, a 4x-concentrated “click-solution” was prepared in pure water:
1253 0.8 mM Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, Sigma-Aldrich #762342), 80 mM
1254 Sodium L-ascorbate (Sigma-Aldrich #A7631), and 0.8mM Copper(II) sulfate pentahydrate
1255 (Sigma-Aldrich #209198). 200 μ l of 4x-click-solution and 200 μ l of alkyne-agarose beads were
1256 first mixed before addition to 400 μ l of Neuro2a lysate. To prevent protease degradation of
1257 peptides, Protease Inhibitor Cocktail Set III, EDTA-Free (Calbiochem/Sigma-Aldrich #539134)
1258 was added to the final solution (1:50 dilution). To allow time for the click reaction to proceed, the
1259 click-bead-lysate mix was briefly vortexed (~8000xg for 5 s) before being placed on an orbital
1260 shaker maintained in the dark at room temperature. Following 3.5 hrs of incubation, alkyne-
1261 agarose beads were briefly centrifuged at 3000xg for 2 min, and resuspended in agarose wash
1262 buffer (100 mM Tris, 1% SDS, 250 mM NaCl, 5 mM EDTA, pH 8.0) containing dithiothreitol
1263 (DTT, 10 mM). To break disulfide bonds, alkyne-agarose beads were incubated with DTT-
1264 solution for 20 min at room temperature, then 10 min at 70°C, at 1000 rpm in a thermomixer
1265 (Eppendorf). Following DTT treatment, alkyne-agarose beads were resuspended in agarose
1266 wash buffer containing 40 mM Iodoacetamide (IAA). For the alkylation of free thiol groups,
1267 alkyne-agarose beads were incubated with IAA for 45 min on an orbital shaker maintained in the
1268 dark at room temperature. Following incubation, alkyne-agarose beads were washed using a
1269 bench top centrifuge (Roth) and 2 ml centrifuge columns (Pierce) with the following solutions, 10
1270 times each: (1) agarose wash buffer, (2) 8 M Urea in 100 mM Tris, and (3) 70% acetonitrile
1271 solution (100 mM ammonium bicarbonate buffer; ABC). Following washing, beads were then
1272 resuspended in 35% acetonitrile (50 mM ABC buffer) before centrifugation at 3000xg for 2 min
1273 to form a bead-pellet. The resulting supernatant was removed and the tube containing the pellet
1274 was frozen on liquid nitrogen before storage at -20°C until on-bead digestion.

1275
1276 *Mass spec analysis.* Proteins from cell lysates were precipitated in 90% ethanol solution at -
1277 20°C followed by 30 min centrifugation at 20000xg at 4°C. Protein pellets and AHA-clicked
1278 beads were resuspended in 2 M urea, 6 M Thiourea, 0.1 M Tris pH 8 solution. Proteins were
1279 reduced and alkylated with 10 mM DTT and 55 mM iodoacetamide at room temperature,
1280 respectively. For lysis, proteins were incubated with lysyl endopeptidase (Wako) at room
1281 temperature for 3 hr. Three volumes of 50 mM ammonium bicarbonate solution were added,
1282 and proteins were further digested with trypsin (Promega) under constant agitation at room

1283 temperature for 16 hr. Peptides were desalted with C18 Stage Tips prior to LC-MS/MS analysis.
1284 Peptide concentration was measured based on 280 nm UV light absorbance.

1285 Reversed-phase liquid chromatography was performed employing an EASY nLC II
1286 (Thermo Fisher Scientific) using self-made C18 microcolumns (75 µm ID, packed with ReproSil-
1287 Pur C18-AQ 1.9 µm resin, Dr. Maisch, Germany) connected on-line to the electrospray ion
1288 source (Proxeon, Denmark) of a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific).
1289 Peptides were eluted at a flow rate of 250 nL/min over 1 or 2 hr with a 9% to 55.2% acetonitrile
1290 gradient in 0.1% formic acid. Settings for mass spectrometry analysis were as follows: one full
1291 scan (resolution, 60,000; m/z, 350-1,800) followed by top 20 MS/MS scans using higher-energy
1292 collisional dissociation (resolution, 15,000; AGC target, 1e⁵; max. injection time, 22 ms; isolation
1293 width, 1.3 m/z; normalized collision energy, 26). The Q Exactive HF-X instruments was operated
1294 in data dependent mode with a full scan in the Orbitrap followed by up to 20 consecutive MS/MS
1295 scans. Ions with an unassigned charge state, singly charged ions, and ions with charge state
1296 higher than six were rejected. Former target ions selected for MS/MS were dynamically
1297 excluded for 20 or 30 s.

1298 All raw files were analyzed with MaxQuant software (v1.6.0.1) with default parameters,
1299 and with match between runs and requantify options on. Search parameters included two
1300 missed cleavage sites, cysteine carbamidomethyl fixed modification, and variable modifications
1301 including methionine oxidation and protein N-terminal acetylation. Peptide mass tolerance was
1302 6ppm and the MS/MS tolerance was 20ppm. Database search was performed with Andromeda
1303 against UniProt/Swiss-Prot mouse database (downloaded on January 2019) with common
1304 serum and enzyme contaminant sequences. False discovery rate (FDR) was set to 1% at
1305 peptide spectrum match (PSM) and protein levels. Minimum peptide count required for protein
1306 quantification was set to two. Potential contaminants, reverse database hits and peptides only
1307 identified by modification were excluded from analysis. MaxQuant normalized SILAC ratios were
1308 used for quantitative data analysis.

1309 We tested for miRNA-like off-target effects using seeds based on the siRNA sequences
1310 in the mouse *siEbp1* (*siPa2g4*) knockdown pool with the cWord software (Rasmussen et al.,
1311 2013). All proteins from our dataset were ranked according to their change ratio (mean H/M
1312 ratio in Forward and Reverse experiments; lowest to highest fold change). UniProt IDs were
1313 converted to Ensembl IDs and searched against mouse 3'UTR using cWords
1314 (<http://servers.binf.ku.dk/cwords/>) (Rasmussen et al., 2013). None of the possible 7-mers from
1315 these seeds showed specific enrichment in either AHA or pSILAC datasets. A cutoff of >2-fold
1316 change in *siEbp1* conditions compared to control in both replicates was considered significant.

1317 Gene ontology (GO) pathway analysis was performed with the Database for Annotation,
1318 Visualization and Integrated Discovery (DAVID) (Huang et al., 2009) for proteins with >2-fold
1319 change from control in *siEbp1* conditions (against all quantified proteins). Importantly, peptides
1320 corresponding to Ebp1 measured in *siEbp1* samples did not meet the minimum requirements for
1321 quantification, confirming robust knockdown, and therefore show no fold-change ratio. Mass
1322 spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
1323 (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository for reviewer
1324 access, and for immediate release on publication:

1325 ProteomeXchange PXD014740

1326 Username: reviewer84416@ebi.ac.uk

1327 Password: BwylH8kX

1328

1329 **Primary neocortical culture and immunocytochemistry**

1330 Primary E12.5 neocortical cultures (**Figure 6F**) were prepared from *Nex:Cre;Ai9* animals, as
1331 previously described (Turko et al., 2018). Briefly, dissected neocortex tissue was dissociated
1332 with Papain for 25 min (1.5 mg/ml) before trituration in bovine serum albumin (10 mg/ml). Cells
1333 were then resuspended in Neurobasal (medium, supplemented with 1x B27, 1x Glutamax, and
1334 100 U/ml Penicillin-Streptomycin). Dissociated cells were grown on 12 mm round, glass
1335 coverslips coated with Poly-L-Lysine (20 µg/ml) in 24-well plates. Cells were plated in 40 µl
1336 droplets at a concentration of 500 cells per µl (total: 20,000 cells per coverslip). Cultures were
1337 grown in humidified conditions at 37°C, 5% CO₂. Cells were cultured for 5 days to allow for
1338 neural stem cell (NSC) differentiation into post-mitotic *Nex*-positive neurons.

1339 At days *in vitro* 0, 2, 4 and 5 coverslips were fixed and analyzed by
1340 immunocytochemistry for Ebp1 expression in Nestin-positive NSCs and *Nex*-positive neurons
1341 as described previously (Turko et al., 2018). In brief, cells were fixed for 15 min in 4%
1342 paraformaldehyde (PFA), 4°C solution before subsequent washes in: 0.1 M phosphate buffered
1343 solution (PB) and phosphate buffered saline (PBS). All antibodies were diluted (1:1000) in PBS
1344 with 0.1% Triton-X 100, and incubated overnight at 4°C on an orbital shaker. Primary
1345 antibodies: anti-Nestin (mouse, Millipore #MAB353), anti-Ebp1^{NT} (rabbit, Millipore #ABE43).
1346 Secondary antibodies: Alexa Fluor 647-conjugated anti-mouse (goat, Jackson
1347 ImmunoResearch) and Alexa Fluor 488-conjugated anti-rabbit (goat, Jackson
1348 ImmunoResearch). DAPI was applied to visualize nuclei (NucBlue, Molecular Probes, Invitrogen
1349 #R37606). Coverslips were mounted on glass slides using Fluoromount-G (Southern Biotech,
1350 #0100-01). Images were captured on an upright confocal microscope (FV-1000, Olympus) using

1351 30x silicon oil-immersion objective (1.05 NA, 0.8 mm WD). Images were analyzed using the FIJI
1352 distribution of ImageJ software (Schindelin et al., 2012) (<https://fiji.sc/>), maintaining constant
1353 LUT parameters across images.

1354

1355 **Immunofluorescence labeling in neocortex tissue**

1356 Tissue processing and immunohistochemistry (**Figures 2C and S4**) was performed similar to
1357 the previously described method (Kraushar et al., 2014). In brief, embryonic (E12.5, E14, E15.5,
1358 E17) and postnatal (P0) mouse brains were dissected at 4°C in ice cold PBS (ThermoFisher
1359 #14040133), and initially immersion-fixed with 4% (w/v) paraformaldehyde (PFA) in PBS (PBS-
1360 PFA; pH 7.4) at room temperature for 30 min, followed by overnight PBS-PFA fixation at 4°C.
1361 Fixed brains were then embedded in 3.2% agarose-PBS, and coronally sectioned at 70 µm on a
1362 Leica vibratome (VT1000S). Sections of the anterior sensorimotor neocortex were collected,
1363 incubated in blocking solution (PBS, 10% normal donkey serum, 2% w/v BSA, 0.2% w/v glycine,
1364 0.2% w/v lysine), then incubated overnight in probing solution with 0.4% Triton-X and primary
1365 antibody at 4°C. Primary antibodies: anti-Map2 (chicken, Millipore #AB5543), anti-Ebp1^{CT} (rabbit,
1366 Abcam, #ab35424), anti-Ebp1^{NT} (rabbit, Millipore #ABE43). Samples were washed in PBS, then
1367 all secondary antibodies, Alexa 488 anti-rabbit (goat, Jackson ImmunoResearch) and Alexa 647
1368 anti-chicken (goat, Jackson ImmunoResearch), were applied at 1:250 dilution in probing
1369 solution for 2 hr at room temperature, washed, incubated with DAPI (NucBlue, Molecular Probes,
1370 Invitrogen #R37606) for 10 min, and mounted with Vectashield. Confocal imaging was
1371 performed with an upright confocal microscope (FV-1000, Olympus), 20x air objective,
1372 maintaining constant parameters and setting across all images. Images were likewise analyzed
1373 using FIJI software, including the pairwise stitching plugin (Preibisch et al., 2009), maintaining
1374 constant LUT parameters across images.

1375

1376 ***In utero* electroporation and morphology analysis**

1377 The mouse *shEbp1* plasmid was obtained from the Sigma MISSION collection (*shPa2g4*; oligo
1378 name: TRCN0000236756; RefSeq NM_011119) in bacterial glycerol stock format, and amplified
1379 according to the manufacturer's protocol, followed by plasmid purification with the Nucleobond
1380 Xtra Midi Kit (Macherey & Nagel #740410.100). The non-targeting scrambled shRNA control
1381 was generated as described in a prior study (Ambrozkiwicz et al., 2018). The *Ebp1*
1382 overexpression plasmid was generated by insert amplification from the Clone IRAVp968A0190D
1383 I.M.A.G.E. Fully Sequenced cDNA (Source BioScience) with primers forward 5'-
1384 gtctcatcatttggcaagATGTACCCATACGATGTTCCAGATTACGCTTCGGGCGAAGACGAG-3'

1385 and reverse 5'-cggccgcgatatcctcgaggTCAGTCCCCAGCTCCATTC-3', followed by cloning into
1386 the pCAGIG (pCAG-IRES-GFP) backbone (Ambrozkiwicz *et al.*, 2018) with the restriction
1387 enzyme EcoRI (NEB). Co-electroporation of the pCAG-IRES-GFP plasmid was used as a
1388 transfection reporter.

1389 E12 *In utero* electroporation (IUE) of control, *shEbp1*, and *shEbp1+oeEbp1* conditions
1390 with the CAG-GFP reporter followed by analysis at E16 with confocal imaging, morphology
1391 tracing, and Sholl analysis (**Figures 7A-D**) was performed as described (Ambrozkiwicz *et al.*,
1392 2018). Briefly, GFP labeling of electroporated neurons in confocal images was analyzed by
1393 morphology tracing with the Neurite Tracer plugin (Longair *et al.*, 2011) by a blinded investigator,
1394 followed by the Sholl analysis (Ferreira *et al.*, 2014) plugin run in FIJI with 1 μ m radius of
1395 concentric circles, plotting the average intersections over distance from the soma and average
1396 total summed intersections in each condition. Significance was assessed by one-way ANOVA
1397 followed by Bonferroni corrected *post hoc* testing in GraphPad Prism software, with $p < 0.05$
1398 considered significant.

1399

1400 **QUANTIFICATION AND STATISTICAL ANALYSIS**

1401 **Mass spectrometry**

1402 MaxQuant software (v1.6.0.1) (Cox and Mann, 2008) was run with default parameters, and with
1403 match between runs and requantify options on. Protein quantification across samples was
1404 performed using the label-free quantification (LFQ) algorithm (Cox *et al.*, 2014). A minimum
1405 peptide count required for LFQ protein quantification was set to two. Only proteins quantified in
1406 at least two out of the three biological replicates in input, 80S, and polysome samples, and two
1407 out of two (label swap) biological replicates in pSILAC/AHA samples, were considered for
1408 further analyses. LFQ intensities were log₂-transformed and imputation for missing values was
1409 performed in Perseus software (Tyanova *et al.*, 2016) based on a simulated normal distribution
1410 to represent low abundance values below the noise level (generated at 1.8 standard deviations
1411 of the total intensity distribution, subtracted from the mean, and a width of 0.3 standard
1412 deviations). For stoichiometry matrices, the IBAQ algorithm (Schwanhäusser *et al.*, 2011) was
1413 used to quantify within-sample abundance. Database search was performed with Andromeda
1414 (Cox *et al.*, 2011) against UniProt/Swiss-Prot mouse database with common serum and enzyme
1415 contaminant sequences. False discovery rate (FDR) was set to 1% at peptide spectrum match
1416 (PSM) and protein levels. Minimum peptide count required for protein quantification was set to
1417 two. Potential contaminants, reverse database hits and peptides only identified by modification
1418 were excluded from analysis.

1419 For input, 80S, and polysome MS performed in biological triplicate, Ebp1 and the median
1420 protein abundance within protein groups (Rpl, Rps, translation-associated) were tested for
1421 significantly changing levels across developmental stages by one-way ANOVA with Bonferroni
1422 corrected *post hoc* testing, with $p < 0.05$ considered significant. For pSILAC/AHA MS performed
1423 in biological duplicate with SILAC label swap, MaxQuant normalized SILAC ratios were used for
1424 quantitative data analysis. All proteins from our dataset were ranked according to their change
1425 ratio (mean H/M ratio in Forward and Reverse experiments; lowest to highest fold change). A
1426 cutoff of >2-fold change from control in both replicates was considered significant.

1427

1428 **RNAseq**

1429 Samples were prepared in biological duplicate at each developmental stage. Reads were
1430 aligned to the mouse M12 genome using the splice aware aligner STAR (Dobin et al., 2013),
1431 and GENCODE (Frankish et al., 2019) gene annotation GRCm38.p5. Gene-level counts were
1432 produced using the subread package. Significantly changing levels over time of Ebp1, or the
1433 median value of Rpl, Rps, and translation-associated gene groups, was assessed by one-way
1434 ANOVA followed by Bonferroni corrected *post hoc* testing vs. E12.5, with $p < 0.05$ considered
1435 significant.

1436

1437 **Sucrose density gradient ultracentrifugation fractionation curves**

1438 Analytic gradient area-under-the-curve (AUC) analysis for 40S-60S, 80S, and polysome peaks
1439 was calculated from real-time A260 values measured by PicoLogger recorder and software
1440 during sample fractions in biological duplicate or triplicate at each developmental stage. A
1441 Reimann sum was used to calculate the AUC corresponding to 40-60S, 80S, and polysome
1442 peaks of the gradient. Significance was tested by one-way ANOVA with Dunnett's *post hoc* test
1443 vs. E12.5, performed in GraphPad Prism, with $p < 0.05$ considered significant.

1444

1445 **Quantitative Western blot**

1446 Western blot band signal intensity measured in duplicate membranes was quantified using GE
1447 Amersham Imager 600 software, with significance testing by two-tailed unpaired t-test (≤ 2
1448 comparisons), vs. E12.5 with GraphPad Prism software, with $p < 0.05$ considered significant.

1449

1450 **Sholl analysis**

1451 Neuronal morphology tracings of GFP signal were generated with the Neurite Tracer plugin
1452 (Longair et al., 2011) in FIJI, then analyzed by the Sholl analysis plugin (Ferreira et al., 2014)

1453 with 1 μ m radius of concentric circles, plotting the average intersections over distance from the
1454 soma, and average total summed intersections in each condition. Significance of total summed
1455 intersections was assessed by one-way ANOVA followed by Bonferroni corrected *post hoc*
1456 testing in GraphPad Prism software, with $p < 0.05$ considered significant.

1457

1458 **DATA AVAILABILITY**

1459 Mass spectrometry proteomics data (**Figures 1B-C, 6C-D, and S2-S3**) have been deposited to
1460 the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the
1461 PRIDE partner repository for reviewer access, and for immediate release on publication:

1462 ProteomeXchange PXD014740

1463 Username: reviewer84416@ebi.ac.uk

1464 Password: BwylH8kX

1465

1466 RNAseq data (**Figure 2B**) have been deposited in the NIH Gene Expression Omnibus (GEO)
1467 for reviewer access, and for immediate release on publication:

1468 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136199>)

1469 NIH GEO GSE136199

1470 Password: cbkfgscwvlszfab

1471

1472 Cryo-EM maps for the neocortical 80S•Ebp1 complex (**Figures 4-5 and S7-S10**), including both
1473 the rotated state with eEF2 and the classical state with A/A+P/P tRNAs, have been deposited in
1474 the Worldwide Protein Data Bank (wwPDB; <https://www.wwpdb.org/>) with accession code EMD-
1475 10321, for immediate release on publication.

1476

1477 The neocortical 60S•Ebp1 atomic model (**Figures 4-5, S8, and S11**) has been deposited in the
1478 wwPDB with accession code PDB ID 6SWA, for immediate release on publication. A PDB
1479 validation report is available upon request with the submission of this manuscript.

1480 **SUPPLEMENTARY FIGURE LEGENDS**

1481 **Supplementary Figure 1. Preparative sucrose density gradient fractionations for MS**
1482 **samples, associated with Figure 1**

1483 Mouse neocortical lysates were subjected to preparative sucrose density gradient
1484 ultracentrifugation fractionation in biological triplicate to purify 80S and polysomal ribosome
1485 complexes at E12.5, E14, E15.5, E17, and P0. Input lysate, pooled 80S fractions, and pooled
1486 polysome fractions were analyzed by LC-MS/MS.

1487
1488 **Supplementary Figure 2. Hierarchical clustering of MS samples, associated with Figure 1**

1489 Hierarchical clustering of neocortex MS data for **(A)** total input lysates and **(B)** 80S and
1490 polysomes in biological triplicate at E12.5, E14, E15.5, E17, and P0. Clustering of ANOVA
1491 significant (FDR = 0.05) proteins based on one minus Pearson correlation with an average
1492 linkage method. Heat maps colored by higher (orange) and lower (purple) protein expression
1493 per row (protein ID) max and min, respectively. Results demonstrate clustering by replicates,
1494 80S vs. polysomes, and developmental stages.

1495
1496 **Supplementary Figure 3. Scatter plots and stoichiometry cluster heat maps for input and**
1497 **80S proteins, associated with polysome samples in Figures 1B-C**

1498 **(A-B)** Scatter plots of ribosomal complex protein enrichment measured by MS comparing early
1499 neurogenesis E12.5 vs. each subsequent stage. (A) 80S MS showing Ebp1 (red arrow)
1500 enriched among ribosomal proteins (RPs) of the large (Rpl, blue) and small (Rps, yellow)
1501 subunits, similar to the polysome MS (**Figure 1B**). Ebp1 enrichment is shown relative to the
1502 level of translation-associated proteins (black), and all other proteins (grey). (B) Input MS,
1503 showing Ebp1 is among the most abundant proteins in the neocortex. **(C-D)** Stoichiometry
1504 cluster heat maps comparing the enrichment of each RP (Rpl, blue; Rps, yellow), translation-
1505 associated proteins (black), and Ebp1 (red arrow) in comparison to every other protein per
1506 developmental stage in the (C) 80S MS and (D) total input MS, corresponding to the polysome
1507 MS in **Figure 1C**. The expression of adjacent proteins on the x-axis is shown as higher (orange),
1508 lower (purple), or similar (black) relative to each protein on the y-axis (legend and histogram at
1509 top left for each stage). Ebp1 is expressed at levels comparable to RPs in neocortical total
1510 lysates, and is nearly stoichiometric to RPs in the 80S, similar to polysomes. In contrast, other
1511 translation-associated proteins are sub-stoichiometric.

1512

1513 **Supplementary Figure 4. Ebp1^{NT} immunohistochemistry in the developing neocortex,**
1514 **associated with Figure 2C**

1515 Immunohistochemistry analysis of Ebp1 expression in coronal sections of the developing
1516 neocortex with the Ebp1^{NT} antibody (green), reinforcing findings with the Ebp1^{CT} antibody. Ebp1
1517 levels are particularly high in early-born NSCs in ventricular zone (VZ), and nascent cortical
1518 plate (CP), at E12.5-E14. Ebp1 is expressed in the lower layers (LL) and upper layers (UL) of
1519 the expanding cortical plate at E15.5-P0, albeit at decreased levels. Co-immunostaining with
1520 Map2 (red) as a marker of maturing neurons in the CP, along with DAPI (blue) marking nuclei.

1521

1522 **Supplementary Figure 5. Full Western blots associated with Figure 2F, and sucrose**
1523 **density gradient fractionations and Western blots of each fraction, associated with**
1524 **Figure 2G**

1525 Western blot membranes of total neocortical lysates from E12.5, E14, E15.5, E17, and P0
1526 probed with **(A)** C-terminal specific (Ebp1^{CT}, membrane from **Figure 2A**; Abcam #ab35424) and
1527 **(B)** N-terminal specific (Ebp1^{NT}, separate replicate; Millipore #ABE43) (Xia et al., 2001) anti-
1528 Ebp1, in comparison to full-length recombinant Ebp1 (Ebp1-His) as a band marker. Ebp1^{CT}
1529 antibody would be expected to identify both full-length Ebp1 (“p48”; ~48kDa) and the N-terminal
1530 truncated isoform (“p42”; ~42kDa), which lacks the first 54 amino acids (Liu et al., 2006). The
1531 Ebp1^{NT} antibody should exclusively identify full-length Ebp1. Results demonstrate dominant
1532 signal concordant with Ebp1 full-length at ~48kDa (arrows), migrating slightly lower than
1533 recombinant Ebp1-His. Faint bands are seen at ~55kDa and ~35kDa (stars). Membranes were
1534 reprobed with Gapdh as a loading control. We concluded that the starred bands in (A) and (B)
1535 are both non-specific signal not corresponding to Ebp1, since these bands could not be
1536 replicated with both antibodies. Of note, all Ebp1 Western blots in this paper were performed
1537 with anti-light chain secondary antibodies, since application of anti-heavy chain secondaries
1538 was found to introduce strong artifact signal at ~50kDa, creating an obstacle to the
1539 interpretation of the 48kDa Ebp1. **(C)** Total neocortical lysates at E12.5, E15.5, and P0 were
1540 A260 normalized, and fractionated by preparative sucrose density gradient ultracentrifugation
1541 into eleven fractions in biological duplicate, followed by **(D)** Western blot analysis of Ebp1 levels
1542 in each fraction corresponding to extra-ribosomal (free), 80S, and polysomes (replicate #1).
1543 Gapdh is a marker for pre-ribosomal free fractions, while uL30 is a marker for ribosome-
1544 associated fractions. While pre-ribosomal free Ebp1 levels are stable across neocortical
1545 development, ribosome-associated Ebp1 levels decrease in concert with decreasing levels of
1546 80S and polysomes, seen in both the A260 curves (C) and likewise in uL30 protein levels (D).

1547 Individual fractions from replicate #2 were pooled to constitute free, 80S, and polysome samples
1548 in **Figure 2G**.

1549

1550 **Supplementary Figure 6. Biochemical analysis of Ebp1•ribosome binding, associated**
1551 **with Figure 3**

1552 **(A)** 40S and 60S subunits were purified from P0 mouse neocortex, and reconstituted with
1553 recombinant Ebp1-His, as in **Figure 3A** with rabbit-derived subunits. Escalating doses of Ebp1
1554 (100nM, 200nM) were mixed with a constant 100nM of each subunit, and pelleted through a
1555 sucrose cushion to separate free unbound Ebp1 in the supernatant, vs. Ebp1•subunit
1556 complexes in the pellet. Western blot analysis demonstrates a dose-dependent binding of Ebp1
1557 specifically to the 60S subunit. Marker for the 60S is uL30, and for 40S uS7. **(B)** Interpretation of
1558 binding data related to **Figure 3C**. Curves were fit to the data using a nonlinear least-squares fit,
1559 with one-site binding (left, $r^2=0.70$), two-site binding (middle, $r^2=0.87$), or one-site binding and
1560 Hill slope accommodation (right, $r^2=0.99$). The best fit-to-data approximated by one-site binding
1561 and Hill slope accommodation ($h=5$) suggests that the 60S site serving as a receptor for Ebp1
1562 binding acquires a conformational state (active state, 60S*) that is present with a higher
1563 probability when increasing concentrations of Ebp1 are present, yielding a higher probability of
1564 Ebp1 re-binding.

1565

1566 **Supplementary Figure 7. Immuno-electron microscopy with Ebp1^{CT} and Ebp1^{NT}**
1567 **antibodies, associated with Figure 3E**

1568 **(A)** Immunogold labeling for Ebp1^{CT} (black dots) in sections of the neocortex at E12.5, E15.5,
1569 and P0. Neural stem cells (NSC) and neurons (N) are identified by their distinctive nuclear
1570 morphologies (highlighted in blue, NSC and red, N) and positions in the developing cortical
1571 layers (ventricular zone, NSC; expanding cortical plate, N). Ebp1 labeling is predominantly
1572 found in clusters in the cytoplasm of these cells, but shows no association with the nucleolar site
1573 of RP synthesis (n), the endoplasmic reticulum (er), mitochondria (m, in green), or the plasma
1574 membranes at cell-cell junctions (arrows; blue on NSC side, red on N side). These results are in
1575 agreement with those obtained for Ebp1^{NT} in **Figure 3E**. **(B)** Electron micrographs of a dendritic
1576 branch (D) labeled for Ebp1^{NT} (black dots). Immunogold particles labeling Ebp1 are present in
1577 clusters in the dendritic cytoplasm, but not associated with mitochondria or the plasma
1578 membrane.

1579

1580 **Supplementary Figure 8. Cryo-EM data collection and model statistics, associated with**
1581 **Figures 4-5**

1582 **(A)** Statistics corresponding to cryo-EM data collection, map refinement, model characteristics,
1583 data resolution estimation, and cross correlation (CC) of model vs. data. **(B)** Fourier Shell
1584 Correlations (FSCs) for masked vs. unmasked maps. **(C)** Representative cryo-EM map (mesh)
1585 to model correspondence for rRNA, β -sheet, and α -helix structures.

1586

1587 **Supplementary Figure 9. Multiparticle sorting and refinement of mouse neocortical**
1588 **ribosome states, associated with Figures 4-5**

1589 Cryo-EM imaging of pooled 80S and polysome complexes derived from the P0 mouse
1590 neocortex *ex vivo* yielded 208206 particles for *in silico* analysis. Initial multiparticle sorting of
1591 data at six times decimation (DC6) for large-scale heterogeneity generated ribosomes in the
1592 rotated and classical states, and a junk population. Further sorting within the rotated and
1593 classical states proceeded at DC4. In the rotated state, populations with eEF2 and eEF2+P/E
1594 tRNA emerged. In the classical state, populations with A/A+P/P tRNAs, E/E tRNA, and without
1595 tRNA emerged. In each of these five populations, extra-ribosomal density was observed at the
1596 peptide tunnel exit. Further sorting within each of these five populations proceeded at DC4 with
1597 a focus mask applied to this extra-ribosomal density as described in the Methods, to disentangle
1598 cofactor-positive and cofactor-negative ribosome sub-states. Each of these five populations
1599 yielded cofactor-positive and -negative populations. Final high-resolution refinement at DC2
1600 proceeded for cofactor-positive (red arrow) and -negative populations of the rotated state with
1601 eEF2 (3.1Å global resolution), and the classical state with A/A+P/P tRNAs (3.3Å global
1602 resolution). These high-resolution data allowed for the identification of the cofactor as Ebp1,
1603 with cofactor-positive and -negative sub-states revealing 60S structural changes with Ebp1
1604 binding.

1605

1606 **Supplementary Figure 10. Global and local resolution measurements of cryo-EM maps,**
1607 **associated with Figures 4-5**

1608 Particle orientation distribution and global resolution Fourier Shell Correlation (FSC) for the **(A,**
1609 **C)** rotated state with eEF2, and **(B, D)** classical state with A/A+P/P tRNAs, both with and
1610 without Ebp1. Local resolution heat maps for the **(E, E', F, F', I, I', J)** rotated state with eEF2,
1611 and **(G, G', H, H', K, K', I)** classical state with A/A+P/P tRNAs, both with (E, E', I, I'; G, G', K, K')
1612 and without (F, F', J; H, H', L) Ebp1. Maps are shown in both surface (E, F, G, H, I, J, K, L) and
1613 cross-section (E', F', G', H', I', K'). The local resolution of Ebp1 is ~4-6Å.

1614

1615 **Supplementary Figure 11. Cryo-EM density for H59 and H53 of Ebp1-positive and Ebp1-**
1616 **negative maps associated with the models shown in Figure 5A, electrostatics associated**
1617 **with Figure 5A, and Ebp1:Metap2 structure comparison associated with Figures 5C-D**

1618 Cryo-EM density (mesh) for the rotated state with eEF2 in **(A)** Ebp1-positive (blue) and **(B)**
1619 Ebp1-negative (green) sub-states. Density for base U-2687 (yellow) demonstrates flipping out
1620 when Ebp1 is bound, along with flipping in of base G-2690 (orange), and global reorganization
1621 of the H59 tip backbone away from H53. Base G-2690 in the Ebp1-negative state demonstrates
1622 density bridging to H53 bases G-2501, G-2502, and C-2513 (magenta) to stabilize H59's
1623 canonical position, opening a gap (star) in H59 once occupied by the G-2690 intra-helical base
1624 stacking interactions. **(C)** Reorientation of H59 U-2687 into a pocket of Ebp1's insert domain,
1625 facilitating Ebp1 stabilization on the 60S tunnel exit surface. Ebp1 shown as electrostatic
1626 potential map. **(D)** Global alignment of Ebp1 (red, PDB 2V6C) and Metap2 (grey, PDB 1KQ9),
1627 highlighting structural differences with Ebp1's $\alpha 5$ domain, and overall structural similarity, such
1628 as the insert domain. Ebp1 residues making electrostatic interactions (yellow) with 60S TE
1629 rRNA helices and proteins are highlighted.

1630

1631 **Supplementary Figure 12. Sequence alignment of mouse Ebp1 with orthologs and**
1632 **structural homologs, associated with Figures 4-5**

1633 Ebp1 amino acid sequence alignment of human (*Homo sapiens* PA2G4 full-length, iso-1; N-
1634 terminal truncated, iso-2), mouse (*Mus musculus* Pa2g4 full length iso-1), chicken (*Gallus gallus*
1635 Pa2g4), and zebrafish (*Danio rerio* Pa2g4-a/b) orthologs with CLUSTAL Omega (1.2.4) (Sievers
1636 *et al.*, 2011), default settings (<https://www.ebi.ac.uk/Tools/msa/clustalo/>) and visualized in
1637 Unipro UGENE (Okonechnikov *et al.*, 2012). Alignment with structurally homologous proteins
1638 *Mus musculus* Metap2, *Saccharomyces cerevisiae* Arx1, and *Chaetomium thermophilum* Arx1
1639 is also shown. Ebp1 residues involved in 60S binding are outlined in yellow aligned with
1640 homologous residues, colored by hydrophobicity. All other residues colored by percentage
1641 identity (grey). Percent similarity to the human full-length sequence is shown at left. Amino acid
1642 sequences were obtained from UniProt (The UniProt Consortium, 2019)
1643 (<https://www.uniprot.org/>) with entry number and name for each protein shown at top left.

1644

1645 **Supplementary Figure 13. Transcriptional landscape of 60S tunnel exit binding cofactor**
1646 **expression in the developing neocortex derived from (Telley *et al.*, 2019), associated with**
1647 **Figure 5E**

1648 Expression heat maps from scRNAseq data plotting NSC birthdate (x-axis) and differentiation
1649 (y-axis) scores, for the relative enrichment of mRNAs coding for 60S tunnel exit cofactors in the
1650 developing neocortex (ribosome-binding subunits shown). In each graph, the early-born apical
1651 progenitor (AP) NSC pool is plotted in the bottom left, with their corresponding differentiated
1652 lower layer neurons (N4d) in the top left. Late-born NSCs are plotted in the bottom right, with
1653 their corresponding differentiated upper layer neurons in the top right. Data from:
1654 http://genebrowser.unige.ch/telagiridon/#query_the_atlas

1655

1656 **Supplementary Figure 14. Ebp1 association with Neuro2a 80S and polysomes, and**
1657 **analysis associated with Figure 6**

1658 **(A)** Western blot of Neuro2a, HEK-293T, and rabbit reticulocyte (RRL) total lysates probed with
1659 Ebp1^{CT} antibody. **(B)** Preparative sucrose density gradient fractionation of Neuro2a cell lysates,
1660 followed by **(C)** Western blot analysis of Ebp1 enrichment of each fraction. Ebp1 associates with
1661 80S and polysomes in Neuro2a cells, similar to mouse neocortical cells (**Figures S5C-D**). uL30
1662 is a marker for ribosome-associated fractions. **(D)** Gene ontology (GO) pathways analysis with
1663 the Database for Annotation, Visualization and Integrated Discovery (DAVID) of proteins with
1664 >2-fold change from control in *siEbp1* conditions (against all quantified proteins) measured by
1665 pSILAC/AHA MS (**Figures 6C-D**). **(E)** Ribosome Profiling (Riboseq) derived from (Zappulo et al.,
1666 2017), highlighting the relative enrichment of Ebp1-regulated targets (red) in soma vs. neurites
1667 (y-axis) protein synthesis compared overall RPKM (x-axis) of cultured neurons. **(F)** Schematic
1668 summary of Ebp1's impact on neuronal proteostasis, associated with **Figures 6C-D**, showing
1669 proteins that have been previously reported to influence neurogenesis. Ebp1 impacts cell
1670 adhesion molecules (de Wit and Ghosh, 2016), such as L1cam (Maness and Schachner, 2007),
1671 Mcam (Taira et al., 2005), Cadm1 (Robbins et al., 2010), and Cdh15 (Bhalla et al., 2008), in
1672 addition to the CAM modulator Slc3a2 (Feral et al., 2005). Ebp1 further regulates the
1673 synaptogenesis protein Sparc (Kucukdereli et al., 2011; López-Murcia et al., 2015), a
1674 membrane scaffold for calcium channels Ahnak (Jin et al., 2019), the neuronal migration and
1675 neurite outgrowth protein Marcks (Brudvig and Weimer, 2015), and the synaptogenic
1676 membrane-type metalloproteinase Mt3 (Sanz et al., 2018). Several of these proteins, in addition
1677 to Cald1 (Morita et al., 2012) and Cnn2 (Ulmer et al., 2013), interact with the cytoskeleton in
1678 growing neurites. Among the proteins modulating synaptic transmission that are sensitive to
1679 Ebp1 knockdown are chromogranins a/b (Chga/b) and the granin Scg5, that regulate the
1680 secretion of neuronal hormones, neurotransmitters, and growth factors (Bartolomucci et al.,
1681 2011). Ebp1 may further influence proteostasis through its regulation of protein aggregation

Kraushar ML, *et al.* Submission.

1682 modulators Nucb1 (Bonito-Oliva et al., 2017; Niphakis et al., 2015; Tulke et al., 2016) and Scg5
1683 (Bartolomucci et al., 2011; Helwig et al., 2013). The impact of Ebp1 on the developmental
1684 neurogenic proteome is apparent in many of the proteins above, in addition to regulators of NSC
1685 signaling, such as Cxxc5 (Andersson et al., 2009) and Hand2 (Hendershot et al., 2007; Lei and
1686 Howard, 2011).

1687

1688 **REFERENCES: MAIN**

- 1689 Ambrozkiwicz, M.C., and Kawabe, H. (2015). HECT-type E3 ubiquitin ligases in nerve cell
1690 development and synapse physiology. *FEBS Lett.* **589**, 1635–1643.
- 1691 Balchin, D., Hayer-Hartl, M., and Hartl, F.U. (2016). In vivo aspects of protein folding and quality
1692 control. *Science.* **353**, aac4354.
- 1693 Behrmann, E., Loerke, J., Budkevich, T. V., Yamamoto, K., Schmidt, A., Penczek, P.A., Vos,
1694 M.R., Bürger, J., Mielke, T., Scheerer, P., et al. (2015). Structural snapshots of actively
1695 translating human ribosomes. *Cell* **161**, 845–857.
- 1696 Bhalla, K., Luo, Y., Buchan, T., Beachem, M.A., Guzauskas, G.F., Ladd, S., Bratcher, S.J.,
1697 Schroer, R.J., Balsamo, J., DuPont, B.R., et al. (2008). Alterations in CDH15 and KIRREL3 in
1698 Patients with Mild to Severe Intellectual Disability. *Am. J. Hum. Genet.* **83**, 703–713.
- 1699 Bidet, Y., Jagla, T., Da Ponte, J.P., Dastugue, B., and Jagla, K. (2003). Modifiers of muscle and
1700 heart cell fate specification identified by gain-of-function screen in *Drosophila*. *Mech. Dev.* **120**,
1701 991–1007.
- 1702 Biederer, T., Kaeser, P.S., and Blanpied, T.A. (2017). Transcellular Nanoalignment of Synaptic
1703 Function. *Neuron* **96**, 680–696.
- 1704 Bosco, D.A., Lavoie, M.J., Petsko, G.A., and Ringe, D. (2011). Proteostasis and Movement
1705 Disorders: Parkinson’s Disease and Amyotrophic Lateral Sclerosis. *Cold Spring Harb. Perspect.*
1706 *Biol.* **3**, a007500.
- 1707 Bradatsch, B., Katahira, J., Kowalinski, E., Bange, G., Yao, W., Sekimoto, T., Baumgärtel, V.,
1708 Boese, G., Bassler, J., Wild, K., et al. (2007). Arx1 Functions as an Unorthodox Nuclear Export
1709 Receptor for the 60S Preribosomal Subunit. *Mol. Cell* **27**, 767–779.
- 1710 Cadwell, C.R., Bhaduri, A., Mostajo-Radji, M.A., Keefe, M.G., and Nowakowski, T.J. (2019).
1711 Development and Arealization of the Cerebral Cortex. *Neuron* **103**, 980–1004.
- 1712 Chau, K.F., Shannon, M.L., Fame, R.M., Fonseca, E., Mullan, H., Johnson, M.B., Sendamarai,
1713 A.K., Springel, M.W., Laurent, B., and Lehtinen, M.K. (2018). Downregulation of ribosome
1714 biogenesis during early forebrain development. *Elife* **7**, e36998.
- 1715 DeBoer, E.M., Kraushar, M.L., Hart, R.P., and Rasin, M.-R. (2013). Post-transcriptional
1716 regulatory elements and spatiotemporal specification of neocortical stem cells and projection
1717 neurons. *Neuroscience* **248**, 499–528.
- 1718 Delarue, M., Brittingham, G.P., Pfeffer, S., Surovtsev, I. V., Pinglay, S., Kennedy, K.J., Schaffer,
1719 M., Gutierrez, J.I., Sang, D., Poterewicz, G., et al. (2018). mTORC1 Controls Phase Separation
1720 and the Biophysical Properties of the Cytoplasm by Tuning Crowding. *Cell* **174**, 338–349.
- 1721 Deuerling, E., Gamerding, M., and Kreft, S.G. (2019). Chaperone Interactions at the
1722 Ribosome. *Cold Spring Harb. Perspect. Biol.* a033977.
- 1723 Dieterich, D.C., Link, A.J., Graumann, J., Tirrell, D.A., and Schuman, E.M. (2006). Selective
1724 identification of newly synthesized proteins in mammalian cells using bioorthogonal
1725 noncanonical amino acid tagging (BONCAT). *Proc. Natl. Acad. Sci.* **103**, 9482–9487.
- 1726 Eichelbaum, K., Winter, M., Diaz, M.B., Herzig, S., and Krijgsveld, J. (2012). Selective

- 1727 enrichment of newly synthesized proteins for quantitative secretome analysis. *Nat. Biotechnol.*
1728 **30**, 984–990.
- 1729 Feral, C.C., Nishiya, N., Fenczik, C.A., Stuhlmann, H., Slepak, M., and Ginsberg, M.H. (2005).
1730 CD98hc (SLC3A2) mediates integrin signaling. *Proc. Natl. Acad. Sci.* **102**, 355–360.
- 1731 Gamerdinger, M., Hanebuth, M.A., Frickey, T., and Deuerling, E. (2015). The principle of
1732 antagonism ensures protein targeting specificity at the endoplasmic reticulum. *Science.* **348**,
1733 201–207.
- 1734 Gamerdinger, M., Kobayashi, K., Wallisch, A., Kreft, S.G., Sailer, C., Schlömer, R., Sachs, N.,
1735 Jomaa, A., Stengel, F., Ban, N., et al. (2019). Early Scanning of Nascent Polypeptides inside
1736 the Ribosomal Tunnel by NAC. *Mol. Cell* **75**, 996–1006.
- 1737 Genuth, N.R., and Barna, M. (2018). Heterogeneity and specialized functions of translation
1738 machinery: from genes to organisms. *Nat. Rev. Genet.* **19**, 431–452.
- 1739 Greber, B.J., Gerhardy, S., Leitner, A., Aebersold, R., Panse, V.G., Ban, N., Boehringer, D.,
1740 Leulliot, N., Aebersold, R., Panse, V.G., et al. (2016). Insertion of the Biogenesis Factor Rei1
1741 Probes the Ribosomal Tunnel during 60S Maturation. *Cell* **164**, 91–102.
- 1742 Hafner, A.-S., Donlin-Asp, P.G., Leitch, B., Herzog, E., and Schuman, E.M. (2019). Local
1743 protein synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments.
1744 *Science.* **364**, 363184.
- 1745 Hanus, C., and Schuman, E.M. (2013). Proteostasis in complex dendrites. *Nat. Rev. Neurosci.*
1746 **14**, 638–648.
- 1747 Harris, K.D., and Shepherd, G.M.G. (2015). The neocortical circuit: themes and variations. *Nat.*
1748 *Neurosci.* **18**, 170–181.
- 1749 Hipp, M.S., Kasturi, P., and Hartl, F.U. (2019). The proteostasis network and its decline in
1750 ageing. *Nat. Rev. Mol. Cell Biol.* **20**, 421–435.
- 1751 Holt, C.E., and Schuman, E.M. (2013). The Central Dogma Decentralized: New Perspectives on
1752 RNA Function and Local Translation in Neurons. *Neuron* **80**, 648–657.
- 1753 Horváth, B.M., Magyar, Z., Zhang, Y., Hamburger, A.W., Bakó, L., Visser, R.G.F., Bachem,
1754 C.W.B., and Bögre, L. (2006). EBP1 regulates organ size through cell growth and proliferation in
1755 plants. *EMBO J.* **25**, 4909–4920.
- 1756 Howden, A.J.M., Geoghegan, V., Katsch, K., Efstathiou, G., Bhushan, B., Boutureira, O.,
1757 Thomas, B., Trudgian, D.C., Kessler, B.M., Dieterich, D.C., et al. (2013). QuaNCAT:
1758 Quantitating proteome dynamics in primary cells. *Nat. Methods* **10**, 343–346.
- 1759 Jayaraj, G.G., Hipp, M.S., and Hartl, F.U. (2019). Functional Modules of the Proteostasis
1760 Network. *Cold Spring Harb. Perspect. Biol.* a033951.
- 1761 Jung, H., Yoon, B.C., and Holt, C.E. (2012). Axonal mRNA localization and local protein
1762 synthesis in nervous system assembly, maintenance and repair. *Nat. Rev. Neurosci.* **13**, 308–
1763 324.
- 1764 Jung, H., Gkogkas, C.G., Sonenberg, N., and Holt, C.E. (2014). Remote Control of Gene
1765 Function by Local Translation. *Cell* **157**, 26–40.

- 1766 Kapur, M., and Ackerman, S.L. (2018). mRNA Translation Gone Awry: Translation Fidelity and
1767 Neurological Disease. *Trends Genet.* **34**, 218–231.
- 1768 Kapur, M., Monaghan, C.E., and Ackerman, S.L. (2017). Regulation of mRNA Translation in
1769 Neurons — A Matter of Life and Death. *Neuron* **96**, 616–637.
- 1770 Knorr, A.G., Schmidt, C., Tesina, P., Berninghausen, O., Becker, T., Beatrix, B., and Beckmann,
1771 R. (2019). Ribosome–NatA architecture reveals that rRNA expansion segments coordinate N-
1772 terminal acetylation. *Nat. Struct. Mol. Biol.* **26**, 35–39.
- 1773 Ko, H.R., Hwang, I., Ahn, S.Y., Chang, Y.S., and Park, W.S. (2017). Neuron-specific expression
1774 of p48 Ebp1 during murine brain development and its contribution to CNS axon regeneration.
1775 *BMB Rep.* **50**, 126–131.
- 1776 Kowalinski, E., Bange, G., Bradatsch, B., Hurt, E., Wild, K., and Sinning, I. (2007). The crystal
1777 structure of Ebp1 reveals a methionine aminopeptidase fold as binding platform for multiple
1778 interactions. *FEBS Lett.* **581**, 4450–4454.
- 1779 Kraushar, M.L., Viljetic, B., Wijeratne, H.R.S., Thompson, K., Jiao, X., Pike, J.W., Medvedeva,
1780 V., Groszer, M., Kiledjian, M., Hart, R.P., et al. (2015). Thalamic WNT3 Secretion
1781 Spatiotemporally Regulates the Neocortical Ribosome Signature and mRNA Translation to
1782 Specify Neocortical Cell Subtypes. *J. Neurosci.* **35**, 10911–10926.
- 1783 Kraushar, M.L., Popovitchenko, T., Volk, N.L., and Rasin, M.-R. (2016). The frontier of RNA
1784 metamorphosis and ribosome signature in neocortical development. *Int. J. Dev. Neurosci.* **55**,
1785 131–139.
- 1786 Kriegstein, A., and Alvarez-Buylla, A. (2009). The glial nature of embryonic and adult neural
1787 stem cells. *Annu. Rev. Neurosci.* **32**, 149–184.
- 1788 Kucukdereli, H., Allen, N.J., Lee, A.T., Feng, A., Ozlu, M.I., Conatser, L.M., Chakraborty, C.,
1789 Workman, G., Weaver, M., Sage, E.H., et al. (2011). Control of excitatory CNS synaptogenesis
1790 by astrocyte-secreted proteins Hevin and SPARC. *Proc. Natl. Acad. Sci.* **108**, E440–E449.
- 1791 Kwan, K.Y., Sestan, N., and Anton, E.S. (2012). Transcriptional co-regulation of neuronal
1792 migration and laminar identity in the neocortex. *Development* **139**, 1535–1546.
- 1793 Kwon, I.S., and Ahn, J.Y. (2011). P48 Ebp1 acts as a downstream mediator of Trk signaling in
1794 neurons, contributing neuronal differentiation. *Neurochem. Int.* **58**, 215–223.
- 1795 Lein, E.S., Belgard, T.G., Hawrylycz, M., and Molnár, Z. (2017). Transcriptomic Perspectives on
1796 Neocortical Structure, Development, Evolution, and Disease. *Annu. Rev. Neurosci.* **40**, 629–652.
- 1797 Lessor, T.J., Yoo, J.Y., Xia, X., Woodford, N., and Hamburger, A.W. (2000). Ectopic expression
1798 of the ErbB-3 binding protein Ebp1 inhibits growth and induces differentiation of human breast
1799 cancer cell lines. *J. Cell. Physiol.* **183**, 321–329.
- 1800 Li, C., Liu, X., Qiang, X., Li, X., Li, X., Zhu, S., Wang, L., Wang, Y., Liao, H., Luan, S., et al.
1801 (2018). EBP1 nuclear accumulation negatively feeds back on FERONIA-mediated RALF1
1802 signaling.
- 1803 Liu, Z., Ahn, J.-Y., Liu, X., and Ye, K. (2006). Ebp1 isoforms distinctively regulate cell survival
1804 and differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 10917–10922.

- 1805 Loerke, J., Giesebrecht, J., and Spahn, C.M.T. (2010). Multiparticle Cryo-EM of Ribosomes.
1806 *Methods Enzymol.* **483**, 161–177.
- 1807 López-Murcia, F.J., Terni, B., and Llobet, A. (2015). SPARC triggers a cell-autonomous
1808 program of synapse elimination. *Proc. Natl. Acad. Sci.* **112**, 13366–13371.
- 1809 Maness, P.F., and Schachner, M. (2007). Neural recognition molecules of the immunoglobulin
1810 superfamily: Signaling transducers of axon guidance and neuronal migration. *Nat. Neurosci.* **10**,
1811 19–26.
- 1812 Mills, E.W., and Green, R. (2017). Ribosomopathies: There's strength in numbers. *Science.* **358**,
1813 ean2755.
- 1814 Missler, M., Südhof, T.C., and Biederer, T. (2012). Synaptic cell adhesion. *Cold Spring Harb.*
1815 *Perspect. Biol.* **4**, 1–18.
- 1816 Molyneaux, B.J., Arlotta, P., Menezes, J.R.L., and Macklis, J.D. (2007). Neuronal subtype
1817 specification in the cerebral cortex. *Nat. Rev. Neurosci.* **8**, 427–437.
- 1818 Monie, T.P., Perrin, A.J., Birtley, J.R., Sweeney, T.R., Karakasiliotis, I., Chaudhry, Y., Roberts,
1819 L.O., Matthews, S., Goodfellow, I.G., and Curry, S. (2007). Structural insights into the
1820 transcriptional and translational roles of Ebp1. *EMBO J.* **26**, 3936–3944.
- 1821 Neilson, K.M., Abbruzzesse, G., Kenyon, K., Bartolo, V., Krohn, P., Alfandari, D., and Moody,
1822 S.A. (2017). Pa2G4 is a novel Six1 co-factor that is required for neural crest and otic. *Dev. Biol.*
1823 **421**, 171–182.
- 1824 Nguyen, D.Q., Hoang, D.H., Nguyen Vo, T.T., Huynh, V., Ghoda, L., Marcucci, G., and Nguyen,
1825 L.X.T. (2018). The role of ErbB3 binding protein 1 in cancer: Friend or foe? *J. Cell. Physiol.* 1–
1826 11.
- 1827 Nonato, M.C., Widom, J., and Clardy, J. (2006). Human methionine aminopeptidase type 2 in
1828 complex with l- and d-methionine. *Bioorganic Med. Chem. Lett.* **16**, 2580–2583.
- 1829 Nowakowski, T.J., Bhaduri, A., Pollen, A.A., Alvarado, B., Mostajo-Radji, M.A., Di Lullo, E.,
1830 Haeussler, M., Sandoval-Espinosa, C., Liu, S.J., Velmeshev, D., et al. (2017). Spatiotemporal
1831 gene expression trajectories reveal developmental hierarchies of the human cortex. *Science.*
1832 **358**, 1318–1323.
- 1833 Oberst, P., Fièvre, S., Baumann, N., Concetti, C., Bartolini, G., and Jabaudon, D. (2019).
1834 Temporal plasticity of apical progenitors in the developing mouse neocortex. *Nature* **573**, 370–
1835 374.
- 1836 Pilipenko, E. V., Pestova, T. V., Kolupaeva, V.G., Khitrina, E. V., Poperechnaya, A.N., Agol, V.I.,
1837 and Hellen, C.U.T. (2000). A cell cycle-dependent protein serves as a template-specific
1838 translation initiation factor. *Genes Dev.* **14**, 2028–2045.
- 1839 Radomski, N., and Jost, E. (1995). Molecular cloning of a muring cDNA encoding a novel
1840 protein, p38-2G4, which varies with the cell cycle. *Exp. Cell Res.* **220**, 434–445.
- 1841 Rakic, P. (2009). Evolution of the neocortex: a perspective from developmental biology. *Nat.*
1842 *Rev. Neurosci.* **10**, 724–735.
- 1843 Robbins, E.M., Krupp, A.J., Perez de Arce, K., Ghosh, A.K., Fogel, A.I., Boucard, A., Südhof,

- 1844 T.C., Stein, V., and Biederer, T. (2010). SynCAM 1 Adhesion Dynamically Regulates Synapse
1845 Number and Impacts Plasticity and Learning. *Neuron* 68, 894–906.
- 1846 Schwanhäusser, B., Gossen, M., Dittmar, G., and Selbach, M. (2009). Global analysis of cellular
1847 protein translation by pulsed SILAC. *Proteomics* 9, 205–209.
- 1848 Shao, S., Brown, A., Santhanam, B., and Hegde, R.S. (2015). Structure and assembly pathway
1849 of the ribosome quality control complex. *Mol. Cell* 57, 433–445.
- 1850 Shen, K., Gamberinger, M., Chan, R., Gense, K., Martin, E.M., Sachs, N., Knight, P.D.,
1851 Schlömer, R., Calabrese, A.N., Stewart, K.L., et al. (2019). Dual Role of Ribosome-Binding
1852 Domain of NAC as a Potent Suppressor of Protein Aggregation and Aging-Related
1853 Proteinopathies. *Mol. Cell* 74, 729–741.
- 1854 Shi, Z., and Barna, M. (2015). Translating the Genome in Time and Space: Specialized
1855 Ribosomes, RNA Regulons, and RNA-Binding Proteins. *Annu. Rev. Cell Dev. Biol.* 31, 31–54.
- 1856 Silbereis, J.C., Pochareddy, S., Zhu, Y., Li, M., and Sestan, N. (2016). The Cellular and
1857 Molecular Landscapes of the Developing Human Central Nervous System. *Neuron* 89, 248–268.
- 1858 Sinturel, F., Gerber, A., Mauvoisin, D., Wang, J., Gatfield, D., Stubblefield, J.J., Green, C.B.,
1859 Gachon, F., and Schibler, U. (2017). Diurnal Oscillations in Liver Mass and Cell Size
1860 Accompany Ribosome Assembly Cycles. *Cell* 169, 651–663.
- 1861 Somanath, P., Bush, K.M., and Knoepfler, P.S. (2018). ERBB3-Binding Protein 1 (EBP1) Is a
1862 Novel Developmental Pluripotency-Associated-4 (DPPA4) Cofactor in Human Pluripotent Cells.
1863 *Stem Cells* 36, 671–682.
- 1864 Sossin, W.S., and Costa-Mattioli, M. (2018). Translational Control in the Brain in Health and
1865 Disease. *Cold Spring Harb. Perspect. Biol.* a032912.
- 1866 Squatrito, M., Mancino, M., Donzelli, M., Areces, L.B., and Draetta, G.F. (2004). EBP1 is a
1867 nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes.
1868 *Oncogene* 23, 4454–4465.
- 1869 Squatrito, M., Mancino, M., Sala, L., and Draetta, G.F. (2006). Ebp1 is a dsRNA-binding protein
1870 associated with ribosomes that modulates eIF2alpha phosphorylation. *Biochem. Biophys. Res.*
1871 *Commun.* 344, 859–868.
- 1872 Taira, E., Kohama, K., Tsukamoto, Y., Okumura, S., and Miki, N. (2005). Gicerin/CD146 is
1873 involved in neurite extension of NGF-treated PC12 cells. *J. Cell. Physiol.* 204, 632–637.
- 1874 Tanabe, A., Shiraishi, M., Negishi, M., Saito, N., Tanabe, M., and Sasaki, Y. (2012). MARCKS
1875 dephosphorylation is involved in bradykinin-induced neurite outgrowth in neuroblastoma SH-
1876 SY5Y cells. *J. Cell. Physiol.* 227, 618–629.
- 1877 Telley, L., Agirman, G., Prados, J., Amberg, N., Fièvre, S., Oberst, P., Bartolini, G., Vitali, I.,
1878 Cadilhac, C., Hippenmeyer, S., et al. (2019). Temporal patterning of apical progenitors and their
1879 daughter neurons in the developing neocortex. *Science*. 364, eaav2522.
- 1880 Theis, T., Mishra, B., Von Der Ohe, M., Loers, G., Prondzynski, M., Pless, O., Blackshear, P.J.,
1881 Schachner, M., and Kleene, R. (2013). Functional role of the interaction between polysialic acid
1882 and myristoylated alanine-rich C kinase substrate at the plasma membrane. *J. Biol. Chem.* 288,
1883 6726–6742.

- 1884 Turko, P., Groberman, K., Browa, F., Cobb, S., and Vida, I. (2018). Differential Dependence of
1885 GABAergic and Glutamatergic Neurons on Glia for the Establishment of Synaptic Transmission.
1886 *Cereb. Cortex* 29, 1230–1243.
- 1887 Voorhees, R.M., Fernandez, I.S., Scheres, S.H.W., and Hegde, R.S. (2014). Structure of the
1888 mammalian ribosome-Sec61 complex to 3.4Å resolution. *Cell* 157, 1632–1643.
- 1889 Weimer, J.M., Yokota, Y., Stanco, A., Stumpo, D.J., Blackshear, P.J., and Anton, E.S. (2009).
1890 MARCKS modulates radial progenitor placement, proliferation and organization in the
1891 developing cerebral cortex. *Development* 136, 2965–2975.
- 1892 de Wit, J., and Ghosh, A. (2016). Specification of synaptic connectivity by cell surface
1893 interactions. *Nat. Rev. Neurosci.* 17, 22–35.
- 1894 Xu, X.H., Deng, C.Y., Liu, Y., He, M., Peng, J., Wang, T., Yuan, L., Zheng, Z.S., Blackshear,
1895 P.J., and Luo, Z.G. (2014). MARCKS regulates membrane targeting of Rab10 vesicles to
1896 promote axon development. *Cell Res.* 24, 576–594.
- 1897 Xue, S., and Barna, M. (2012). Specialized ribosomes: a new frontier in gene regulation and
1898 organismal biology. *Nat. Rev. Mol. Cell Biol.* 13, 355–369.
- 1899 Yoo, J.Y., Wang, X.W., Rishi, A.K., Lessor, T., Xia, X.M., Gustafson, T.A., and Hamburger, A.W.
1900 (2000). Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by
1901 heregulin. *Br. J. Cancer* 82, 683–690.
- 1902 Yuzwa, S.A., Borrett, M.J., Innes, B.T., Voronova, A., Ketela, T., Kaplan, D.R., Bader, G.D., and
1903 Miller, F.D. (2017). Developmental Emergence of Adult Neural Stem Cells as Revealed by
1904 Single-Cell Transcriptional Profiling. *Cell Rep.* 21, 3970–3986.
- 1905 Zappulo, A., Van Den Bruck, D., Ciolli Mattioli, C., Franke, V., Imami, K., McShane, E., Moreno-
1906 Estelles, M., Calviello, L., Filipchuk, A., Peguero-Sanchez, E., et al. (2017). RNA localization is a
1907 key determinant of neurite-enriched proteome. *Nat. Commun.* 8, 1–12.
- 1908 Zhang, Y., Lu, Y., Zhou, H., Lee, M., Liu, Z., Hassel, B.A., and Hamburger, A.W. (2008).
1909 Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice. *BMC*
1910 *Cell Biol* 9, 69.
- 1911 Zhang, Y., Ma, C., Yuan, Y., Zhu, J., Li, N., Chen, C., Wu, S., Yu, L., Lei, J., and Gao, N. (2014).
1912 Structural basis for interaction of a cotranslational chaperone with the eukaryotic ribosome. *Nat.*
1913 *Struct. Mol. Biol.* 21, 1042–1046.
- 1914

1915 **REFERENCES: SUPPLEMENTARY**

- 1916 Adams, P.D., Afonine, P. V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J.,
1917 Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: A comprehensive
1918 Python-based system for macromolecular structure solution. *Acta Crystallogr. Sect. D Biol.*
1919 *Crystallogr.* **66**, 213–221.
- 1920 Ambrozkiewicz, M.C., Schwark, M., Kishimoto-Suga, M., Borisova, E., Hori, K., Salazar-Lázaro,
1921 A., Rusanova, A., Altas, B., Piepkorn, L., Bessa, P., et al. (2018). Polarity Acquisition in Cortical
1922 Neurons Is Driven by Synergistic Action of Sox9-Regulated Wwp1 and Wwp2 E3 Ubiquitin
1923 Ligases and Intronic miR-140. *Neuron* 1–19.
- 1924 Andersson, T., Södersten, E., Duckworth, J.K., Cascante, A., Fritz, N., Sacchetti, P., Cervenka,
1925 I., Bryja, V., and Hermanson, O. (2009). CXXC5 is a novel BMP4-regulated modulator of Wnt
1926 signaling in neural stem cells. *J. Biol. Chem.* **284**, 3672–3681.
- 1927 Bartolomucci, A., Possenti, R., Mahata, S.K., Fischer-Colbrie, R., Loh, Y.P., and Salton, S.R.J.
1928 (2011). The extended granin family: Structure, function, and biomedical implications. *Endocr.*
1929 *Rev.* **32**, 755–797.
- 1930 Behrmann, E., Loerke, J., Budkevich, T. V., Yamamoto, K., Schmidt, A., Penczek, P.A., Vos,
1931 M.R., Bürger, J., Mielke, T., Scheerer, P., et al. (2015). Structural snapshots of actively
1932 translating human ribosomes. *Cell* **161**, 845–857.
- 1933 Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N.,
1934 and Bourne, P.E. (2000). The Protein Data Bank. *Nucleic Acids Res.* **28**, 235–242.
- 1935 Bhalla, K., Luo, Y., Buchan, T., Beachem, M.A., Guzauskas, G.F., Ladd, S., Bratcher, S.J.,
1936 Schroer, R.J., Balsamo, J., DuPont, B.R., et al. (2008). Alterations in CDH15 and KIRREL3 in
1937 Patients with Mild to Severe Intellectual Disability. *Am. J. Hum. Genet.* **83**, 703–713.
- 1938 Bonito-Oliva, A., Barbash, S., Sakmar, T.P., and Graham, W.V. (2017). Nucleobindin 1 binds to
1939 multiple types of pre-fibrillar amyloid and inhibits fibrillization. *Sci. Rep.* **7**, 42880.
- 1940 Brown, A., Shao, S., Murray, J., Hegde, R.S., and Ramakrishnan, V. (2015). Structural basis for
1941 stop codon recognition in eukaryotes. *Nature* **254**, 493–496.
- 1942 Brudvig, J.J., and Weimer, J.M. (2015). X MARCKS the spot: myristoylated alanine-rich C
1943 kinase substrate in neuronal function and disease. *Front. Cell. Neurosci.* **9**, Article 407.
- 1944 Carragher, B., Kisseberth, N., Kriegman, D., Milligan, R.A., Potter, C.S., Pulokas, J., and Reilein,
1945 A. (2000). Leginon: An Automated System for Acquisition of Images from Vitreous Ice
1946 Specimens. *J. Struct. Biol.* **132**, 33–45.
- 1947 Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray,
1948 L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: All-atom structure validation
1949 for macromolecular crystallography. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **66**, 12–21.
- 1950 Chou, F.C., Sripakdeevong, P., Dibrov, S.M., Hermann, T., and Das, R. (2013). Correcting
1951 pervasive errors in RNA crystallography through enumerative structure prediction. *Nat. Methods*
1952 **10**, 74–76.
- 1953 Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized

- 1954 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**,
1955 1367–1372.
- 1956 Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J. V., and Mann, M. (2011).
1957 Andromeda: A peptide search engine integrated into the MaxQuant environment. *J. Proteome*
1958 *Res.* **10**, 1794–1805.
- 1959 Cox, J., Hein, M.Y., Lubner, C.A., Paron, I., Nagaraj, N., and Mann, M. (2014). Accurate
1960 Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio
1961 Extraction, Termed MaxLFQ. *Mol. Cell. Proteomics* **13**, 2513–2526.
- 1962 Dieterich, D.C., Link, A.J., Graumann, J., Tirrell, D.A., and Schuman, E.M. (2006). Selective
1963 identification of newly synthesized proteins in mammalian cells using bioorthogonal
1964 noncanonical amino acid tagging (BONCAT). *Proc. Natl. Acad. Sci.* **103**, 9482–9487.
- 1965 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,
1966 and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21.
- 1967 Edgar, R., Domrachev, M., and Lash, A.E. (2002). Gene Expression Omnibus: NCBI gene
1968 expression and hybridization array data repository. *Nucleic Acids Res.* **30**, 207–210.
- 1969 Eichelbaum, K., Winter, M., Diaz, M.B., Herzig, S., and Krijgsveld, J. (2012). Selective
1970 enrichment of newly synthesized proteins for quantitative secretome analysis. *Nat. Biotechnol.*
1971 **30**, 984–990.
- 1972 Emsley, P., and Cowtan, K. (2004). Coot: Model-building tools for molecular graphics. *Acta*
1973 *Crystallogr. Sect. D Biol. Crystallogr.* **60**, 2126–2132.
- 1974 Feral, C.C., Nishiya, N., Fenczik, C.A., Stuhlmann, H., Slepak, M., and Ginsberg, M.H. (2005).
1975 CD98hc (SLC3A2) mediates integrin signaling. *Proc. Natl. Acad. Sci.* **102**, 355–360.
- 1976 Ferreira, T.A., Blackman, A. V., Oyrer, J., Jayabal, S., Chung, A.J., Watt, A.J., Sjöström, P.J.,
1977 and van Meyel, D.J. (2014). Neuronal morphometry directly from bitmap images. *Nat. Methods*
1978 **11**, 982–984.
- 1979 Flis, J., Holm, M., Rundlet, E.J., Loerke, J., Hilal, T., Dabrowski, M., Bürger, J., Mielke, T.,
1980 Blanchard, S.C., Spahn, C.M.T., et al. (2018). tRNA Translocation by the Eukaryotic 80S
1981 Ribosome and the Impact of GTP Hydrolysis. *Cell Rep.* **25**, 2676–2688.e7.
- 1982 Frank, J., Radermacher, M., Penczek, P., Zhu, J., Li, Y., Ladjadj, M., and Leith, A. (1996).
1983 SPIDER and WEB: Processing and visualization of images in 3D electron microscopy and
1984 related fields. *J. Struct. Biol.* **116**, 190–199.
- 1985 Frankish, A., Diekhans, M., Ferreira, A.M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.M.,
1986 Sisu, C., Wright, J., Armstrong, J., et al. (2019). GENCODE reference annotation for the human
1987 and mouse genomes. *Nucleic Acids Res.* **47**, D766–D773.
- 1988 Goddard, T.D., Huang, C.C., Meng, E.C., Pettersen, E.F., Couch, G.S., Morris, J.H., and Ferrin,
1989 T.E. (2018). UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein*
1990 *Sci.* **27**, 14–25.
- 1991 Grant, T., Rohou, A., and Grigorieff, N. (2018). cisTEM, user-friendly software for single- particle
1992 image processing. *Elife* **7**, e35383.

- 1993 Greber, B.J., Boehringer, D., Leibundgut, M., Bieri, P., Leitner, A., Schmitz, N., Aebersold, R.,
1994 and Ban, N. (2014). The complete structure of the large subunit of the mammalian mitochondrial
1995 ribosome. *Nature* *515*, 283–286.
- 1996 Grigorieff, N. (2016). FREALIGN: An Exploratory Tool for Single-Particle Cryo-EM. *Methods*
1997 *Enzymol.* *579*, 191–226.
- 1998 Helwig, M., Hoshino, A., Berridge, C., Lee, S.N., Lorenzen, N., Otzen, D.E., Eriksen, J.L., and
1999 Lindberg, I. (2013). The neuroendocrine protein 7B2 suppresses the aggregation of
2000 neurodegenerative disease-related proteins. *J. Biol. Chem.* *288*, 1114–1124.
- 2001 Hendershot, T.J., Liu, H., Sarkar, A.A., Giovannucci, D.R., Clouthier, D.E., Abe, M., and Howard,
2002 M.J. (2007). Expression of Hand2 is sufficient for neurogenesis and cell type-specific gene
2003 expression in the enteric nervous system. *Dev. Dyn.* *236*, 93–105.
- 2004 Howden, A.J.M., Geoghegan, V., Katsch, K., Efstathiou, G., Bhushan, B., Boutureira, O.,
2005 Thomas, B., Trudgian, D.C., Kessler, B.M., Dieterich, D.C., et al. (2013). QuaNCAT:
2006 Quantitating proteome dynamics in primary cells. *Nat. Methods* *10*, 343–346.
- 2007 Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of
2008 large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* *4*, 44–57.
- 2009 Imami, K., Milek, M., Bogdanow, B., Yasuda, T., Kastelic, N., Zauber, H., Ishihama, Y.,
2010 Landthaler, M., and Selbach, M. (2018). Phosphorylation of the Ribosomal Protein RPL12/uL11
2011 Affects Translation during Mitosis. *Mol. Cell* *72*, 1–15.
- 2012 Ishihama, Y., Rappsilber, J., Andersen, J.S., and Mann, M. (2002). Microcolumns with self-
2013 assembled particle frits for proteomics. *J. Chromatogr. A* *979*, 233–239.
- 2014 Jin, J., Bhatti, D.L., Lee, K.W., Medrihan, L., Cheng, J., Wei, J., Zhong, P., Yan, Z., Kooiker, C.,
2015 Song, C., et al. (2019). Ahnak scaffolds p11/Anxa2 complex and L-type voltage-gated calcium
2016 channel and modulates depressive behavior. *Mol. Psychiatry* *doi: 10.10*.
- 2017 Jurrus, E., Engel, D., Star, K., Monson, K., Brandi, J., Felberg, L.E., Brookes, D.H., Wilson, L.,
2018 Chen, J., Liles, K., et al. (2018). Improvements to the APBS biomolecular solvation software
2019 suite. *Protein Sci.* *27*, 112–128.
- 2020 Kowalinski, E., Bange, G., Wild, K., and Sinning, I. (2007). Expression, purification,
2021 crystallization and preliminary crystallographic analysis of the proliferation-associated protein
2022 Ebp1. *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* *63*, 768–770.
- 2023 Kraushar, M.L., Thompson, K., Wijeratne, H.R.S., Viljetic, B., Sakers, K., Marson, J.W.,
2024 Kontoyiannis, D.L., Buyske, S., Hart, R.P., and Rasin, M.-R. (2014). Temporally defined
2025 neocortical translation and polysome assembly are determined by the RNA-binding protein Hu
2026 antigen R. *Proc. Natl. Acad. Sci. USA* *111*, E3815–E3824.
- 2027 Kraushar, M.L., Viljetic, B., Wijeratne, H.R.S., Thompson, K., Jiao, X., Pike, J.W., Medvedeva,
2028 V., Groszer, M., Kiledjian, M., Hart, R.P., et al. (2015). Thalamic WNT3 Secretion
2029 Spatiotemporally Regulates the Neocortical Ribosome Signature and mRNA Translation to
2030 Specify Neocortical Cell Subtypes. *J. Neurosci.* *35*, 10911–10926.
- 2031 Kucukdereli, H., Allen, N.J., Lee, A.T., Feng, A., Ozlu, M.I., Conatser, L.M., Chakraborty, C.,
2032 Workman, G., Weaver, M., Sage, E.H., et al. (2011). Control of excitatory CNS synaptogenesis

- 2033 by astrocyte-secreted proteins Hevin and SPARC. *Proc. Natl. Acad. Sci.* *108*, E440–E449.
- 2034 Lei, J., and Howard, M.J. (2011). Targeted deletion of Hand2 in enteric neural precursor cells
2035 affects its functions in neurogenesis, neurotransmitter specification and gangliogenesis, causing
2036 functional aganglionosis. *Development* *138*, 4789–4800.
- 2037 Liu, Z., Ahn, J.-Y., Liu, X., and Ye, K. (2006). Ebp1 isoforms distinctively regulate cell survival
2038 and differentiation. *Proc. Natl. Acad. Sci. U. S. A.* *103*, 10917–10922.
- 2039 Loerke, J., Giesebrecht, J., and Spahn, C.M.T. (2010). Multiparticle Cryo-EM of Ribosomes.
2040 *Methods Enzymol.* *483*, 161–177.
- 2041 Longair, M.H., Baker, D.A., and Armstrong, J.D. (2011). Simple neurite tracer: Open source
2042 software for reconstruction, visualization and analysis of neuronal processes. *Bioinformatics* *27*,
2043 2453–2454.
- 2044 López-Murcia, F.J., Terni, B., and Llobet, A. (2015). SPARC triggers a cell-autonomous
2045 program of synapse elimination. *Proc. Natl. Acad. Sci.* *112*, 13366–13371.
- 2046 Maness, P.F., and Schachner, M. (2007). Neural recognition molecules of the immunoglobulin
2047 superfamily: Signaling transducers of axon guidance and neuronal migration. *Nat. Neurosci.* *10*,
2048 19–26.
- 2049 Mindell, J.A., and Grigorieff, N. (2003). Accurate determination of local defocus and specimen
2050 tilt in electron microscopy. *J. Struct. Biol.* *142*, 334–347.
- 2051 Monie, T.P., Perrin, A.J., Birtley, J.R., Sweeney, T.R., Karakasiliotis, I., Chaudhry, Y., Roberts,
2052 L.O., Matthews, S., Goodfellow, I.G., and Curry, S. (2007). Structural insights into the
2053 transcriptional and translational roles of Ebp1. *EMBO J.* *26*, 3936–3944.
- 2054 Morita, T., Mayanagi, T., and Sobue, K. (2012). Caldesmon regulates axon extension through
2055 interaction with myosin II. *J. Biol. Chem.* *287*, 3349–3356.
- 2056 Moriya, T., Saur, M., Stabrin, M., Merino, F., Voicu, H., Huang, Z., Penczek, P.A., Raunser, S.,
2057 and Gatsogiannis, C. (2017). High-resolution Single Particle Analysis from Electron Cryo-
2058 microscopy Images Using SPHIRE. *J. Vis. Exp.* *123*, e55448.
- 2059 Niphakis, M.J., Lum, K.M., Cognetta, A.B., Correia, B.E., Ichu, T.A., Olucha, J., Brown, S.J.,
2060 Kundu, S., Piscitelli, F., Rosen, H., et al. (2015). A Global Map of Lipid-Binding Proteins and
2061 Their Ligandability in Cells. *Cell* *161*, 1668–1680.
- 2062 Okonechnikov, K., Golosova, O., Fursov, M., and the UGENE team (2012). Unipro UGENE: A
2063 unified bioinformatics toolkit. *Bioinformatics* *28*, 1166–1167.
- 2064 Penczek, P.A., Frank, J., and Spahn, C.M.T. (2006). A method of focused classification, based
2065 on the bootstrap 3D variance analysis, and its application to EF-G-dependent translocation. *J.*
2066 *Struct. Biol.* *154*, 184–194.
- 2067 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and
2068 Ferrin, T.E. (2004). UCSF Chimera - A visualization system for exploratory research and
2069 analysis. *J. Comput. Chem.* *25*, 1605–1612.
- 2070 Pisarev, A. V, Unbehaun, A., Hellen, C.U.T., and Pestova, T. V (2007). Assembly and Analysis
2071 of Eukaryotic Translation Initiation Complexes (Elsevier Inc.).

- 2072 Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003). A graphical user interface to
2073 the CCP4 program suite. *Acta Crystallogr. Sect. D Biol. Crystallogr.* *D59*, 1131–1137.
- 2074 Preibisch, S., Saalfeld, S., and Tomancak, P. (2009). Globally optimal stitching of tiled 3D
2075 microscopic image acquisitions. *Bioinformatics* *25*, 1463–1465.
- 2076 Rakwalska, M., and Rospert, S. (2004). The Ribosome-Bound Chaperones RAC and Ssb1/2p
2077 Are Required for Accurate Translation in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* *24*, 9186–
2078 9197.
- 2079 Rappsilber, J., Mann, M., and Ishihama, Y. (2007). Protocol for micro-purification, enrichment,
2080 pre-fractionation and storage of peptides for proteomics using StageTips. *Nat. Protoc.* *2*, 1896–
2081 1906.
- 2082 Rasmussen, S.H., Jacobsen, A., and Krogh, A. (2013). CWords - systematic microRNA
2083 regulatory motif discovery from mRNA expression data. *Silence* *4*, 1–9.
- 2084 Reynolds, E.S. (1963). The Use of Lead Citrate at High pH as an Electron-Opaque Stain in
2085 Electron Microscopy. *J. Cell Biol.* *17*, 208–212.
- 2086 Robbins, E.M., Krupp, A.J., Perez de Arce, K., Ghosh, A.K., Fogel, A.I., Boucard, A., Südhof,
2087 T.C., Stein, V., and Biederer, T. (2010). SynCAM 1 Adhesion Dynamically Regulates Synapse
2088 Number and Impacts Plasticity and Learning. *Neuron* *68*, 894–906.
- 2089 Sanz, R.L., Ferraro, G.B., Kacervosky, J., Salesse, C., Gowing, E., Hua, L., Rambaldi, I.,
2090 Beaubien, F., Holmbeck, K., Cloutier, J.F., et al. (2018). MT3-MMP Promotes Excitatory
2091 Synapse Formation by Promoting Nogo-66 Receptor Ectodomain Shedding. *J. Neurosci.* *38*,
2092 518–529.
- 2093 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
2094 Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: An open-source platform for biological-
2095 image analysis. *Nat. Methods* *9*, 676–682.
- 2096 Schwanhäusser, B., Gossen, M., Dittmar, G., and Selbach, M. (2009). Global analysis of cellular
2097 protein translation by pulsed SILAC. *Proteomics* *9*, 205–209.
- 2098 Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., and
2099 Selbach, M. (2011). Global quantification of mammalian gene expression control. *Nature* *473*,
2100 337–342.
- 2101 Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H.,
2102 Remmert, M., Söding, J., et al. (2011). Fast, scalable generation of high-quality protein multiple
2103 sequence alignments using Clustal Omega. *Mol. Syst. Biol.* *7*, 539.
- 2104 Sprink, T., Ramrath, D.J.F., Yamamoto, H., Yamamoto, K., Loerke, J., Ismer, J., Hildebrand,
2105 P.W., Scheerer, P., Bürger, J., Mielke, T., et al. (2016). Structures of ribosome-bound initiation
2106 factor 2 reveal the mechanism of subunit association. *Sci. Adv.* 1–7.
- 2107 Suloway, C., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J., Stagg, S., Potter,
2108 C.S., and Carragher, B. (2005). Automated molecular microscopy: The new Legimon system. *J.*
2109 *Struct. Biol.* *151*, 41–60.
- 2110 Taira, E., Kohama, K., Tsukamoto, Y., Okumura, S., and Miki, N. (2005). Gicerin/CD146 is
2111 involved in neurite extension of NGF-treated PC12 cells. *J. Cell. Physiol.* *204*, 632–637.

- 2112 Tang, G., Peng, L., Baldwin, P.R., Mann, D.S., Jiang, W., Rees, I., and Ludtke, S.J. (2007).
2113 EMAN2: An extensible image processing suite for electron microscopy. *J. Struct. Biol.* **157**, 38–
2114 46.
- 2115 Telley, L., Agirman, G., Prados, J., Amberg, N., Fièvre, S., Oberst, P., Bartolini, G., Vitali, I.,
2116 Cadilhac, C., Hippenmeyer, S., et al. (2019). Temporal patterning of apical progenitors and their
2117 daughter neurons in the developing neocortex. *Science*. **364**, eaav2522.
- 2118 The UniProt Consortium (2019). UniProt: A worldwide hub of protein knowledge. *Nucleic Acids*
2119 *Res.* **47**, D506–D515.
- 2120 Tulke, S., Williams, P., Hellysaz, A., Ilegems, E., Wendel, M., and Broberger, C. (2016).
2121 Nucleobindin 1 (NUCB1) is a Golgi-resident marker of neurons. *Neuroscience* **314**, 179–188.
- 2122 Turko, P., Groberman, K., Browa, F., Cobb, S., and Vida, I. (2018). Differential Dependence of
2123 GABAergic and Glutamatergic Neurons on Glia for the Establishment of Synaptic Transmission.
2124 *Cereb. Cortex* **29**, 1230–1243.
- 2125 Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann, M., and Cox, J.
2126 (2016). The Perseus computational platform for comprehensive analysis of (prote)omics data.
2127 *Nat. Methods* **13**, 731–740.
- 2128 Ulmer, B., Hagenlocher, C., Schmalholz, S., Kurz, S., Schweickert, A., Kohl, A., Roth, L., Sela-
2129 Donenfeld, D., and Blum, M. (2013). Calponin 2 Acts As an Effector of Noncanonical Wnt-
2130 Mediated Cell Polarization during Neural Crest Cell Migration. *Cell Rep.* **3**, 615–621.
- 2131 Vizcaíno, J.A., Deutsch, E.W., Wang, R., Csordas, A., Reisinger, F., Ríos, D., Dianes, J.A., Sun,
2132 Z., Farrah, T., Bandeira, N., et al. (2014). ProteomeXchange provides globally coordinated
2133 proteomics data submission and dissemination. *Nat. Biotechnol.* **32**, 223–226.
- 2134 de Wit, J., and Ghosh, A. (2016). Specification of synaptic connectivity by cell surface
2135 interactions. *Nat. Rev. Neurosci.* **17**, 22–35.
- 2136 Xia, N., Cheng, A., Lessor, T., Zhang, Y., and Hamburger, A.W. (2001). Ebp1, an ErbB-3
2137 binding protein, interacts with Rb and affects Rb transcriptional regulation. *J. Cell. Physiol.* **187**,
2138 209–217.
- 2139 Zappulo, A., Van Den Bruck, D., Ciolli Mattioli, C., Franke, V., Imami, K., McShane, E., Moreno-
2140 Estelles, M., Calviello, L., Filipchuk, A., Peguero-Sanchez, E., et al. (2017). RNA localization is a
2141 key determinant of neurite-enriched proteome. *Nat. Commun.* **8**, 1–12.
- 2142 Zhang, C., Cantara, W., Jeon, Y., Musier-Forsyth, K., Grigorieff, N., and Lyumkis, D. (2019).
2143 Analysis of discrete local variability and structural covariance in macromolecular assemblies
2144 using Cryo-EM and focused classification. *Ultramicroscopy* **203**, 170–180.
- 2145 Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017).
2146 MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron
2147 microscopy. *Nat. Methods* **14**, 331–332.

Graphical abstract

Kraushar ML, et al. Submission.




Figure 1

Kraushar ML, et al. Submission.




Figure 2

Kraushar ML, et al. Submission.




Figure 3

Kraushar ML, et al. Submission.




Figure 4




Figure 5

Kraushar ML, et al. Submission.







Figure 6






Figure 7

Kraushar ML, et al. Submission.


A




B



C




D



Supplementary Figure 1

Kraushar ML, *et al.* Submission.



Supplementary Figure 2


Kraushar ML, et al. Submission.

- E12.5 total
- E14 total
- E15.5 total
- E17 total
- P0 total




- E12.5 80S + E12.5 poly
- E14 80S + E14 poly
- E15.5 80S + E15.5 poly
- E17 80S + E17 poly
- P0 80S + P0 poly


A




B




A




B



C




D




Supplementary Figure 4


Kraushar ML, *et al.* Submission.




A




B



C




D




Supplementary Figure 6

Kraushar ML, et al. Submission.


A




B



A



B



A


Data collection				
Voltage (keV)	300			
Defocus range (μm)	0.5-2.5			
Pixel size (Å) on object scale	0.66			
Electron dose (e ⁻ /Å ²)	31.78			
Map refinement				
	Rotated (+)eEF2		Classical (+)A/A, P/P tRNAs	
	(+)Ebp1	(-)Ebp1	(+)Ebp1	(-)Ebp1
Particles	23907	29466	15262	14973
Resolution (Å)	3.1	3.1	3.3	3.3

Model	
Composition:	
Chains	58
Atoms	135402 (Hydrogens: 0)
Residues	
Protein	6385
Nucleotide	3887
Water	0
Ligands	
Zn	3
Mg	257
Bonds (RMSD):	
Length Å (# > 4σ)	0.010 (7)
Angles (°) (# > 4σ)	0.702 (45)
MolProbity score	1.47
Clash score	4.06
Ramachandran plot (%)	
Outliers	0.02
Allowed	4.1
Favored	95.89
Rotamer outliers (%)	0.16
Cβ outliers (%)	0
Peptide plane (%)	
Cis proline/general	0.4/0.0
Twisted proline/general	0.4/0.1
CaBLAM outliers (%)	
ADP (B-factors)	2.74
Iso/Aniso (#)	135402/0
min/max/mean	
Protein	43.66/282.25/79.40
Nucleotide	44.27/574.49/99.91
Ligand	29.57/202.48/57.93
Water	---
Occupancy	
Mean	1
occ = 1 (%)	100
0 < occ < 1 (%)	0
occ > 1 (%)	0




Data		
Box		
Lengths (Å)	238.81, 218.91, 270.65	
Angles (°)	90.00, 90.00, 90.00	
Supplied Resolution (Å)	3.3	
Resolution Estimates (Å)	Masked	Unmasked
d FSC (half maps; 0.143)	---	---
d 99 (full/half1/half2)	3.5/---/---	3.5/---/---
d model	3.4	3.4
d FSC model (0/0.143/0.5)	2.9/3.1/3.3	2.9/3.1/3.6
Map min/max/mean	-10.76/22.03/0.00	

Model vs. Data	
CC (mask)	0.84
CC (box)	0.69
CC (peaks)	0.55
CC (volume)	0.82
Mean CC for ligands	0.75

B




C




Supplementary Figure 9

Kraushar ML, et al. Submission.



Supplementary Figure 10


Kraushar ML, et al. Submission.




Supplementary Figure 11

Kraushar ML, et al. Submission.


A




B



C




D




Supplementary Figure 12

Kraushar ML, et al. Submission.



Supplementary Figure 13

Kraushar ML, et al. Submission.



Supplementary Figure 14

Kraushar ML, et al. Submission.

